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1. Preface
This thesis is proudly presented to you, as it is the product of years of 
collaborative work of urologists and radiologists. I think it provides a fine 
example of integrating knowledge and research interests of both disciplines 
into one body and is a perfect example of a 1+1=3 doctrine. Also, the 
pathologists involved in this research have played a crucial role in providing 
the gold standard for the diagnosis, grading and staging of prostate cancer 
(PCa). I am convinced that this collaboration will continue in the future in 
the clinical as well as the research setting, advancing our diagnostic 
strategies for PCa to a higher level. 
The main scope of this thesis is in improving diagnostic algorithms including 
advanced multiparametric MRI (MP-MRI) techniques to facilitate personalized 
care for PCa, as it enables more accurate diagnosis, grading and staging of an 
individual’s PCa. This thesis is comprised of a chapter on increasing the 
efficacy of PCa diagnosis using prostate biopsy (chapter 3), a chapter on the 
ability of diffusion-weighted MR imaging (DWI) in grading PCa (chapter 4) 
and a chapter on risk-stratified staging of PCa by MP-MRI, while also 
exploring pathological characteristics of the radical prostatectomy (RP) 
specimen to identify subjects at greatest risk of therapy failure, possibly 
benefitting from immediate adjuvant therapy (chapter 5). Integrating the 
results of the research presented in this thesis in clinical practice will help 
the urologist to define the most accurate strategy for prostate biopsies in 
case of an elevated PSA, while it enables the radiologist to perform a 
meaningful MP-MRI evaluation and report in case of a (suspected) PCa 
diagnosis. Using this knowledge in multidisciplinary consensus meetings 
has every mean to reduce the individual patient’s risk of overtreatment 
while improving the outcome of any curative intervention undertaken. 
Most importantly, the future perspectives in chapter 8 outline the challenges 
we will have to meet in ongoing research on this subject. 
Diederik M. Somford
Urologist, Canisius-Wilhelmina Hospital, Nijmegen
Chapter 2
INTRODUCTION  
AND OUTLINE OF THESIS
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2. Introduction and outline of thesis
Prostate cancer (PCa) has many faces, ranging from low-grade, low-volume 
cancers, often referred to as clinically insignificant or indolent PCa, to more 
aggressive cancers, which are likely to progress to or present with metastatic 
disease. While low-risk PCa is not likely to influence an individual patient’s 
morbidity and mortality importantly, intermediate and high-risk PCa have 
the potential of severely limiting the patient’s (future) quality of life and 
overall survival depending on age and comorbidity1. Considering this wide 
range of disease characteristics, it is important to bear in mind that PCa is 
the most commonly diagnosed non-skin cancer in men and overall PCa- 
specific mortality is significant1,2. Incidence of PCa has dramatically risen 
with the advent of prostate specific antigen (PSA) testing, leading only to a 
modest decrease in PCa-specific mortality3. This suggests predominantly an 
increase in diagnosis of low-risk PCa by PSA testing and it has turned PCa 
diagnosis into a challenging field of research. 
Evidence for reduction of PCa-specific mortality by PSA screening is 
accumulating, however, at the cost of significant overtreatment of patients 
diagnosed with low-risk PCa. The European Randomized Study of Screening 
for Prostate Cancer (ERSPC), the most referenced study on this subject, 
showed a 20% mortality reduction at the cost of 1410 men needed to screen 
and 48 additional cases of PCa treated4. In this landmark series Schröder et 
al. defined the substantial rate of overdiagnosis as the main limitation for 
PSA as a screening tool. Prolonged follow-up within the ERSPC shows a 
reduction of the number needed to screen and number needed to treat5, but 
PSA screening will remain controversial as long as the medical community is 
not able to differentiate those PCa patients that will benefit from early 
treatment from those that can be safely surveilled, as defined in a mission 
statement by the European Association of Urology (EAU)6. More recently the 
U.S. Preventive Services Task Force (USPSTF) also recommended against 
population-based PSA screening, defining overtreatment for low-risk PCa as 
a possible harm induced by a PCa diagnosis following PSA-based screening.
As far as curative treatment for PCa is concerned, the only modality that has 
shown a significant reduction of PCa-specific mortality compared to expectant 
management is radical prostatectomy (RP)7. Whether this stands true in the 
current PSA-era remains unknown and a recently published series showed 
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the safety of such programs and reduce the now substantial secondary 
intervention rates. Even when risk stratification at inclusion in AS protocols 
would be very accurate, we are confronted with the limitations of 
aforementioned criteria to detect progression and thus the indication for 
curative treatment during follow-up. These two factors limit the value of AS, 
and withhold AS to evolve to an effective strategy to reduce overtreatment 
in a majority of eligible PCa patients from a PSA-screened population.
Multiparametric MR-imaging (MP-MRI) of the prostate has evolved to the 
most adequate diagnostic, grading and staging tool for PCa currently 
available and combines anatomical imaging of the prostate by T2-weighted 
sequences with advanced functional parameters, such as dynamic contrast-
enhanced (DCE) MRI and diffusion-weighted MR imaging (DWI). DCE-MRI 
has proven merits in PCa detection and localization both in the pre-thera-
peutic arena as well as in the area of recurrent disease following treatment 
with curative intent16,17. This thesis, however, predominantly focuses on DWI 
and its quantitative functional derivative, the apparent diffusion coefficient 
(ADC), as this modality has the most potential in aiding adequate 
pre-treatment grading of PCa, which might turn out to be the holy grail in 
correctly identifying PCa patients eligible for AS.
2.1 Prostate biopsy for the diagnosis of prostate cancer
On one hand we face overdiagnosis and overtreatment of low-risk PCa. On 
the other hand we are not able to identify all patients with intermediate to 
high-risk PCa straightforward with the current standard of care: PSA, digital 
rectal examination (DRE) and TRUS-guided biopsy. 
TRUS-guided biopsy, for example, is known to be false negative in a 
substantial number of patients with an elevated PSA18 and (multiple) 
repeated biopsy sessions are not uncommon in current clinical practice to 
establish a diagnosis of PCa. Furthermore, the Gleason score is frequently 
underestimated by TRUS-guided biopsies19,20, limiting its value as a grading 
tool. The optimal biopsy strategy in case of an elevated PSA remains unclear 
and is at least partially based upon data from older series at a time when 
PSA-testing was not as common as it is nowadays. Current guidelines 
recommend a 10-12 core peripheral zone (PZ) baseline set of TRUS-guided 
biopsies, while recommending against incorporating standard transition 
zone (TZ) biopsies21,22. Chapter 3.1 of this thesis elaborates on the value of TZ 
only a significant mortality reduction following RP for a selected population 
of high-risk PCa patients8, which was confirmed in another series showing 
little survival benefit for patients over 70 years old and/or Gleason 6, 
non-palpable disease9. In conclusion, one might wonder if limiting 
overdiagnosis is the real challenge or rather preserving treatment to those 
patients diagnosed with PCa who will benefit. In this context there is a 
burning need for tools to differentiate those patients eligible for active 
surveillance (AS) for their PCa from those who are likely to progress and 
therefor have an indication for upfront curative treatment. 
Currently the indications for AS in a curative setting remain very limited and 
are based upon PSA, digital rectal examination (DRE) and transrectal 
ultrasound (TRUS)-guided biopsy criteria10. Probably, many more patients 
would be good candidates for AS as RP only influences PCa-specific mortality 
in a selected category of high-risk patients as mentioned earlier. At this 
point, however, we are not able to reliably identify those patients who will 
benefit from curative treatment while diagnosed with localized PCa. AS is 
most likely the key to reduce overtreatment in low-risk PCa patients, 
however, at the risk of withholding active treatment in some patients that 
would benefit. The main limitation for more liberal inclusion in AS protocols 
is the substantial rate of undergrading and/or understaging in AS 
candidates, causing the need to adhere to very strict criteria to limit the 
inclusion of intermediate to high-risk PCa patients in AS protocols as much 
as possible. Several RP correlated series have shown that up to one-third of 
patients considered eligible for AS do harbor intermediate to high-risk PCa 
characteristics in their RP specimen11,12. This is also underlined in series 
where immediate restaging TRUS-guided biopsy showed adverse character-
istics in about one out of four patients13,14. While AS studies, such as the 
Prostate Cancer Research International Active Surveillance (PRIAS) 
initiative15, mature, it becomes evident that approximately 30% of patients 
will be reclassified at the first repeat biopsy at one year, based upon biopsy 
Gleason score and/or biopsy PCa volume criteria, and will therefor be advised 
to undergo active treatment. It is, however, very likely that this reclassifica-
tion group represents a heterogeneous population of patients with either 
true progression of a low-risk PCa as well as patients undergraded and/or 
understaged at initial evaluation by TRUS-guided biopsies. We suggest that 
the focus of AS inclusion should shift to detecting patients subject to 
incorrect risk stratification as early as possible as this might further increase 
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quantify this freedom of water movement (or diffusion) which is strongly 
correlated with the cellular density of tissue28. In PCa, with increasing 
Gleason grade, cellular density increases and there is significant loss of 
glandular differentiation (see figure 2), which will both lead to a limitation 
of diffusion and decrease in the ADC. Correct identification of the most 
aggressive parts of PCa for obvious reasons can be very helpful to guide 
targeted biopsies and possibly focal therapy. Beyond the scope of this thesis 
is the possibility that DWI might also function as a follow-up tool for therapy 
response in PCa as cellular damage from successful therapies will lead to 
apoptosis and disruption of cellular membranes29, which can be monitored 
by DWI (see figure 1C).
biopsies (TZB) at baseline TRUS-guided biopsy. For obvious reasons leaving 
out TZB at baseline biopsy leads to a selection of TZ PCa to be detected by 
repeat biopsy sets. However, the TZ is technically not easily sampled by 
TRUS-guided biopsies23. To detect these TZ cancers with better accuracy 
MR-guided biopsies (MRGB) have been advocated22,24. While MRGB is a 
promising tool for repeat biopsy following negative TRUS-guided biopsies, 
the current limitation is that it has only been evaluated in expert centers in 
highly selected patients25,26. Chapter 3.2 presents an early series of MRGB in 
patients with at least 2 prior negative TRUS-guided biopsy sets. 
Even following a diagnosis of PCa, MRGB can be used as an important adjunct 
diagnostic tool to better establish the Gleason score, which is especially 
important in patients considered for AS or delayed treatment with curative 
intent. It has now been established that biopsy Gleason scores obtained by 
MRGB correlate significantly better with the true Gleason score at RP than 
those obtained by TRUS-guided biopsies27. This reduces the level of 
uncertainty about the Gleason score when using TRUS-guided biopsies, as 
these are subject to substantial degrees of Gleason undergrading. Chapter 3.3 
illustrates the value of a combination of MP-MRI and MRGB in a population 
considered eligible for AS based upon PSA, DRE and TRUS-guided biopsy 
characteristics. While AS is the most important mean to reduce overtreatment 
of low-risk PCa diagnosed in a PSA-screened population, adequate identification 
of true low-risk PCa is of paramount importance and MP-MRI is a promising 
tool for this. 
2.2  Diffusion-weighted MR imaging (DWI) as a grading tool 
for prostate cancer
DWI determines the random motion of water molecules, also known as 
Brownian motion. Brownian motion takes place in an unrestricted 
environment in which water molecules are able to diffuse freely and in equal 
extent in every direction (see figure 1A). However, within tissue extra- and 
intracellular compartments, such as vascular and ductal structures, cellular 
membranes and intracellular organelles, restrict the free motion of water 
molecules. Freedom of water movement in tissue is determined by the 
extracellular structures, such as glandular ducts, and the ratio of 
extracellular versus intracellular components, as water can move more freely 
in the extracellular compartment where there is less restriction by 
intracellular structures (see figure 1B). By means of the ADC DWI is able to 
Figure 1   Principles of diffusion
(A) shows the random movement of water (diffusion) in an unrestricted environment. 
Figure (B) shows the diffusion of water in a cellular environment limiting the free 
movement of water due to cellular and tubular structures. With increasing cellular 
density and loss of tubular structures, such as occurs in prostate cancer, this 
movement will be further limited. Figure (C) shows the effects of cellular damage, eg 
following treatment of prostate cancer, leading to an increase in the diffusion of 
water.
Adapted from Gayyum, Radiographics 2009.
C
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extent of PSMs is of major importance to optimize the outcome of RP. As it is 
the only prognostic factor to be influenced by surgical method and 
nerve-sparing strategies during RP, correct pre-operative clinical staging of 
PCa is of paramount importance. Knowledge of the presence and localization 
of EPE is likely to reduce the rate of PSMs since it enables the surgeon to more 
accurately select patients eligible for nerve-sparing procedures and counsel 
the patient accordingly35-37. The staging performance of 3-T MRI has been 
thoroughly documented with sensitivity and specificity rates of 67-88% and 
67-100%, respectively, depending on technique and reader experience16. 
Predictive values of a test are very dependent on the prevalence of a condition 
in the population evaluated38, and it is very likely that the predictive values 
MP-MRI combines DWI and DCE-MRI (or perfusion MR imaging) with 
conventional anatomical T1- and T2-weighted imaging, as described in a 
review of literature in chapter 4.1. In this thesis we explore the ability of 
MP-MRI to grade PCa and identify candidates suitable for AS. We have also 
just begun to appreciate the possibilities of MP-MRI to detect progression of 
low-risk PCa while on AS. It seems likely that, as experience with MP-MRI 
and MRGB in AS accumulates, in the near future the inclusion criteria for AS 
can be extended with the use of MP-MRI, while also being able to pick up PCa 
progression within the curative window. DWI is of special interest in this 
context and has been shown to be able to predict Gleason grade at RP with 
good accuracy. Chapter 4.2 presents a series exploring this ability. Leading 
investigators from the PRIAS study already supported the potential of MRI to 
monitor patients with low-risk PCa and to help identify those who might be 
better off with radical treatment30 and a sub-study of PRIAS incorporating 
MP-MRI and MRGB at inclusion in PRIAS (MR-PRIAS, Dutch Trial Register, 
NTR2006) was initiated in 2009 in the Dutch region of Nijmegen (see 
appendix 1). Within a MP-MRI setting DWI seems the most promising 
modality to identify patients subject to Gleason undergrading upon 
TRUS-guided biopsy in an AS population31. Chapter 4.3 aims to compare the 
ADC-characteristics of patients subject to undergrading by TRUS-guided 
biopsy compared with those correctly graded in a RP correlated series. The 
first reported results of MR-PRIAS presented in chapter 4.4 aim to identify 
patients subject to undergrading in a subset of patients in the PRIAS protocol 
using MP-MRI and MRGB. MP-MRI, including DWI, with consequent MRGB is 
used to obtain histological verification of cancer-suspicious regions (CSR), 
and the ADC-values of CSRs containing no PCa, low-grade PCa or high-grade 
PCa (any Gleason 4 and/or 5 component) are compared. The rate of under - 
staging detected by MP-MRI/MRGB at inclusion can easily be compared with 
the ≈10% of patients excluded from the conventional PRIAS for Gleason 
upgrading upon repeat biopsy at one year15,32. 
2.3 Staging of prostate cancer in radical prostatectomy subjects
The overall survival rates of RP are excellent and in absence of extraprostatic 
extension (EPE) and positive surgical margins (PSM), the rates of biochemical 
recurrence (BCR) are low. This does not stand true for patients with a PSM, a 
common pathological feature, with a prevalence reported in up to 43% of 
cases following RP33. PSM has been identified as one of the most important 
predictors for BCR following RP34. Reduction of the number as well as the 
Figure 2    The original drawing by Dr. Donald Gleason showing the five 
histological Gleason grade patterns
Adapted from Gleason, Urologic Pathology: the Prostate 1977.
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of MP-MRI for EPE differ for PCa risk categories. Chapter 5.1 outlines the 
performance of MP-MRI for prediction of EPE at RP, stratified for the different 
risk groups according to pre-treatment d’Amico criteria39 (see table 1). 
Knowledge of the predictive values of MP-MRI for EPE for different risk 
groups enables the urologist to interpret a staging MP-MRI study more 
accurately and counsel the patient accordingly.
Even in case of correct pre-operative staging by MP-MRI, PSM’s will continue 
to occur. In these cases adjuvant therapy, such as radiotherapy, could be 
considered. The EORTC 22911 trial established that adjuvant radiotherapy 
following RP improves BCR-free survival in patients with locally advanced 
PCa40. However, if all expectantly managed patients in this trial had received 
immediate radiotherapy, over fifty percent would have received adjuvant 
treatment without ever progressing to BCR at the cost of potentially 
considerable radiotherapeutic toxicity. Re-evaluation of the EORTC 22911 
data stressed that amongst patients with adverse pathological features upon 
RP, those with a PSM benefit most from adjuvant radiotherapy, preventing 
291 BCR events for every 1,000 treated41. Characterization of patients at high 
risk for BCR following RP would be of great help to identify those patients 
most likely to benefit from immediate adjuvant radiotherapy. While several 
predictors of BCR in a population with a PSM have been identified, including 
length and localization of PSM42-44, bilateral and/or multiple PSM could be an 
important and easy-to-use predictor of BCR. As such we hypothesized in 
chapter 5.2 that the number and/or bilaterality of PSMs are an additional 
risk factor for BCR following RP, and may indicate who might be ideal 
candidates for adjuvant post-operative radiotherapy.
Table 1    d’Amico risk classification for localized prostate cancer
Low-risk PSA less than or equal to 10, combined Gleason score less than 
or equal to 6, and clinical stage T1-2a
Intermediate risk PSA between 10 and 20 and/or Gleason score 7 and/or clinical 
stage T2b
High-risk PSA more than 20 and/or combined Gleason score equal or 
larger than 8 and/or clinical stage T2c-3a
PSA: prostate specific antigen       
Adapted from d’Amico et al. JAMA 1998.
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Introduction
The most recent published (inter)national guidelines on prostate cancer 
(PCa) advocate an eight to twelve core random biopsy scheme for baseline 
transrectal ultrasound (TRUS)-guided prostate biopsy1. At the same time 
most guidelines recommend that a baseline biopsy set should be focusing on 
the posterior and lateral regions of the prostate, thus predominantly 
sampling the peripheral zone (PZ), and should not include transition zone 
(TZ) sampling. However, the number of published series on the value of TZ 
sampling upon baseline TRUS-guided biopsy remains limited and exhibit 
conflicting results2-5. Interestingly, TZ cancers are been reported to have 
better prognosis as estimated by biochemical recurrence (BCR) free 
survival6,7. This finding is underlined by a series reporting PCa detected by 
initial 21-core biopsy, including TZ biopsy, to display significantly less 
unfavourable PCa characteristics upon radical prostatectomy (RP) than PCa 
detected by sextant PZ biopsy alone8.
Most RP series predominantly report PZ cancers with involvement of the TZ in 
6.4-24.7% of cases2,6,7,9,10. One might argue that, while most clinically used 
schematic TRUS-guided biopsy scheme are predominantly focusing upon 
extensive PZ sampling, the higher incidence of PZ cancers in most RP series 
could be due to a sampling error, which is underlined by a series by Davis et 
al.11 showing that the volume of TZ cancers, if detected at all, is more 
frequently underestimated by TRUS- guided biopsy than PZ PCa. It has been 
established in autopsy series that the majority of incidental prostate cancers 
originate from the PZ as well12, and about 25% of all synchronous diagnosed 
PCa in a cystoprostatectomy series for bladder cancer were TZ cancers13.
In our series we performed a classical sextant biopsy scheme of the PZ with 
addition of one TZ biopsy (TZB) on either side of the prostate as well as one 
midline apical biopsy (MAB), thus accounting for a 9-core baseline prostate 
biopsy protocol. Our first objective was to establish whether TZB and MAB at 
baseline TRUS-guided biopsy would improve detection rates for PCa. 
Secondly, we investigated whether TZB and MAB positive for PCa in the 
context of positive PZ biopsies (PZB) would add clinically relevant 
information, such as additional high-grade (Gleason 4 and/or 5 components) 
PCa, not sampled by PZB.
Abstract
Purpose To determine the diagnostic yield of transition zone (TZB) and 
midline apical biopsies (MAB) in baseline transrectal ultrasound 
(TRUS)-guided biopsies and to establish whether TZB and MAB for the 
diagnosis of prostate cancer (PCa) add clinical relevant information.
Methods We performed baseline 9-core TRUS-guided biopsy in 412 
consecutive subjects using sextant biopsies of the PZ (PZB), with an 
additional TZB on either side and a MAB at the prostatic apex. We determined 
the incremental diagnostic value of additional TZB an MAB to sextant PZB.
Results Within a cohort of 412 patients with a median PSA of 7.5 ng/ml, 178 
(43.2%) patients were diagnosed with PCa upon baseline TRUS-guided 
biopsies. In 102 cases at least one TZB was positive for PCa, with 6/412 (1.4%) 
cases displaying PCa in the TZB only. MAB alone was positive for PCa in 4/412 
(1.0%) cases. One case (1/412; 0.2%) had only a TZB and a MAB positive for 
PCa without positive PZB. Thus 11/412 (2.7%) of cases would not have been 
diagnosed with PCa at baseline TRUS- guided biopsy had only sextant PZ 
biopsy been performed. TZB detected a high-grade Gleason component 
(Gleason 4 and/or 5) not present in the PZB in 2.4% of PCa cases.
Conclusions There is limited value for TZB and MAB in the context of sextant 
PZB at baseline TRUS-guided biopsies for PCa.
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PCa, combined Gleason score and volume-percentage (Vol%) of PCa was 
documented using the International Society of Urogenital Pathology (ISUP)-
modified Gleason score classification14.
Statistical analysis
T-testing was performed to detect differences in patient characteristics 
between patients with or without a diagnosis of PCa upon baseline TRUS- 
guided biopsy. Detection rates and diagnostic yield for the different subsets 
of biopsy cores according to location (PZB versus TZB versus MAB) were 
established. Univariate analysis was performed using the Mann- Whitney U 
test, followed by multivariable analysis using logistic regression analysis for 
the whole group to identify predictors of any PCa positive biopsy or a TZB 
positive for PCa, incorporating the significant predictors of any PCa positive 
biopsy upon univariable analysis. Statistics were performed using the SPSS 
software package version 19.0 (Statistical Package for Social Sciences™, 
Chicago, IL, USA), with the 2-tailed level of significance set at p<0.05.
Materials and Methods
We retrospectively searched our institutional database for patients who 
underwent TRUS-guided prostate biopsy between January, 2010 and 
November, 2011. Patients that underwent repeat TRUS-guided biopsy with 
an interval less than two years from their previous set were excluded from 
analysis as we aimed to evaluate a true baseline TRUS-guided biopsy series. 
Repeat biopsies within an active surveillance setting were also excluded. 
Patients who underwent an alternative biopsy scheme, including targeted 
biopsies of abnormal regions upon digital rectal examination (DRE), TRUS or 
MRI, or a different number of biopsy cores were excluded as well. From the 
remaining cohort the patients’ charts were searched for patient characteristics 
(age, pre-biopsy PSA, DRE) and the pathology reports were revised for biopsy 
results. 
TRUS-guided biopsy protocol
We used a BK ProFocus ultrasound machine (BK Medical, Herlev, Denmark) 
with a bi-plane side-firing TRUS probe (Type 8808, 5-10 MHz; BK Medical, 
Herlev, Denmark) for TRUS-guided biopsy. DRE and systematic TRUS of the 
prostate were performed before biopsy, reporting any abnormal or suspect 
regions. Prostate volume (PVol) was calculated in every patient using the 
tool provided by the ultrasound manufacturer, incorporating width (at 
maximal transversal diameter), length (bladder neck to apex in the sagittal 
plane) and height (at maximal transversal diameter) for calculation of PVol. 
Schematic TRUS-guided biopsy was performed consequently according to 
the scheme depicted in figure 1, using a disposable 18-gauge core biopsy 
instrument (Bard Monopty, core length 1.7cm; Bard, Tempy, AZ, USA). In 
case of a TZB the needle-point was introduced up to the boundary of the PZ 
and TZ before firing the biopsy instrument and the biopsy core was thus 
taken predominantly from the TZ. The MAB was taken from the apical PZ just 
lateral from the urethra, avoiding unnecessary injury to the urethra.
Pathology Processing of TRUS-guided biopsy cores
All TRUS-guided prostate biopsy cores sent for pathological analysis were 
coded for location of biopsy as follows: sextant biopsy of basal PZ, mid- 
prostate PZ and apical PZ on both sides, TZB on both sides and MAB. At 
reception in our pathology department all biopsy cores were embedded and 
assessed by the pathologist separately. For every biopsy core the presence of 
Figure 1    Scheme for TRUS-guided biopsies including 6 peripheral zone 
biopsies (PZB), two transition zone biopsies (TZB) and one 
midline apical biopsy (MAB)
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positive for PCa. For individual patient characteristics of these subsets we 
refer to table 3. The diagnostic yield for TZB over sextant PZB thus was 4.0% 
with 7 extra PCa cases diagnosed. In all other patients (167/178, 93.8%) at 
least one PZB was positive for PCa. In this group of 167 patients the TZB was 
positive for PCa in 95/167 (56.9%) in the context of one or more positive PZB, 
whereas 65/167 (38.9%) of patients had PCa established in a MAB in the 
context of one or more positive PZB. A higher combined Gleason score in the 
TZB than in the PZB was detected in 10/167 (6.0%) of patients, however TZB 
only detected a high-grade Gleason component (Gleason 4 and/or 5) not 
present in the PZB in 4/167 (2.4%) cases. For MAB a higher combined Gleason 
score than in the PZB was detected in 4/167 (2.4%) patients, with a 
high-grade Gleason component not present in PZB in 2/167 (1.2%) cases.
Results
We identified 600 consecutive subjects that underwent TRUS-guided 
prostate biopsy in the specified period. Of these, 116 patients underwent 
repeat biopsy following earlier negative TRUS-guided prostate biopsy or 
within the context of an active surveillance protocol and were therefore 
excluded. In 72 subjects a biopsy protocol violation was established with a 
different number of cores taken or an alternative biopsy scheme performed 
at the physician’s discretion or due to patients discomfort. This leaves a 
cohort of 412 patients for further analysis that underwent baseline 
TRUS-guided prostate biopsy according to our institutional protocol. Mean 
age for this cohort was 66.1 years (range 41-86), with a median PSA of 7.5 ng/
ml (range 0.5-1582). DRE was classified as suspicious for PCa in 164 (39.8%) 
cases. Detailed patient characteristics stratified for PCa negative and PCa 
positive baseline TRUS-guided biopsies are shown in table 1. Mean follow-up 
after baseline TRUS-guided biopsy was 25.1 months (SD: 6.4 months). A 
histological diagnosis of PCa at baseline TRUS-guided biopsy was established 
in 178/412 patients (43.2%). Univariable analysis identified age, PSA, 
abnormal DRE and lower PVol as significant predictors of PCa upon baseline 
TRUS-guided biopsy. These variables were consequently included in the 
multivariable analysis, establishing abnormal DRE as the strongest predictor 
of PCa upon biopsy with an OR of 4.025, see table 2. Lower PVol was a 
statistically significant predictor of PCa, however, with a very high standard 
deviation its clinical significance is limited. Multivariable analysis of these 
characteristics to identify predictors of positive TZB within the subset 
diagnosed with PCa identified PSA as the only significant predictor of a 
positive TZB (p=0.03), see table 2. However with an OR of 1.04 the clinical 
significance of this finding for identifying patients at increased risk of 
positive TZB before baseline TRUS-guided biopsy remains very limited.
Biopsy characteristics
In 178 patients diagnosed with PCa upon 9-core TRUS-guided prostate 
biopsy, 11 cases (6.2%) were diagnosed with PCa in the context of negative 
sextant PZB, representing a minority of 2.7% (11/412) of the whole cohort 
that underwent TRUS-guided biopsy for a suspicion of PCa. For the men 
diagnosed with PCa upon baseline TRUS-guided biopsy, in 6/178 (3.4%) of 
cases a single TZB core was positive for PCa. In 4/178 (2.2%) cases only a MAB 
was positive for PCa. In a single case (0.6%) a TZB and the MAB core were 
Table 1    Patient characteristics
All No PCa 
upon  
baseline 
TRUS- 
guided 
biopsy
PCa upon 
baseline 
TRUS- 
guided 
biopsy
P-value
Number of patients 412 234 178
Age (mean±SD) 66.1±7.7 65.0±7.7 67.6±7.6 0.001*
PSA (mean±SD) 22.4±108.9 8.7±7.0 40.1±163.4 0.004*
DRE cT1c 237 177 60 <0.001*
cT2a-c 126 49 77
≥cT3a 39 1 38
missing 10 7 3
PVol (mean±SD) 53.1±26.8 58.7±27.7 45.6±23.8 <0.001*
Number of positive  
TRUS-cores (mean±SD)
N/A N/A 4.2±2.8 N/A
Highest biopsy 
Gleason score
≤3+3=6 N/A N/A 88 N/A
3+4=7/4+3=7 N/A N/A 35 N/A
≥4+4=8 N/A N/A 55 N/A
PCa: prostate cancer; TRUS: transrectal ultrasound; PSA: prostate-specific antigen (ng/ml); 
DRE: digital rectal examination; PVol: prostate volume (cm3); N/A: not applicable. *significant at 
p<0.05
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Follow-up
Of 178 patients diagnosed with PCa upon baseline TRUS-guided biopsy 17 
were included in an active surveillance protocol, 74 underwent RP, 28 were 
referred for external beam radiotherapy with or without neo-adjuvant 
hormonal treatment, 3 patients underwent brachytherapy, 2 patients were 
treated with primary cryosurgery of the prostate, 14 were followed with 
watchful waiting and 34 patients were treated with palliative androgen 
suppression therapy. For six patients the definitive treatment could not be 
established. Of the 234 patients not diagnosed with PCa upon baseline 
TRUS-guided biopsy, 51 patients underwent one or more repeated prostate 
biopsy sessions (median 1, range: 1-2) culminating in a total of 71 procedures 
of which 13 were MR-guided biopsy (MRGB) procedures leading to a diagnosis 
of PCa in 19/234 (8.1%) of patients and 19/71 (26.8%) of biopsy procedures 
during follow-up (mean 25.1 months ± 6.4). MRGB was positive for PCa during 
follow-up in 7/13 (53.8%) cases.
Table 2    Uni- and multivariate analysis of predictors of a PCa positive 
baseline TRUS-guided biopsy within the total population (n=412) 
and uni-and multivariate analysis of predictors of positive TZB 
within the subset diagnosed with PCa (n=178)
Univariate 
analysis
Multivariate 
analysis
P-value OR P-value
Any positive 
biopsy
Age (continuous) 0.002* 1.039 0.033*
PSA (continuous) <0.001* 1.028 0.035*
Abnormal DRE 
(yes/no)
<0.001* 4.025 <0.001*
PVol (continuous) <0.001* 0.979 <0.001*
Positive TZB Age (continuous) 0.001* 1.029 0.274
PSA (continuous) <0.001* 1.040 0.030*
Abnormal DRE 
(yes/no)
<0.001* 1.967 0.086
PVol (continuous) <0.001* 0.983 0.059
PCa: prostate cancer; TRUS: transrectal ultrasound; TZB: transition zone biopsy; PSA: prostate-
specific antigen (ng/ml); DRE: digital rectal examination; PVol: prostate volume (cm3). 
*significant at p<0.05
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a transperineal approach it is easier to target the TZ and using transperineal 
biopsy procedures, following one or more negative previous TRUS-guided 
biopsy sets, 45.3-85% of the detected PCa cases involve the TZ and/or ventral 
areas of the prostate19-22. MRGB following one or more negative TRUS-guided 
biopsy sessions is reported to have a high rate of PCa detection ranging from 
41% to 59% in different small series from a limited number of centers23-26. 
Interestingly, in patients diagnosed with PCa upon MRGB, PCa lesions are 
located in the anterior and apical regions of the prostate in the majority of 
patients24, again suggesting a bias of TRUS-guided biopsy towards diagnosing 
PCa in the PZ, regardless of the incorporation of TZB in the TRUS-guided 
biopsy scheme.
Limitations of our series are its retrospective nature, thus allowing for 
alternative biopsy schemes at the physicians discretion, possibly excluding 
a relative high proportion of patients with an abnormal DRE, suspect lesion 
upon TRUS, or a high PSA-level suggestive for advanced local or metastatic 
disease. Furthermore, PZ sampling in our series might have been inadequate 
with 6-core sextant biopsy27. Probably, in the context of more extensive PZ 
sampling, even less PCa diagnoses would have been attributed to TZB and/or 
MAB only. Therefor we think that the already limited value of TZB and/or 
MAB as found in our series might even be considered an overestimation of its 
diagnostic value in the context of state-of-the-art extended PZB protocols. 
In general, it remains questionable whether adequate TZ sampling is 
obtained with TRUS-guided TZB. Earlier series showed that positive TZB did 
not correlate well with TZ cancer upon RP, with 39.5% of patients with a 
positive TZB having no PCa in the TZ upon RP28. This underperformance of 
TRUS-guided TZB for prediction of involvement of the TZ upon RP underlines 
the suggested value of other techniques (eg. imaging-based) and/or 
approaches (eg. transperineal) for prostate biopsy in a population with an 
expected high prevalence of TZ PCa, such as patients with a persistent 
suspicion of PCa following a negative baseline set of schematic TRUS-guided 
biopsies of the PZ29. Another limitation of our series might be the fact that 
the indications for repeat TRUS-guided biopsy or MRGB during follow-up 
were not well defined and decisions regarding any repeat biopsy procedure 
were made upon the physician’s discretion.
We conclude that the incremental value of TZB at baseline schematic 
TRUS-guided biopsy is limited and could therefore be omitted. The ideal 
Discussion
In our presented series 93.8% of diagnosed PCa at baseline TRUS-guided 
biopsy would have been detected by sextant PZB alone, leaving little 
incremental value for TZB and/or MAB in a baseline biopsy setting. 
Furthermore, TZB positive for PCa in addition to PCa positive PZB did not add 
significant clinically relevant information as only in 2.4% of cases a high-grade 
Gleason component (Gleason 4 and/or 5) not present in the sextant biopsies 
was detected. Reissigl et al. found 28% of screen-detected PCa in TZB only in 
the context of sextant PZB and therefore conclude that TZB should not be 
omitted for baseline TRUS-guided biopsy3. Although their TRUS-guided biopsy 
scheme is comparable to ours, we could not reproduce their high diagnostic 
yield of TZB. This might be attributed to their evaluation of an early screening 
population without an abnormal DRE in all cases, whereas we performed our 
series in a referral population with a higher proportion of abnormal DRE, more 
likely to represent higher volume and/or predominant PZ PCa. Guichard et al. 
concluded from their series that TZB had to be considered at baseline biopsy as 
the addition of TZB to a 12-core PZB scheme increased the diagnostic yield by 
7.2%, however increasing the cancer detection rate only slightly from 38.7% to 
41.5%4. This is comparable to the present series in which TZB increased the 
detection rate of sextant biopsy from 40.5% to 42.2%, with a diagnostic yield 
for TZB of 4.0%. Pelzer et al. documented a diagnostic yield of 0.6% for TZB in 
the context of a 10-core schematic TRUS-guided biopsy scheme5. However, 
their series is not directly comparable to ours as they included imaging-guided 
(contrast enhanced color Doppler TRUS) targeted biopsies in their baseline 
biopsy set. This might have led to an underestimation of the diagnostic yield 
of TZB in a schematic TRUS-guided biopsy setting, improving the diagnosis 
rates of PZ PCa in comparison to TZ PCa by using augmented TRUS. The overall 
low incremental value of TZB for baseline TRUS-guided biopsy was underlined 
by a review of the literature by Chun et al.2 and has led to the removal of 
baseline TZB in most recent guidelines on PCa diagnosis. 
Following baseline sextant biopsies the additional value of TZB at repeat 
TRUS-guided biopsy remains limited15,16, and its value following a more 
extended baseline PZB protocol (10-12 cores), as advised by all current 
guidelines, remains unknown. Other series found the location of PCa in 
repeat TRUS-guided biopsy in the regions typically less sampled by an initial 
biopsy set, including the apical and ventral regions of the prostate17,18. Using 
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scheme for repeated TRUS-guided biopsy remains to be determined. It is 
important to acknowledge that based upon their RP specimen 54.5% (6/11) 
patients with a PCa diagnosis upon TZB and/or MAB only had a Gleason 
>3+3=6 and/or stage pT3a PCa, see table 3., and there remains a need for 
repeated biopsies following initial negative PZ biopsies. As the prevalence of 
TZ PCa is likely to increase in a population following negative baseline 
TRUS-guided biopsy aimed at the PZ, we assume that there might be a role for 
TZB in the repeat biopsy setting. More importantly, PCa detection in a repeat 
biopsy population might be improved by a transperineal schematic and/or 
imaging-guided approach, as TRUS-guided biopsy might be unable to 
adequately sample the TZ. As far as the presented diagnostic yield of MAB is 
concerned, we think in our series it should be regarded as an additional PZB. 
As it is known that increasing the number of PZB from sextant to 8-12 core 
biopsy increases diagnostic yield, MAB of the PZ should be seen in this 
context. Thus we agree that the focus of baseline TRUS-guided biopsy should 
be on adequate, more extensive PZ sampling rather than on the addition of 
TZB. Prospective series on added value of TZB in repeat TRUS-guided biopsies 
to establish the most appropriate scheme and/or approach for repeat prostate 
biopsy in case of a persistent suspicion of PCa following a negative baseline 
set of TRUS-guided biopsies are warranted.
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Magnetic resonance imaging 
guided prostate biopsy  
in men with repeat negative 
biopsies and increased prostate 
specific antigen
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Introduction
In 2008 prostate cancer (PCa) was the most commonly diagnosed cancer in 
men, accounting for 25% of all cancers. The most widely used tests to screen 
for PCa are digital rectal examination (DRE) and the prostate-specific antigen 
(PSA) blood serum test. Increased PSA is not cancer-specific since numerous 
benign prostate conditions can increase PSA. Urologists are increasingly 
faced with the dilemma of how best to treat a patient with increased PSA in 
whom repeat transrectal ultrasound (TRUS)-guided biopsies reveals no 
cancer.
Systematic prostate TRUS-guided biopsy is the standard procedure for 
prostate histological sampling. Prostate cancer is often multifocal and the 
volume sampled by systematic TRUS-guided biopsies is relatively small. The 
value of magnetic resonance imaging (MRI) to accurately localize prostate 
cancer is well established1. The accuracy of cancer localization on anatomical 
T2-weighted imaging remains low2. Thus, dynamic contrast-enhanced MR 
imaging (DCE-MRI) and diffusion weighted MR imaging (DWI) have been 
implemented to improve the accuracy of prostate cancer localization. A multi-
parametric MRI (MP-MRI) approach using a combination of these techniques 
appears to be optimal3.
Imaging-guided biopsies are advocated to improve tumor detection. However, 
grayscale TRUS, the most commonly used technique for biopsy guidance, has 
low sensitivity to localize prostate cancer4. A combined approach that appears 
more useful is systematic and additional lesion directed biopsies of 
suspicious areas at contrast-enhanced TRUS5,6.
Our principal aim was to determine the tumor detection yield of MP-MRI 
followed by directed MR-guided biopsy (MRGB) in a large patient group 
clinically suspicious for cancer but with repeat negative systematic TRUS- 
guided biopsies. We also determined whether detected tumors were clinically 
significant.
Abstract
Purpose Undetected cancer in repeated transrectal ultrasound (TRUS)- 
guided prostate biopsies in patients with increased prostate specific antigen 
(PSA) greater than 4 ng/ml is a considerable concern. We investigated the 
tumor detection rate of cancer-suspicious regions (CSR) on 3-Tesla (3-T) multi - 
parametric magnetic resonance imaging (MP-MRI) and subsequent magnetic 
resonance guided biopsy (MRGB) in 68 men with repeat negative TRUS-guided 
prostate biopsies. We compared results to those in a matched TRUS-guided 
prostate biopsy population. Also, we determined the clinical significance of 
detected tumors.
Materials and Methods A total of 71 consecutive patients with PSA greater 
than 4 ng/ml and 2 or greater negative TRUS-guided prostate biopsy sessions 
underwent 3-T MP-MRI. In 68 patients this was followed by MRGB directed 
towards CSRs. A matched multisession TRUS-guided prostate biopsy population 
from our institutional database was used for comparison. The clinical 
significance of detected tumors was established using accepted criteria, 
including PSA, Gleason grade, stage and tumor volume.
Results The tumor detection rate of multimodal 3 Tesla magnetic resonance 
imaging guided biopsy was 59% (40 of 68 cases) using a median of 4 cores. 
The tumor detection rate was significantly higher than that of TRUS-guided 
prostate biopsy in all patient subgroups (p<0.01) except in those with PSA 
greater than 20 ng/ml, prostate volume (PVol) greater than 65 cc and 
PSA-density (PSA-D) greater than 0.5 ng/ml/cc, in which similar rates were 
achieved. Of the 40 patients with identified tumors 37 (93%) were considered 
highly likely to harbor clinically significant disease. 
Conclusions MP-MRI is an effective technique to localize prostate cancer. 
MRGB of CSRs is an accurate method to detect clinically significant prostate 
cancer in men with repeat negative TRUS-guided prostate biopsies and 
increased PSA.
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previously described translation technique10 using a MR compatible biopsy 
device was used to obtain 18 gauge biopsy cores of re-identified CSRs with a 
MR compatible biopsy gun. Briefly, a needle guider attached to the arm of the 
biopsy device was inserted rectally and adjusted to aim toward the CSR in the 
prostate. Biopsies were obtained through the needle guider. Only 
CSR-directed biopsies were obtained with no random biopsies. All biopsies 
were done by one radiologist (TH). Samples were processed by routine histo-
pathological fixation and staining, and evaluated by a histopathologist.
Statistical Analysis
The chi-square test was used to calculate significant differences between 
the MRGB and TRUS-guided biopsy subgroups. The Mann-Whitney U test was 
done to compare mean age, PSA, PVol and PSA-D between groups with 
significant differences considered at p<0.05. Statistical analysis was 
performed with SPSS®, version 16.0.01.
Tumor Clinical Significance
The clinical significance of detected tumors was determined by currently 
accepted criteria11–14. In patients in whom radical prostatectomy (RP) was 
done after positive biopsy a Gleason grade 4 or 5 component, stage pT3 or 
tumor volume greater than 0.5cc was considered to represent clinically 
significant disease. In patients diagnosed with cancer in whom no RP was 
done cancer was considered significant when PSA at biopsy was greater than 
10 ng/ml and PSA-D greater than 0.15 ng/ml/cc or Gleason grade 4 or 5 was 
found at biopsy.
Results
In 70 of 71 patients CSRs were identified on MP-MRI. One patient refused 
biopsy and in another none was performed due to a high bleeding risk and no 
certain evidence of tumor on MP-MRI. Thus, 68 patients underwent MRGB. 
In the 68 patients mean age was 63 years (range 48 to 74) and median PSA 
was 13 ng/ml (range 4 to 243). They underwent a median of 3 previous 
negative TRUS-guided biopsy sessions (range 2 to 7). The median duration of 
prostate MRGB was 30 minutes (range 14 to 75). The tumor detection rate of 
MRGB was 59% (40 of 68 cases). A total of 260 prostate cores (directed cores 
only with no random cores) were obtained from 114 CSRs with a CSR tumor 
Methods
Patients
Between August 2006 and March 2008, 71 consecutive patients with PSA 
greater than 4 ng/ml and 2 or greater negative TRUS-guided biopsy sessions 
(of which the last session included at least an extended scheme of 8, 9 or 10 
cores, including TZ sampling) were referred from the departments of Urology 
at the Radboud University Nijmegen Medical Centre and the Canisius- 
Wilhelmina Hospital, Nijmegen, The Netherlands, for clinically routine prostate 
MP-MRI. The institutional review board approved this study.
The histopathology database at our institution was searched for consecutive 
patients from January 2000 to December 2006 with 2 or more TRUS-guided 
biopsy sessions. Only patients who underwent at least 1 systematic biopsy 
protocol of 8 to 10 cores, including TZ biopsy, were included in analysis. At 
each TRUS-guided biopsy session the principal diagnosis, patient age, PSA 
and prostate volume were noted. To remove the bias effect of differences in 
PSA and prostate volume tumor detection rates were compared by subgroup 
analysis of PSA, prostate volume (PVol) and PSA-density (PSA-D).
Localization
To identify possible tumor site(s) MRI was done with a 3-T MR scanner (Trio 
Tim, Siemens, Erlangen, Germany) with an endorectal coil (Medrad) in 28 
patients and with pelvic phased array coils only in 40. Axial, sagittal and 
coronal T2-weighted images, axial DWI and DCE-MR images were obtained 
using 15 ml gadopentetate dimeglumine. Prostate images were viewed on an 
in-house developed analytical software work station that projected 
calculated DCE-MRI parameters7 and apparent diffusion coefficient (ADC) 
maps as color overlays over T2-weighted images. All patient images were read 
in consensus by 2 readers (TH, JF) with 2 and 5 years of experience, respectively, 
with prostate MRI. MP-MRI images were used to determine up to 3 cancer-
suspicious regions (CSR) per patient using features described in the 
literature8,9.
MR Guided Biopsy
An average of 2 weeks (range 1 to 6) after initial MP-MRI to localize possible 
tumors and identify CSR for MRGB planning patients underwent 3-T prostate 
MRGB. Antibiotic prophylaxis was given with 500 mg ciprofloxacin orally. A 
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detection rate of 40% (46 of 114). The median number of biopsies per patient 
was 4 (range 2 to 7). Table 1 lists patient and pathological findings. A total of 
28 patients had no tumor.
RP was done in 20 of the 40 patients with tumor. A Gleason score 7 or greater 
was found in 10 of these 20 patients (50%) with extracapsular disease 
evident in 6 of 20 (30%). In 10 of 20 cases tumor volume was greater than 0.5 
cc with Gleason score 6. Thus, all patients with RP harbored clinically 
significant disease. The remaining 20 patients underwent external beam 
radiotherapy (11), brachytherapy (3), hormonal ablation (3) or active 
surveillance (3). In these patients biopsy Gleason score, PVol and PSA were 
used to assess clinically significant disease with biopsy Gleason score 7 or 
greater in 9 and PSA greater than 10 ng/ml plus PSA-D greater than 0.15 ng/
ml/cc in 10. One patient had skeletal metastasis. Thus, clinically significant 
disease was considered present in 17 of the 20 patients (85%) and in 37 of all 
40 (93%) with tumor. Aggressive cancer was evident in at least 19 of the 40 
patients (48%) with tumor (Gleason score 7 or greater and/or pT3/N1/M1). 
Table 2 lists tumor characteristics. The principal tumor site was the most 
ventral aspect of the TZ in 26 of 46 cases (57%), followed by the PZ paramedian 
region in 9 (20%) and the PZ anterior horns in 5 (11%) (fig. 1). Figure 2 shows 
MRI in a patient in whom tumor was detected by MRGB.
In our reference database we identified 248 patients with at least 2 TRUS- 
guided biopsy sessions and 65 with 3 sessions. No MRI was done before 
biopsy in these men and biopsies were performed on a systematic basis only. 
Overall tumor detection rate at biopsy sessions 2 and 3 was 22% (55 of 248 
cases) and 15% (10 of 65), respectively. Table 2 shows tumor detection rate in 
the TRUS-guided biopsy and MRGB subgroups according to PSA, PVol and 
PSA-D. MRGB achieved a significantly higher tumor detection rate in all PSA 
subgroups (p<0.01), and for prostate volume (p<0.01) and PSAD (p<0.05). 
However, in patients with PSA greater than 20 ng/ml, PVol greater than 65cc, 
and PSA-D less than 0.15 and greater than 0.5 ng/ml/cc superior results were 
evident but not significant (p>0.05, figs. 3 to 5). Self-limiting transurethral 
hemorrhage and uncomplicated urinary tract infection in one case each 
were the only procedure-related complications.
Table 1    Patient, radiological and pathological features
All patients Tumor No tumor
Mean age (range) 63(48-76) 65 (48-76) 62 (54-70)
Median PSA (ng/ml; range) 13 (4-243) 13 (5-243) 12 (4-58)
No. pos PCa family history (%) 4 (6) 2 (50) 2 (50)
No. suspicious DRE (%) 2 (3) 1 (50) 1 (50)
Median no. previous TRUS-GB (range) 3 (2-8) 3 (2-7) 3 (2-8)
No. CSRs/pt (range) 1 (1-3) 1 (1-3) 2 (2-3)
Median no. biopsy cores (range) 4 (2-7) 3 (2-6) 4 (2-7)
Median mins MRGB (range) 30 (14-75) 29 (14-75) 33 (15-55)
No. principal histologic diagnosis
Tumor 40
Chronic prostatitis 15
Prostatitis + reactive atypia 2
Acute prostatitis 1
Atypia suspicious for malignancy 2
Atypical adenomatous hyperplasia 2
Fibromuscular nodule 2
Necrosis 1
No abnormality 3
No. highest Gleason score (%) 40
5 3 (7)
6 19 (48)
7 10 (25)
8 5 (12)
9 3 (8)
No. disease clinical significance 40
GS 7 or greater 18
RP GS 7 or greater 10
MRGB GS 7 or greater + no RP 9
Tumor greater than 0.5cc in RP + GS 6 or less 8
M+, GS 6 or less + no RP 1
M+, GS 7 or greater 2
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Table 1    Continued
All patients Tumor No tumor
Stage pT3 at RP 5
PSA >10ng/ml + PSA-D>0.15, GS 6 or less + 
no RP 
10
Insignificant disease not ruled out 3
No. advanced disease 8 (20%)
N+/M+ 3
Stage T3 in RP 5
PSA: prostate-specific antigen; PCa: prostate cancer; DRE: digital rectal examination; TRUS-GB: 
TRUS-guided biopsy; CSR: cancer-suspicious region; MRGB: MR-guided biopsy; GS: Gleason 
score; RP: radical prostatectomy; PSA-D: PSA-density.
Figure 1    Prevalence of 46 tumor positive CSRs (for 9 biopsies 2 adjacent 
regions were positive for total of 55 tumor maps) in prostate on 
MRGB
Prostate was divided into 5 craniocaudal segments equal to apex (a), mid apex (b), 
mid (c), mid base (d) and basal (e) levels. Red areas indicate 5 or greater positive CSRs. 
Orange areas indicate 4 positive CSRs. Yellow areas indicate 3 positive CSRs. Green 
areas indicate 2 positive CSRs. Blue areas indicate 1 positive CSR. R, right. L, left. VT, 
ventral TZ. MT, middle TZ. DT, dorsal TZ. AH, PZ anterior horn. DL, dorsolateral PZ. D, 
dorsal PZ.
Figure 2    ERC 3-T MP-MRI in 64-year-old male with 4 previous negative 
TRUS-guided biopsies, including 2×8, 10 and 12 cores, and PSA 
18 ng/ml
T2-weighted axial (a) and coronal (b) images show low signal intensity lesions (arrow) 
in ventral portion of apex. This area showed restriction on ADC-map (c) and high Ktrans 
on DCE-MRI (d). Axial T2-weighted true fast imaging with steady state precession 
during MRGB demonstrates needle guider (dashed red line) directed toward CSR 
(dashed yellow oval) (e). Histopathological analysis of biopsy cores revealed GS 4+3=7 
PCa, consequent pelvic lymph node dissection showed metastatic disease.
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Figure 3    Tumor detection rate in PSA subgroups at TRUS-guided biopsy 
sessions 2 (blue bars) and 3 (red bars), and MRGB session  
(green bars)
Figure 4    Tumor detection rate in prostate volume subgroups at 
TRUS-guided biopsy sessions 2 (blue bars) and 3 (red bars), and 
MRGB session (green bars)
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Discussion
Using state-of-the-art 3-T MP-MRI to localize tumors we noted that a definite 
diagnosis of prostate cancer could be made in 40 of 68 patients (59%) in 
whom repeated TRUS-guided prostate biopsies remained negative but 
continuous concern regarding cancer was evident. Of the 40 patients 
diagnosed with prostate cancer 37 (93%) were considered to harbor clinically 
significant disease. Therefore, it is justifiable to deduce that prostate MRI 
accurately portrays tumor sites and, thus, offers urologists a method to 
improve biopsy outcomes. Since MRGB is limited by restricted general 
availability, other methods of MRI targeted biopsy techniques could be 
considered, such as MR-TRUS fusion during TRUS-guided biopsy. 
Nevertheless, MRGB is probably the most accurate technique because 
translating CSRs to another imaging modality is not required.
For comparison we selected a TRUS-guided biopsy population from our 
institution that was clinically matched for age, atypia prevalence on previous 
biopsy, PSA, PVol and PSA-D. We also determined tumor detection rate in 
each subgroup. In most studies of 8 to 12-core extended schemes cancer was 
detected in around 10% to 17% of patients on the second biopsy16-18. Thus, 
the overall 22% and 15% tumor detection rates at TRUS-guided biopsy 
sessions 2 and 3, respectively, at our institution are in agreement with 
reported data.
Since different PSA values can predict the likelihood of finding tumor and 
represent a bias for comparison, cases were substratified according to 
different PSA levels. MRGB detection rate was superior to repeat TRUS-GB 
sessions in all PSA subgroups (p<0.01) except in the group with a PSA greater 
than 20 ng/ml, in which a similar detection rate was achieved (50% vs 43%).
PVol is another important factor that has a role in the tumor detection rate 
achieved by different biopsy protocols. In a previous series 8 cores were 
appropriate in patients with less than 30 cc prostates, 10 to 12 were needed 
in 30 to 50 cc prostates and greater than 12 were needed in prostates greater 
than 50 cc19. In all prostate volume groups MRGB significantly outperformed 
TRUS-GB for tumor detection (p<0.05) except in excessively large prostates 
greater than 65 cc, in which similar rates were achieved.
In patients with tumor, PSA-D less than 0.15 ng/ml/cc is considered a good 
prognostic feature with a low progression rate13. MRGB did not achieve 
significant detection improvements over TRUS-guided biopsies in this 
patient subset with probably insignificant disease. In contrast, in the 
greater than 0.50 ng/ml/cc PSA-D group tumors were likely to have larger 
volume and, therefore, they were more easily diagnosed by TRUS-guided 
biopsy.
In cases of negative TRUS-guided biopsies radical measures involving 24 to 
64-core saturation biopsy were advocated with a reported detection rate of 
18% to 34% at session 220,21. No widespread application and acceptance of 
this technique by urologists exist with conflicting published results22,23. 
Saturation biopsy appears to increase tumor detection in high risk cases but 
the additional use of analgesia/anesthesia, the higher incidence of side 
effects and the high cost of processing the large amount of pathological 
material are its greatest drawbacks. Since our study shows that MRGB has a 
high tumor detection yield and requires a low number of cores (median 4), 
this method could be an appealing alternative to patient, urologist and 
pathologist alike.
Figure 5    Tumor detection rate in subgroups by PSA-D at TRUS-guided 
biopsy sessions 2 (blue bars) and 3 (red bars), and MRGB session 
(green bars)
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Whether prostate MRGB detects a substantial proportion of potentially 
insignificant tumors is a legitimate question. Higher sensitivity to detect 
tumor implies a higher chance of finding tumors that do not need treatment, 
so-called clinically insignificant cancer. For PCa overtreatment of these 
tumors remains controversial24. In the 1990s the concept of insignificant PCa 
based on tumor size and favorable pathological characteristics was 
proposed25. Clinical criteria to predict such tumors were later defined as PSA 
of 10 ng/ml or less, Gleason score 6 or less, clinical stage pT2 or less and tumor 
volume 0.5 cc or less11,12,26. In RP series the predominant tumor site is the PZ 
in almost 70% of cases27. Therefore, current systematic biopsy schemes 
extensively sample the PZ and, thus, the prostate dorsal region. In contrast, 
31 of the 46 tumors (68%) in our series were anterior, 26 (57%) were in the 
ventral TZ and 5 (11%) were in the PZ anterior horns. This may explain the 
previous negative TRUS-guided biopsies in our patient group.
The current literature on prostate MRGB is sparse. The few currently available 
reports included a small number of patients, had excessively long imaging 
and biopsy times, and described only conventional T2-weighted MRI to 
determine CSRs for MRGB after 1 previous negative TRUS biopsy28-30. 
Limitations of the current study relate principally to the fact that a direct 
comparison of our results to other literature could not be made. This was 
because of differences in PSA, PVol, the number of previous negative biopsies 
sessions and the biopsy schemes used at the initial sessions. A prospective, 
randomized trial would be superior. To determine the potential benefit we 
compared our study cohort with our institutional database, selecting similar 
patients but with TRUS-guided multiple biopsies and subgrouped by PSA, 
PVol and PSA-D. Since our institution is a referral hospital, patients with 
MRGB underwent heterogeneous previous biopsy protocols. The highest 
number of cores per biopsy session was 8 to 10, 12 and 18, and even saturation 
biopsy was done. Patients selected for study inclusion based on PSA greater 
than 10 ng/ml may represent a selection bias in relation to determining the 
clinical significance of detected tumors.
Conclusions
Results indicate that MP-MRI is highly effective to detect and localize 
clinically significant prostate cancer. Since guided biopsies toward CSRs on 
MP-MRI detect clinically significant tumor in a substantial proportion of 
patients, MRI should be considered essential in any evaluation protocol in 
patients suspected of harboring malignancy but who have had successive 
negative biopsies. Also, MRGB directed toward CSRs on MP-MRI is useful to 
accurately validate the correct sampling of suspicious prostate tissue. 
Because of the low number of cores needed, MRGB appears to be an appealing 
alternative to procedures such as saturation biopsy. Finally, detected tumors 
were mostly located in areas not explicitly sampled by routine schemes. 
Future studies of tumor detection rate using MR-TRUS fusion during 
TRUS-guided biopsies, including saturation targeting of suspicious areas, 
transperineal sampling of the anterior prostate or changing sampling sites 
on TRUS-guided biopsies in patients with repeat sessions, are needed and 
ideally should be compared to a MRI directed MRGB technique.
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Introduction
Prevalence of low-risk prostate cancer (PCa) has increased due to the 
application of prostate specific antigen (PSA) testing1. Low-risk PCa patients 
are prone to overtreatment and its complications, which can undermine a 
patient’s quality of life1,2. To avoid overtreatment, active surveillance (AS) is 
an accepted treatment alternative for low-risk PCa patients3. 
AS is mostly performed within trials, such as the Prostate Cancer Research 
International Active Surveillance (PRIAS) initiative4. Selected patients 
with presumed low-risk PCa are followed by regular PSA measurements, 
digital rectal examinations (DRE) and annual repeat systematic transrectal 
ultrasound (TRUS)-guided biopsy. PSA kinetics, Gleason grade upgrading 
(Gleason 4 and/or 5 component) and volume progression are generally used 
as criteria for disease progression5. However, rather due to TRUS-guided 
biopsy undersampling upon inclusion than due to true cancer progression, 
20-30% of AS patients actually harbor intermediate- to high-risk PCa at 
inclusion5,6,7. Early identification of these patients, who were incorrectly 
deemed suitable for AS, may be essential to maintain the opportunity for 
appropriate curative treatment within their window of curability. The 
detection of a Gleason 4 and/or 5 component or of a larger cancer volume or 
of multifocality of a Gleason ≤3 PCa5, results in re-stratification of these PCa 
patients into a higher risk category. Risk re-stratification implies that a 
patient cannot continue AS and needs radical treatment.
MR-guided biopsy (MRGB) has shown to improve identification of patients 
with Gleason 4-5 cancers due to a better highest Gleason grade concordance 
(88%) with prostatectomy specimens compared to TRUS-guided biopsies 
(55%, p=0.001). This higher Gleason concordance of MRGB specimens with 
radical prostatectomy (RP) specimens is possible due to better detection and 
targeting of the most aggressive area of a cancer suspicious region (CSR) on 
MP-MRI8. Only a few studies have related MR imaging results to AS 
outcome9-13.
To our knowledge, MRGB has not previously been evaluated at AS inclusion. 
Our hypothesis is that combined MP-MRI and MRGB will improve current 
TRUS-guided biopsy based selection of patients for AS by early detection of 
patients harboring intermediate- to high-risk PCa. Therefore, our purpose is 
Abstract
Purpose To evaluate 3-T multiparametric MR imaging (MP-MRI) and 
MR-guided biopsy (MRGB) for early risk re-stratification of patients on active 
surveillance (AS) in the Prostate Cancer Research International Active 
Surveillance (PRIAS) trial.
Materials and Methods Within 4 hospitals participating in PRIAS, a side- 
study was initiated in 66 of 82 consecutively and prospectively included 
patients (2009-2012). Informed consent was obtained and institutional 
review boards approved our study. Pelvic MR imaging, prostate MP-MRI and 
MRGB were performed at 3 and at 12 months after prostate cancer (PCa) 
diagnosis. Cancer suspicious regions (CSR) were defined on MP-MRI using 
PI-RADS scores. Risk re-stratification criteria for AS discontinuance were 1) 
based on MR imaging: histopathologically proven MR imaging suspicion of 
node/bone metastases and/or 2) based on MRGB specimen histopathology: 
Gleason grade 4 and/or 5 and/or a stage ≥ pT3 (cancer invading peri-prostatic 
fat or seminal vesicles) and/or cancer multifocality (≥ 3 foci).
Results Based on MP-MRI and MRGB an additional 24% (15/64) and 10% 
(3/30) of patients were risk re-stratified at 3 and 12 months of follow-up. An 
overall CSR PI-RADS ≤2 had a negative predictive value (NPV) of 84% (38/45) 
and 100% (45/45) for detection of cancer and Gleason 4 and/or 5 PCa upon 
MRGB. A CSR PI-RADS ≥4 had a sensitivity of 92% (11/12) for detection of 
Gleason 4 and/or 5 PCa upon MRGB.
Conclusion Application of MP-MRI and MRGB in AS may contribute in early 
identification of patients with Gleason 4 and/or 5 PCa, while improving the 
selection of AS suitable patients. 
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to evaluate the value of 3-T MP-MRI and MRGB for early risk re-stratification 
of patients on AS in the PRIAS trial.
Materials and Methods
Within 4 reference centers participating in PRIAS, a prospective side-study 
was initiated (MR-PRIAS) consecutively including patients from August 2009 
to March 2012. Patient selection is presented in Figure 1. Patient informed 
consent was obtained for the study as well as for the side-study and institutional 
review boards of the participating hospitals approved our study. Inclusion and 
exclusion criteria are depicted in Appendix 1. In our side-study, patients on AS 
underwent MP-MRI in the second and MRGB in the third month of follow-up 
after initial PCa diagnosis upon systematic TRUS-guided biopsy (time-point 
zero). Initial systematic TRUS-guided biopsy existed of 9-10 cores, sampling 
both the peripheral zone (PZ) and the transition zone (TZ). Part of our patient 
population has been reported earlier14. The earlier paper described the value of 
apparent diffusion coefficient (ADC) values of diffusion-weighted MR imaging 
(DWI) scans for PCa differentiation in PCa on AS. The current study reports on 
overall outcome of incorporating MP-MRI and MRGB in AS and the consequences 
for patient management.
MR imaging
Pelvic MR imaging for lymph node and bone staging (30 min) was followed by 
MP-MRI of the prostate, consisting of T2-weighted MR imaging, DWI and 
dynamic contrast-enhanced MR imaging (DCE-MRI) (40 min protocol). 
Imaging was performed on a 3-T MR system (Trio Tim, Siemens, Erlangen, 
Germany) using a pelvic phased-array and an endorectal coil (ERC) (Medrad, 
Pittsburgh, USA) filled with 40 mL of perfluorcarbon (Fomblin, Solvay-
Solexis, Milan, Italy). DCE- MRI was performed by initial acquisition of 
proton-density weighted images, followed by spoiled T1-weighted gradient 
echoes during fast (2,5 mL/s) intravenous injection of 0,1 mmol of 
gadopentetate dimeglumine (Dotarem, Guerbet, Paris, France) per kilogram 
of bodyweight. MR imaging parameters are presented in appendix 2.
MR imaging interpretation
An experienced radiologist (JOB) with 18 years of experience in prostate MR 
imaging evaluated the MP-MRI examinations on in-house developed Figure 1    Study-flow-diagram showing patient selection
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Follow-up
After 11-12 months of follow-up repeated MP-MRI of the prostate, with 
identical imaging parameters to the initial MR imaging exam, was performed. 
Pelvic nodal and skeletal MR imaging was only repeated when the initial 
exam was suspicious for lymph node or bone metastases. Based on repeat 
MP-MRI, an additional repeated MRGB, similar in procedure to the initial 
MRGB, was performed in a second separate imaging session. After repeated 
MRGB, a repeated TRUS-guided biopsy was also performed later on the same 
day. TRUS-guided biopsy risk re-stratification criteria consisted of PCa 
presence in >2 cores or a GS ≥7 (7). Risk re-stratification criteria for repeat 
MP-MRI and repeat MRGB were conform initial criteria.
Histopathology
All biopsy samples were processed by routine fixation and staining and were 
evaluated by one genitourinary pathologist (CHK) with 19 years of 
experience, who was blinded to prior histopathology results. Gleason 
grading was performed according the consensus of the International Society 
of Urological Pathology in 200521. 
Statistical analysis
Patient risk re-stratification rates were determined for initial and repeated 
MRGB and for repeated TRUS-guided biopsy. Kolmogorov-Smirnov and 
Shapiro-Wilk tests were used to test variables for normality. Parametric 
continuous variables were reported as mean +/- 95% confidence interval, 
whereas and non-parametric continuous variables were reported as median 
and the inter-quartile range. Parametric variables were analyzed using 
independent t-tests and non-parametric variables were evaluated using 
Mann-Whitney U tests. Two-sided Pearson Chi-square tests were used to 
compare proportions. ROC analyses were applied to compare different 
MP-MRI techniques. Analyses were performed using PASW Statistics version 
18 (SPSS Inc. Hong Kong). The threshold for significance was set at P<0.05.
Results
Initial risk re-stratification
Sixty-six patients were included in our side-study and underwent MP-MRI. 
Two patients requested to be excluded from the protocol before MRGB. 
software, while disposing of clinical patient data15. On the software, T2- 
weighted MR imaging, DWI and DCE-MRI were interpreted simultaneously15. 
The PI-RADS system was used to define CSRs16. Every CSR was scored on a 1-5 
point scale for T2-weighted MR imaging, DWI and DCE-MRI separately. 
Subsequently an overall 5 point score, based on the whole MP-MRI exam, was 
given for every CSR17. The five-point scale was defined as 1) highly unlikely 2) 
unlikely 3) equivocal 4) likely 5) highly likely presence of clinically 
significant PCa. PCa staging was performed in compliance with established 
criteria18. When MP-MRI lacked CSRs, AS was continued without performing 
MRGB. 
MR guided prostate biopsy
Only when MP-MRI showed one or more CSRs, another experienced radiologist 
(CMH) with 3 years of experience in MRGB performed MRGB of every predefined 
CSR on a 3-T scanner in a separate examination session (MAGNETOM Skyra, 
Siemens, Erlangen, Germany)16. MRGB was performed for every CSR, regardless 
of CSR PI-RADS scores.
Risk re-stratification 
Risk re-stratification was 1) based on MR imaging by histopathologically 
proven MR imaging suspicion of  node/bone PCa metastases4 and/or 2) based 
on MRGB specimens (of local prostate MR imaging CSRs) using criteria of 
presence of a Gleason grade 4 and/or 5 component4 and/or a stage ≥ pT3 
cancer (cancer invading (peri-prostatic) fat or seminal vesicles)19 and/or 
multifocality of ≥ 3 foci (including foci on initial TRUS-guided biopsies) 
Gleason score ≤3+3 cancer. The latter criterion of cancer multifocality was 
applied to evaluate the number of additionally detected cancer foci after 
including MRGB specimens and to compare it to the PRIAS risk re-stratifica-
tion criterion of > 2 cores with PCa in TRUS-guided biopsy4. An MRGB focus 
located contralateral to the initial TRUS-guided biopsy cancer location or a 
focus in the apex versus the base and vice versa was considered a separate 
cancer focus. Risk re-stratified patients were no longer eligible for active 
surveillance and underwent radical treatment. In order to evaluate cancer 
volume using MRGB, we retrospectively measured maximal cancer core 
length (MCCL): the longest MRGB cancer core length taken from one CSR. A 
MCCL ≥ 6 mm is related to a cancer volume ≥ 0.5cc in RP specimens using 
schematic mapping biopsy20. 
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Patient characteristics of the remaining 64 AS patients are shown in table 1. 
One patient was excluded due to MR imaging suspicion of a bone metastasis 
in his third lumbar vertebra, which upon biopsy appeared to be a metastasis 
from malignancy of unknown origin. MRGB was performed in 62 out of the 63 
remaining patients. In one patient MRGB was not performed, as MP-MRI did 
not show a CSR and this patient remained on active surveillance. In the other 
62 patients, a median of 2 (IQR 1-2) CSRs were present and a median of 4 
MRGB cores (IQR 3-5) were taken. A patient example is illustrated in figure 1. 
Twenty four percent (15/63) of the 63 patients were risk re-stratified and 
thus underwent radical treatment. MRGB and MCCL results are presented in 
table 2.
Sixty percent (9/15) of risk re-stratified patients had an MCCL ≥ 6.0 mm. The 
remaining 48 patients continued AS. Sixty-three percent (30/48) of these 
patients had a cancer-negative MRGB specimen. In 70% (21/30) of these 
patients with a cancer-negative MRGB, prostatitis was present in the histo-
pathology specimen.
Risk re-stratification at 12 months follow-up
In 37 out of 48 remaining patients (77%) a follow-up of 12 months was 
available at July 31st 2012. Of these 37 patients 7 patients did not undergo 
repeat examinations due to other reasons as summarized in figure 1. 
Follow-up MRGB and MCCL results for the remaining 30 patients are presented 
in table 3. Forty-seven percent of these follow-up patients (14/30) were risk 
re-stratified based on MRGB (10% (3/30) MRGB only) and/or TRUS-guided 
biopsy. Forty-three percent (6/14) of risk re-stratified patients had an MCCL 
≥6.0 mm. These fourteen risk re-stratified patients remained undetected on 
initial combined MP-MRI and MRGB. In 4 of these patients the CSR was 
detected on initial MP-MRI. The initial MRGB, however, did not sample 
prostate tissue (n=2) or did not detect small cancers (MCCL 1.5-2 mm) (n=2). 
In the other 10 out of 14 patients small lesions (<0.5 cc) were missed on 
MP-MRI (MCCL 0.3-4.5 mm).
For 14 out of 30 patients with an initial cancer-negative MRGB, repeat 
examinations were available. The negative predictive value (NPV) of a cancer- 
negative MRGB for risk re-stratification at repeat examinations was 79% 
(11/14) with a 95% confidence interval of 52%-93%).
Table 1    Patient characteristics of 64 MP-MRI patients
Characteristic All included patients
(n=64)
Age (years),
Median (IQR)
65.7 (62.1-70.1)
PSA (ng/ml)
Mean (CI)
6.5 (5.99-6.93)
PSA density (ng/ml/cc)
Mean (CI)
0.1 (0.12-0.14)
Prostate volume (cc) Median (IQR) 45.8 (38.0-66.1)
Number previous negative TRUS-GB 
sessions Median (Range) 
0 (0-7)
Total number of  TRUS-GB cores at 
diagnosis, Median (IQR)
10 (9-10)
TRUS-GB to MRI interval in months 
Median (IQR)
2.1 (1.6-2.7)
TRUS-GB to MRGB 
Interval months, median (IQR)
2.7 (2.0-3.3)
Characteristic All included patients #
(Percentage, (fraction), [95% confidence 
interval]
Clinical  stage, 
T1c
T2a
T2b
T2c
 76.6  (49/64), [64.8-85.4]
 18.8 (12/64), [10.9-30.1]
 3.1   (2/64),   [0.2-11.3]
 1.6   (1/64),   [0.0-9.1]
 Positive TRUS-GB cores at diagnosis, 
 1
 2
67.2 (43/64), [55.0-77.5]
32.8 (21/64), [22.5-45.0]
Gleason score at diagnosis,
3+3=6
lower
93.8 (60/64), [84.6-98.0]
6.3   (4/64),   [2.0-15.4]
Prostate volume (#) was the only non-parametric continuous variable. P-values were calculated 
using an independent t-test for parametric, a Mann-Whitney u test for non- parametric variables 
and a Chi-square test for proportions. A p-level <0.05* was considered to represent a significant 
difference. # All patients did not include patients excluded on patient request. However this 
column does include the patient, who was excluded due to a bone metastasis of cancer of 
unknown origin. ^= n=47 MRGB patients + 1 patient without MRGB due to lack of CSRs on 
MP-MRI.  = this column of patients with risk re-stratification does not include the patient who 
was risk re-stratified based on a bone metastasis of unknown cancer origin. SD= standard 
deviation, IQR= inter-quartile range, TRUS- Bx= systematic transrectal ultrasound biopsy, AS= 
active surveillance, PSA= prostate specific antigen, MRI = magnetic resonance imaging, CI= 95% 
confidence interval, MRGB= MR guided prostate biopsy
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In cancer-negative CSRs DCE-MRI was more frequently false-positive (with a 
score of 1-3 points higher than the T2-weighted MR imaging score in 43% 
(46/107)) as compared with DWI (in 32% (33/107), p=0.07). An overall CSR 
PI-RADS ≤2 had a NPV of 84% (38/45) for detection of cancer and a NPV of 
100% (45/45) for detection of a Gleason grade 4 and/or 5 PCa upon MRGB. A 
CSR PI-RADS ≥4 had a sensitivity of 75% (36/48) and of 92% (11/12) for 
detection of cancer and of Gleason grade 4 and/or 5 PCa upon subsequent 
MRGB respectively. Sixty-four percent (69/107) of cancer-negative CSRs had 
an overall PI-RADS ≥3.
MR imaging
MP-MRI evaluation on both 3 and 12 months resulted in a total of 168 CSRs. 
As this study started at the beginning of the PI-RADS implementation, 
PI-RADS scores were available for 155 CSRs. Seventy-eight percent (121/155) 
of CSRs were located in the PZ, 15% (23/155) were located in the TZ or at the 
border of the PZ and TZ or seminal vesicles (7% (11/155)). MRGB specimens 
showed cancer in 48/155 (31%) CSRs. Cancer-negative MRGB specimens 
mainly contained prostatitis in 41% (44/107) and healthy prostate tissue in 
38% (41/107). AUC for PCa and Gleason grade 4 and/or 5 PCa detection using 
overall PI-RADS scores were 0.73 (0.65-0.82) and 0.81 (0.70-0.92) respectively. 
Table 2    Reasons for initial patient risk re-stratification and conversion to 
treatment at 3 months of follow-up
MRGB results:
active surveillance  unsuitable 
patients with risk re-stratification
Number 
(%)
Biopsy core specimen
maximal cancer core 
length in mm
(mean, (95% confidence 
interval))*
MRGB GG 4 or 5 and stage ≥pT3
 
2 (13) 8.8 (7.2-10.4)
≥6 mm: n=2
MRGB GG 4 or 5 5 (31) 9.7 (7.7-11.7)
≥6 mm: n= 4
MRGB Multifocality 2 (13) 4.0 (0.0-7.9)
≥6 mm: n=1
MRGB
2 foci GS 3+3#
4 (25) 4.3 (0.9-7.7)
≥6 mm: n=1
MP-MRI suspicion ≥T3, 
local MRGB: GS 3+3 without extra-
capsular extension#
2 (13) 8.5 (6.5-10.5)
≥6 mm: n=1
Total (% MRGB) 15 (24) 6.9 (4.3-9.5)
≥6mm: n=9
# not conform predefined risk re-stratification criteria, MRGB: MR guided prostate biopsy,  GG: 
Gleason grade, GS: Gleason score, MP-MRI: multiparametric MR imaging, MCCL: maximal cancer 
core length. Calculation of MRGB maximal cancer core length is based on the highest MRGB 
maximal cancer core length for every patient. #= The total amount of 63 patients exists of the 62 
patients undergoing MR guided biopsy and 1 patient not undergoing MR guided biopsy due to 
the lack of CSRs.
Table 3    Reasons for patient risk re-stratification and conversion to 
treatment at repeat examinations at 12 months of follow-up.
Repeat MRGB results:
active surveillance  unsuitable 
patients with risk re-stratification 
at 12 months of follow-up
Number 
(% subtotal risk 
re-stratification 
patients)
MRGB maximal cancer  
core length* in mm
(mean, (95% confidence 
interval))
Both MRGB and TRUS-GB GG 4 and/
or 5
4 (31) 5.3 (3.8-6.8)
≥6 mm: n=2
MRGB GG 4 and/or 5 and TRUS-GB GS 
≤3+3 cancer in >2 cores
1 (8) 4.4 (n.a.)
Only TRUS-GB GG 4 and/or 5 1 (8) 2.7 (n.a.)
TRUS-GB GS ≤3+3 cancer in >2 cores 
and
MRGB multifocality
2 (14) 6.5 (5.5-7.5)
≥ 6mm: n=2
Only MRGB multifocality,
(2 foci, n=1#)
3 (21) 4.2 (1.3-7.0)
≥6mm: n=1
Only TRUS-GB GS ≤3+3 cancer in >2 
cores
3 (23) 5.7 (2.8-8.6) 
≥6mm: n=1
Total 
(%  MRGB)
14 (47) 5.0 (3.0-6.0)
≥6 mm: n=6 
# not conform predefined risk re-stratification criteria. Calculation of MRGB maximal cancer 
core length is based on the highest MRGB maximal cancer core length for every patient, MRGB: 
MR guided prostate biopsy, TRUS-Bx: TRUS-guided biopsy, GG: Gleason grade, GS: Gleason score, 
MP-MRI: multiparametric MR imaging.
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intensity (white arrows) is present in the ventral transition zone at the level of the 
mid-prostate. The inhomogeneous nodular pattern of the transition zone has been 
replaced by a drop-shaped homogeneous low-signal intensity. This cancer suspicious 
region has asymmetry to the right side.
(c) Axial overlay of Ktrans parameter in dynamic contrast enhanced MR imaging (three-
dimensional spoiled gradient echo TR 36 ms, TE 1.4 ms, temporal resolution 3.4 s), as 
calculated by the Tofts model, on the axial T2-weighted turbo spin echo image (TR 
4280 ms, TE 99 ms). Red areas of increased contrast enhancement are present in large 
areas of the prostate. Increased enhancement may be present in case of benign 
prostate hyperplasia, prostatitis and prostate cancer. Also in the right ventral 
prostate (dotted line) increased enhancement is present. Enhancement in this region 
was suspicious for prostate cancer, due to wash-out: a decline at the end of therelative 
gadolinium contrast-to-time curve (d).
(b) Axial apparent diffusion coefficient (ADC) map of diffusion weighted imaging 
(single-shot echo planar imaging, TR 2600 ms, TE 90 ms, b-values 0/50/500 and 800 
s/mm2) at the level of the mid-prostate. A low ADC value of ADC 0.50×10-3mm2/s, 
suspicious for prostate cancer, was present in the right side of the ventral transition 
zone (dotted line).
(d) Axial angulated balanced gradient echo image (TR 4.48 ms, TE 2.24 ms) of the 
needle position in the lesion presented in a-c directly after biopsy. The lesion (green 
dotted line) can be appreciated in the prostate (blue dotted line). The needle artifact 
(white line) is present in the lesion. The needle guide (white arrows) is also depicted. 
The MR guided biopsy specimen (total only 4 cores) contained a Gleason score 4+3=7 
prostate cancer in 80 volume- percent. This patient’s management was subsequently 
redirected towards definitive therapy, which existed of EBRT.
Figure 2    Sixty-one year-old male on active surveillance with a PSA level 
of 7.1 ng/ml, a PSA-D of 0.19 ng/ml/cc and a clinical stage T1c. 
This patient was diagnosed with Gleason score 3+3=6 PCa in  
5 volume-percent in 1 out of 12 cores in the PZ at the right base. 
MP-MRI and 4-core MRGB were performed within 3 months after 
diagnosis.
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in active surveillance did not use MP-MRI and/or MRGB9,11-13,24,25. Our accuracies 
of 73% and 81% for detection of PCa and Gleason grade 4 and/or 5 PCa were 
quite reasonable considering the expected prevalence of predominantly 
lower Gleason grade PCa in this selected AS patient population. Lower Gleson 
grade cancers are known to have lower detection rates compared to higher 
Gleason grade cancers23. 
Upon simultaneous MP-MRI reading, DCE-MRI had more false-positive 
results compared to DWI. DCE-MRI may have false-positive results in case of 
benign conditions like prostatitis and/or benign prostatic hyperplasia26. As 
our study is the first to evaluate MRGB in active surveillance, we applied low 
threshold criteria for CSR determination on MP-MRI followed by biopsy of all 
CSRs, also including equivocal (PI-RADS 1-3) regions. This resulted in a high 
number of patients (48% (30/63)) with cancer-negative CSRs upon MRGB. 
With increasing MR imaging experience in AS patients, false-positive results 
may be reduced. However, within the current explorative phase of MP-MRI 
implementation in AS, an important clinical implication of our study is that 
in AS patients acquisition of histopathology of a MP-MRI CSR is required due 
to the large amount of false-positive CSRs. Lack of histopathologic 
confirmation of a CSR may explain the poor results for MP-MRI as a predictive 
tool for active surveillance outcome in other studies9,12,24,25.
Limitations of this study are firstly its small patient population and secondly 
its limited follow-up. Thirdly, as mentioned earlier, our risk re-stratification 
criteria may have been too strict as patients with multifocal Gleason score 
≤3+3=6 cancer in both MRGB and TRUS-guided biopsy also were risk 
re-stratified. Therefore, our risk re-stratification rates may be inaccurate. 
Fourthly, as MP-MRI studies were read by an experienced radiologist, the 
general applicability of our results may be limited.
Conclusion
Incorporation of MP-MRI and MRGB in patients on AS may be useful as it 
results in early additional risk re-stratification and radical treatment of 
patients with intermediate to high-risk PCa, who were undersampled by 
initial TRUS-guided biopsy. Standardized MP-MRI interpretation using 
PI-RADS reveals that MP-MRI is a promising technique for differentiation 
Discussion
Our initial results show that the application of MP-MRI and MRGB in an AS 
protocol may contribute in early identification of patients with Gleason 
grade 4 and/or 5 PCa, while also improving the selection of AS suitable 
patients. Our initial risk re-stratification rate using MP-MRI and MRGB at 3 
months (24%) is comparable to risk re-stratification rates (17-27%) in studies 
on repeated TRUS-guided biopsy within 3 months after initial diagnosis10,22. 
At 12 months of follow-up, combined MP-MRI and MRGB added little to repeat 
systematic TRUS-guided biopsy, as MRGB only additionally risk re-stratified 
3 patients (21% (3/14)) due to PCa multifocality. Most patients, which were 
risk re-stratified by MRGB also were risk re-stratified by TRUS-guided biopsy. 
Due to TRUS-guided systematic sampling of Gleason grade 2 and/or 3 PCa23 or 
of smal(ler) volume Gleason grade 4 and/or 5 PCa, which may have been 
missed on initial and/or repeat MR imaging, repeated TRUS-guided biopsy 
may have risk re-stratified a similar amount of patients compared with 
MRGB. Fourteen patients with risk re-stratification at repeat examinations 
were missed on initial combined MP-MRI and MRGB. Missing cancers on 
initial MP-MR imaging may be caused by low tumor Gleason grade and/or a 
small volume Gleason grade 4 and/or 5 components23. In general, detected 
cancers at 12 months of follow-up had a lower cancer volume (5.0mm MCCL) 
compared with cancers detected at 3 months of follow-up (6.9mm MCCL).
MP-MRI had a sensitivity of 92% for detection of Gleason grade 4 and/or 5 
PCa in case of higher PI- RADS scores (≥4) and a NPV of 100% for detection of 
Gleason grade 4 and/or 5 PCa in case of lower PI-RADS scores (≤2)). 
Furthermore, an initial cancer-negative MRGB specimen had a NPV of 79% 
for risk re-stratification at 12 months follow-up. These results are comparable 
to those of Vargas et al., who reported an NPV of 96-100% and a sensitivity of 
87-96% for biopsy upgrading in case of an MR imaging score ≤2 and ≥5 for PCa 
presence13. While both scoring systems predicted presence of cancer from 
highly unlikely to highly likely on a 5-point scale, the system used by Vargas 
et al. was based on lower signal intensity on T2-weighted MR imaging and/or 
restricted diffusion on ADC maps, while the PI-RADS system also took shape 
and invasion of surrounding structures into account.
Our results for PCa detection accuracy using MP-MRI and MRGB in patients on AS 
are difficult to compare to literature. Other studies on MRI implementation 
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between AS suitable patients and patients with Gleason grade 4 and/or 5 
PCa, the latter needing radical treatment. However, smaller cancers may be 
missed by MP-MRI and MRGB. Follow-up of our preliminary results of initial 
cancer-negative MRGB specimens showed a NPV of 79% of an initial cancer-
negative MRGB specimen for risk re- stratification after 12 months. This 
finding shows that a cancer-negative initial MRGB may be a promising 
prognostic parameter for active surveillance patient selection. In conclusion, 
application of MP-MRI and MRGB biopsy in AS may contribute in early 
identification of patients with Gleason grade 4 and/or 5 PCa, while also 
selecting AS suitable patients. 
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Chapter 4
GRADING OF PROSTATE CANCER 
USING DIFFUSION-WEIGHTED  
MR IMAGING (DWI)
Chapter 4.1
Diffusion and perfusion  
MR imaging of the prostate
Diederik M. Somford, Jurgen J. Fütterer, Thomas Hambrock, 
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Introduction 
MR imaging plays an important role in the initial detection, localization, 
and staging of prostate cancer (PCa) and the assessment of post-treatment 
changes in PCa. In the near future, more image-guided techniques will 
become available, permitting precise biopsies and targeted focal treatment. 
Accurate and detailed information on tumor localization and size is needed 
to perform these image-guided interventions and therapies optimally. This 
article focuses on the role of diffusion-weighted MR imaging (DWI) and 
dynamic contrast-enhanced (DCE) MR imaging (or perfusion-weighted MR 
imaging) of the prostate. Background aspects and the clinical usefulness of 
DWI and DCE-MRI imaging for assessment of prostate cancer are reviewed.
Diffusion-Weighted MR Imaging
Diffusion and Prostate Cancer
Water molecules exhibit random motion in tissue, related to temperature 
(Brownian effect)1. DWI can quantify this water motion in an indirect 
manner2,3. The DWI pulse sequence labels hydrogen nuclei in space, of which 
most is water molecules at any moment, and determines the length of the 
path that water molecules travel over a short period of time. DWI estimates 
the mean distance traveled by all hydrogen nuclei in every voxel of imaged 
tissue. The greater this mean distance the more self-diffusion of water 
molecules has occurred in a certain time interval4. The degree of restriction 
to water diffusion in biologic tissue is inversely correlated to tissue 
cellularity and the integrity of cell membranes. Free motion of water 
molecules is more restricted in tissues with a high cellular density. The 
sensitivity of the DWI sequence to water motion can be varied by changing 
the gradient amplitude, expressed as the b-value. By performing DWI using 
different b-values, quantitative analysis can be made to determine the 
apparent diffusion coefficient (ADC).
In a volume of pure water this self-diffusion is equal in all directions, hence 
isotropic, and not restricted by any barrier. Because diffusion in tissue is 
limited by cellular structures, to establish a reliable estimate of this mean 
distance traveled by hydrogen nuclei, DWI is acquired in at least three 
different orthogonal directions for each b-value4,5. This phenomenon of 
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extracellular water molecules have a far higher range of self-diffusion 
because they are not bound within membranes or by other cellular 
structures10,11. When this is translated to prostate tissue, which is 
predominantly glandular tissue, the predominant contribution of the 
extra-cellular component is from tubular structures and their fluid content, 
whereas the intracellular component is determined by the epithelial and 
stromal cells. Fractional anisotropy is determined along the axis of the 
tubular structures of normal prostate tissue. A prerequisite for the correct 
interpretation of diffusion and ADC images relies on good knowledge of the 
diffusion characteristics of the different anatomic zones of the prostate and 
of benign prostatic conditions compared with prostate cancer12.
The normal prostatic gland is rich in tubular structures. This allows for 
abundant self-diffusion of water molecules within their contents and 
provides high ADC values. In most cases, the peripheral zone can be easily 
discriminated from the central gland on DWI, because it displays relative 
higher ADC values13-15. The exact background of this phenomenon remains 
unclear, because the exact ratio of extracellular to intracellular components 
for the different anatomic zones of the prostate has not yet been described. 
The central gland by observation consists of more compact smooth muscle 
and sparser glandular elements than the peripheral zone (PZ), however, 
leading to lower extracellular to intracellular fluid ratio16. Furthermore, an 
age-related increase of T2 signal intensity of the PZ compared with the 
central gland has been observed17, and an age-related increase in ADC values 
in both central gland and PZ has been observed15, which are most likely 
caused by atrophy in the prostate leading to reduced cell volume and enlarged 
glandular ducts.
Benign prostatic hyperplasia (BPH) gives rise to nodular adenomas in the 
transition zone (TZ) and with time these compress the central zone to form a 
pseudocapsule, occupying the complete central gland. The PZ is usually not 
affected by BPH and retains its own histologic characteristics. BPH is 
defined by hyperplasia of all cells that constitute the TZ, with glandular, 
muscular, and fibrous compartments more or less evenly involved. This 
nodular hyperplasia gives rise to inhomogeneous diffusion patterns and 
because tubular structures often remain in place, the increased cellular 
density of hyperplasia, which is far less predominant than in PCa, might 
explain the observed reduction in ADC levels of the TZ on DWI, because of 
varying restriction of self-diffusion along different axes is called 
‘‘anisotropy’’ and can also be used for tissue characterization. As in linear 
aligned tissue this anisotropy is more pronounced because there is one 
direction that contributes most to the DWI. Diffu- sion tensor imaging is a 
specific technique that quantifies the level of anisotropy in tissue, expressed 
in a fractional anisotropy value. This is low in imaged tissue without 
substantial anisotropy and is higher in imaged tissue in which the larger 
part of diffusion takes place in one direc- tion5,6. Diffusion tensor imaging 
can be used in addition to DWI to determine the structural organization of 
tissue along which diffusion takes place.
DWI typically has T2- and diffusion-weighted characteristics. The intensity 
of the signal on the diffusion-weighted image represents a combination of 
signal from the T2 relaxation and the dephasing caused by water motion in 
the presence of the diffusion gradients. At low b-values there is greater 
contribution from the T2 signal, and at higher b-values contrast is 
determined more by relative diffusion7. When a diffusion image is bright 
because of high T2 signal rather than restricted diffusion, it is known as ‘‘T2 
shine-through’’ effect. ADC maps should be obtained with at least two 
b-values to correct for the T2 shine-through effect, typically a low b-value, 
between 0 and 50 s/mm2, and a high b-value. Tissue microperfusion can 
contaminate the signal attenuation in DWI acquisition, which could be 
de-creased by using an additional low b-value greater than 0 (eg, b=50 s/
mm2) and a high b-value.
To minimize the influence of bulk motion as a distorting factor and 
minimizing T2 shine-through, typically a TE as short as possible is chosen. 
Typical sequence parameters for the prostate (as used in the authors’ 
institution) include TR 2600 milliseconds; TE 91 milliseconds; and b-values 
of 0, 50, 500, 800 s/mm2 in three orthogonal directions with parallel imaging 
(see appendix 2).
Diffusion-Weighted MR Imaging Characteristics of  
Prostate Tissue
DWI was initially used for the early detection of cerebral ischemia8. The 
evolution of DWI characteristics in cerebral ischemia over time has classically 
been attributed to the extracellular to intracellular distribution of hydrogen 
nuclei caused by different types of edema9. It has been postulated that 
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details exceptionally well with high resolution23. T2-weighted imaging is 
also helpful for zonal delineation between the PZ (high T2 signal) and the TZ 
(intermediate and inhomogeneous T2). In addition, T2-weighted imaging is 
necessary for a correct interpretation of ADC mapping. The typical nodular 
appearance of BPH on T2-weighted imaging helps in discriminating BPH 
from PCa on DWI, which both can present with decreased ADC. For localization 
of PCa T2-weighted MR imaging reaches fair sensitivity levels between 54% 
and 81%, with lower specificity levels, ranging from 46% to 61%, depending 
on the series24,25. When used as a staging tool, T2-weighted imaging has a 
lower performance. The addition of MR spectroscopy and DCE-MRI may 
decreased ratio of extracellular to intracellular volume. Because BPH has 
inhomogeneous diffusion characteristics, however, an increase in ADC also 
has been observed18.
Prostatitis almost uniquely originates in the PZ. With respect to MR imaging, 
chronic prostatitis is of far more importance than the acute prostatitis 
counterpart because it is asymptomatic in many cases or its symptoms might 
mimic BPH, often associated with elevated prostate specific antigen (PSA) 
levels, raising the suspicion of PCa. Histologically, chronic prostatitis is 
characterized by extracellular edema surrounding the involved prostatic cells 
with concomitant aggregation of lymphocytes, plasma cells, macro- phages, 
and neutrophils in the prostatic stroma. This abundance in cells as compared 
with normal prostatic tissue may lead to an ADC decrease because of decreased 
extracellular to intracellular fluid volume ratio. To the authors’ knowledge, no 
reports are available on the DWI characteristics of chronic prostatitis.
PCa is histologically characterized by a higher cellular density than normal 
prostate tissue, with replacement of the normal glandular tissue. This leads 
to a decrease in ADC values, compared with normal prostate gland (Fig. 1)12,19. 
Concomitantly with destruction of tubular structures in PCa, fractional 
anisotropy is also reduced20,21. Interestingly, whereas well-differentiated 
PCa displays some tubular formation, with worsening differentiation the 
tubular structures become less predominant, and the cellular component of 
the cancer increases.
Diffusion-Weighted MR Imaging in Addition to T1- and 
T2-Weighted MR Imaging
One of the main drawbacks of DWI of the prostate is its suboptimal spatial 
resolution, even with currently widely available 3-T MR imaging scanners, 
combining pelvic phased array surface coil in combination with an endorectal 
coil for signal reception. T1-weighted imaging has a very limited role for the 
zonal delineation of the prostate and for tumor detection. The main 
usefulness of T1-weighted imaging is for the detection of post-biopsy 
hemorrhage, which can cause restricted diffusion, a possible confounding 
factor for both T2-weighted images and DWI22.
T2-weighted imaging is currently the most widely used sequence for 
localization and staging of prostate carcinoma because it depicts anatomic 
Figure 1    A 52-year-old man with prostate cancer of the left peripheral 
zone imaged at 3-T 
(A) Axial T2-weighted MR image showing the presence of a low signal intensity area 
(white arrows) in the left peripheral zone. (B) ADC map at the same level as in figure A 
shows decreased ADC compared with the normal peripheral zone (black arrows). 
Whole-mount section histopathology (C) confirmed the findings and showed a tumor 
with Gleason Score of 3+3=6 (red area).
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DWI might have potential for grading of PCa. The histopathologic Gleason 
score remains one of the most important prognostic factors for progression-
free and disease-specific survival in prostate cancer33–37. It is known that 
Gleason score obtained with transrectal ultrasound (TRUS)-guided biopsies 
can underestimate the final Gleason score obtained at radical prostatectomy 
(RP) in a substantial number of patients38–40. With evolving therapeutic 
options to consider in patients with localized PCa, accurate pretreatment 
grading for clinical decision making is of paramount importance. These 
therapies range from active surveillance (AS) to minimally invasive therapies, 
such as cryotherapy and high-intensity focused ultrasound, to radical 
therapies, such as RP in all its forms, brachytherapy, and external beam 
radiation therapy. Wang and colleagues41 investigated the ability of MR 
imaging to grade PCa. They found that higher Gleason grades were associated 
with lower tumor-muscle signal intensity ratios on T2-weighted imaging. 
Hypothetically, DWI has far more potential than any other MR imaging 
sequence in grading of PCa, because increased cellular density and loss of 
tubular structures implicate a higher Gleason score and also seriously hamper 
self-diffusion in the involved tissue leading to lower ADC levels on DWI12.
Few reports have been published on the detection of metastasis of PCa using 
DWI and currently this technique is not used for this purpose. One report by 
Nakanishi et al.42 did not show convincing superiority of DWI over skeletal 
scintigraphy for detection of osseous metastasis in a heterogeneous group of 
malignancies, 9 out of 30 being PCa patients. Skeletal scintigraphy still 
remains the gold standard for detection of osseous metastasis in prostate 
cancer. This is supported by a recent report on patients who underwent 
cerebral MR imaging including DWI, in which DWI proved insensitive to skull 
metastasis of PCa when compared with skeletal scintigraphy43. No significant 
reports on the detection of lymph node metastasis in prostate cancer have 
been reported to the authors’ knowledge.
Technical Considerations in 3-T Diffusion-Weighted MR 
Imaging of the Prostate
3-T systems, which are increasingly available, provide improved signal-to-
noise ratios, with improved spatial and temporal resolution compared with 
1.5-T systems44. Functional MR imaging methods, such as MR spectroscopy, 
DCE-MRI and DWI, will likely benefit from 3-T systems, because those have so 
far been hampered by limited resolution45. T2-weighted imaging, which has 
improve the staging performance26,27, mostly because of the improved 
localization, and thereby better evaluation of the prostatic capsule on 
T2-weighted images.
Clinical Applications of Diffusion-Weighted MR Imaging for 
Prostate Carcinoma
Recently, several reports on the use of DWI in patients with PCa, using 
endorectal or phased array coils have been published, with recent reports on 
the use of 3-T systems, proving that the clinical use of DWI is possible. The 
described diffusion acquisition parameters differ, however, mostly regarding 
the use of different b-values. This makes comparison between different 
reports difficult, but a clear identifiable trend in performance is present.
Several small studies have shown that PCa displays significantly lower ADC 
values compared with benign prostatic tissue19,21,28,29, making it a potential 
useful measure for the localization of PCa. In various reports, mean ADC 
values range between 1.30 and 1.35x10-3 mm2/s for malignant prostate 
tissue and 1.60 and 1.96x10-3 mm2/s for benign tissue, including PZ and 
central gland14,21,28. DWI seems to perform better in localization of PCa 
compared with T2-weighted imaging13,30. At 1.5-T, T2-weighted imaging 
yielded sensitivities of 50% to 73%, whereas DWI yielded sensitivities of 73% 
to 84%, with only slightly reduced or comparable specificity. These results 
suggest a potential role of DWI in localization of PCa, especially in 
combination with T2-weighted imaging14,25,31,32. Because of the higher 
baseline ADC of the PZ, DWI performs best in differentiation of PCa from 
normal PZ in which more than 70% of the tumors originate. Compared with 
normal TZ ADC levels, PCa ADC levels are significantly lower14,18.
Because of lack of spatial resolution, DWI alone is not very useful in staging 
of PCa and lags behind conventional T2-weighted imaging. Like other 
advanced MR imaging techniques, however, such as DCE-MRI and MR 
spectroscopy, DWI draws attention to cancer suspicious regions (CSR) and 
this may help the radiologist in identifying regions of interest for local 
staging. Even with increasing spatial resolution caused by improved 
acquisition techniques the value of DWI alone in staging of PCa remains 
limited, but improves localization of lesions in combined reading with 
conventional and other functional MR imaging sequences. To the authors’ 
knowledge, no reports have yet been published on this subject.
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types51. Circulating endothelial progenitor cells derived from bone marrow 
are recruited to sites of active angiogenesis by tumor-derived growth factors, 
such as vascular endothelial growth factor52. The angiogenic process in PCa 
is highly dependent on vascular endothelial growth factor. Concomitantly, 
Jackson and colleagues53 detected vascular endothelial growth factor in 
tumor cells and peritumoral stromal cells of PCa specimens and in 
nonmalignant glandular epithelial cells and interglandular stromal cells in 
BPH specimens. With respect to the vasculature, it is clear that vascular 
endothelial growth factor is required for vascular homeostasis in BPH, and 
the overproduction of vascular endothelial growth factor maintains a high 
fraction of immature vessels (those without investigating pericytes or 
smooth muscle cells) in PCa51,53,54.
A number of features are characteristic of malignant vasculature, many of 
which are amenable to study by DCE-MRI imaging and DWI techniques. These 
include (1) spatial heterogeneity and chaotic structure; (2) poorly formed 
fragile vessels with high permeability to macromolecules because of the 
presence of large endothelial cell gaps, incomplete basement membrane, and 
relative lack of pericytes or smooth muscle association with endothelial 
cells; (3) arteriovenous shunting; (4) intermittent or unstable blood flow; 
and (5) extreme heterogeneity of vascular density, with areas of low vascular 
density mixed with regions of high angiogenic activity51.
These tumor-induced vascular and structural abnormalities result in 
functional impairments that are important to DCE-MRI observations. These 
include (1) increased interstitial pressure as a result of increased vascular 
permeability and poor lymphatic drainage, resulting in an enlarged 
interstitial space; (2) the transcapillary permeability is increased, allowing 
a more rapid exchange of low-molecular-weight contrast agents; and (3) the 
total vascular cross-sectional area may increase and can be combined with 
arteriovenous shunts. This gives rise to increased blood flow overall. The 
global increase in flow in cancers causes the bolus of contrast agent to arrive 
just a little earlier than it does in surrounding normal tissue. In the prostate, 
differences in arrival time between normal and abnormal tissues are short51.
Dynamic Contrast-Enhanced MR Imaging of the Prostate
DCE-MRI is a noninvasive method to probe tumor angiogenesis. DCE-MRI 
following the administration of low-molecular-weight contrast media (<1 
been performed at 1.5-T for years with fair results, also has been proved to 
benefit; however, the window of improvement, as far as signal-to-noise ratio 
and spatial resolution is concerned, is much smaller. The authors’ experience 
is that improved spatial resolution with the use of DWI at 3-T improves zonal 
and tumor delineation and allows improved ability to compare ADC mapping 
with whole-mount sectioned RP specimens for research purposes. It has 
been shown that use of an endorectal coil significantly improves imaging 
quality in T2-weighted imaging. Rectal gas in the absence of an endorectal coil 
may lead to susceptibility artifacts46. The endorectal coil enables better 
staging performance and improves sensitivity for the localization of prostate 
carcinoma with conventional MRI47,48. In the authors’ experience, the use of an 
endorectal coil in conjunction with surface coils and parallel imaging improves 
image quality of DWI. This may result in improved overall performance of DWI 
in the localization, characterization, and delineation of PCa.
Limitations of DWI in PCa remain its low spatial resolution, which can be 
overcome by using this technique in combination with conventional 
T2-weighted MR imaging at 3-T by projecting the ADC maps as color overlay 
images on T2-weighted images. Furthermore, DWI is very susceptible to 
motion artifact, but when using a combination of surface and endorectal 
coil, these facilitate shortened imaging time and the use of a lower TE, while 
concomitantly improving image quality by diminishing susceptibility 
artifact from gas in the rectum.
Dynamic Contrast-Enhanced MR Imaging
Angiogenesis and Prostate Cancer
For a tumor, one critical factor that affects development, growth, 
invasiveness, and progression into the metastatic form is the ability of the 
tumor to generate new blood vessels. Angiogenesis, the sprouting of new 
capillaries from existing blood vessels, and vasculogenesis, the de novo 
generation of new blood vessels, are the two primary methods of vascular 
expansion by which nutrient supply to tumor tissue is adjusted to match 
physiologic needs49. Tumor growth beyond 1 to 2 mm in solid tissues cannot 
occur without vascular support50. The importance of angiogenesis in PCa is 
well established. The angiogenic process is a complex multistep sequence 
involving many growth factors and interactions between varieties of cell 
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Concentration-time curves are mathematically fitted by using one of many 
described pharmokinetic models, and quantitative kinetic parameters are 
derived. These include (1) transfer constant of the contrast agent (Ktrans); (2) 
rate constant (kep); and (3) interstitial extravascular extracellular space 
(Ve)
60. Uncertainties exist with regard to the reliability of kinetic parameters 
estimates derived from the application of kinetic models to T1-weighted 
DCE-MRI datasets. The vascular input function used in the calculations also 
affects the reliability of the data obtained. Robust methods for measuring 
the arterial input function are essential. Currently, these methods are 
emerging but are still not widely available61.
Currently, there are no FDA-approved DCE-MRI post-processing software 
packages available. Every institution is using its own developed software for 
analyzing these large datasets. Some companies are developing these 
packages for data evaluation; however, too little data are available for 
discussion. Furthermore, quantitative evaluation of the kinetic parameters 
has not been performed. There are no thresholds available, like in MR 
spectroscopy, for differentiation between benign and malignant tissue. This 
is probably caused by the inter-patient variability (variable vascular anatomy, 
atherosclerosis, cardiac output). Almost all imaging data in literature are 
evaluated based on qualitative assessment rather than quantitative thresholds.
Functional dynamic imaging parameters are estimated as follows: each MR 
imaging signal enhancement–time curve is first fitted to a general 
exponential signal intensity model. Consequently, the curve is reduced to a 
model with five parameters (t0, time-to-peak, peak enhancement, and 
washin-washout gradient or plateau). The reduced signal enhancement–
time curve is converted to a reduced tracer concentration–time curve (with 
the tracer concentration in millimoles per milliliter) such that peak 
enhancement is effectively converted to gadolinium concentration. In the 
authors’ institution, the reduced plasma concentration–time curve is 
estimated by using a reference tissue method. Deconvolution of the plasma 
profile and estimation of the pharmacokinetic parameters conformed to the 
theoretic derivations but are implemented in the reduced signal space as 
Ktrans=Ve x kep, where Ve is an estimate of the extracellular volume (expressed 
as a percentage); Ktrans is the volume transfer constant (1 per minute); and kep 
is the rate constant (1 per minute) between the extracellular extravascular 
space and the plasma space.
kd) is the most common imaging method for evaluating human tumor 
vascular function in vivo55. Insights into these physiologic processes are 
obtained qualitatively by characterizing kinetic enhancement curves or 
quantitatively by applying complex compartmental modeling techniques56. 
Data reflecting the tissue perfusion (blood flow, blood volume, and mean 
transit time), the microvessel permeability, and the extra-cellular leakage 
space can be obtained.
MR imaging sequences can be designed to be sensitive to the vascular phase 
of contrast me- dium delivery, so-called ‘‘susceptibility-weighted (T2*- 
weighted) DCE-MRI’’, which reflects tissue perfusion and blood volume; or to 
the presence of contrast agent, so-called T1-weighted DCE-MRI, which 
reflects the perfused microvessel area, permeability, and extravascular 
extracellular leakage space57,58. Only the latter technique is discussed 
because this is by far the most common method used. Low-molecular-weight 
extravascular and extracellular contrast agents (gadolinium chelates) 
shorten the T1 relaxation of water and results in an increase in signal 
intensity on T1-weighted MR images. One essential aspect of DCE-MRI 
includes the dynamic MR imaging, referring to the temporal component, 
with complete coverage of the prostate with a fast T1-weighted sequence, 
which is required before, during, and after the bolus injection of a low-mo-
lecular-weight contrast agent (see Appendix 2, DCE-MRI protocol). DCE-MRI 
findings are related to differences in microvascular characteristics observed 
between normal and malignant prostatic tissues51. The obtained T1-weighted 
DCE MR imaging data can be assessed in two ways.
The first is a semi-quantitative approach describing signal intensity changes 
by using a number of parameters, such as (1) the onset time of the signal 
intensity curve (t0=time from appearance in an artery to the arrival of 
contrast agent in the tissue of interest); (2) the slope and height of the 
enhancement curve (time-to-peak); (3) maximum signal intensity (peak 
enhancement); and (4) wash- in-washout gradient or plateau phase59. These 
parameters are limited by the fact that they may not accurately reflect 
contrast agent concentration in tissues and can be influenced by the MR 
imaging scanner settings (including gain and scaling factors).
The second is a quantitative approach using pharmokinetic modeling, which 
is usually applied to changes in the contrast agent concentrations in tissue. 
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additional value of DCE-MRI in local staging, such imaging does seem to 
improve local staging performance. With the use of DCE-MRI the staging 
performance of the less experienced showed a significant improvement of 
the AUC compared with T2-weighted imaging alone (0.66 and 0.82, 
respectively; p<0.01)48.
The application of DCE-MRI for detection of local recurrence after RP or 
external beam radiation therapy is increasingly being used. Haider and 
colleagues64 found that DCE-MRI performs better than T2-weighted imaging 
for the detection and localization of PCa in the PZ after external beam 
radiotherapy. DCE-MRI had significantly better sensitivity (72% versus 
38%), positive predictive value (PPV) (46% versus 24%), and negative 
predictive value (NPV) (95% versus 88%) compared with T2-weighted 
imaging. Sciarra et al.65 reported the use of DCE-MRI and MR spectroscopic 
imaging for the detection of local recurrence in patients post-RP, and they 
concluded that the combination of these techniques is accurate for 
identification of local prostate cancer recurrence with biochemical failure 
(87% sensitivity and 94% specificity). This information could be helpful in 
the planning of salvage therapy.
Current research and focuses for the furure  
in diffusion-weighted MR imaging and dynamic 
contrast-enhanced MR imaging of the prostate 
The technical feasibility of DWI and DCE-MRI techniques for prostate 
imaging is now well established. Current and future research should focus 
on the additive values of DWI and DCE-MRI to conventional and other MR 
imaging techniques of the prostate.
The performance of prostate DWI and DCE-MRI is likely to gain from comput-
er-assisted diagnosis66. The combination of the quantitative functional data 
makes these techniques very suitable for computer analysis and prospective 
malignancy likelihood calculations. It was recently shown in 18 patients 
imaged at 3-T, that computer-assisted diagnosis software had a good 
diagnostic accuracy of discriminating normal from malignant prostate 
tissue with an AUC of 0.77 for DWI alone. For differentiation between PCa and 
normal PZ the AUC reached 0.89, whereas for differentiation from normal TZ 
the AUC was limited to 0.64. This is in concordance with other reports13,14,30,32. 
Clinical Application of Dynamic Contrast-Enhanced MR 
Imaging for Prostate Carcinoma
A fair number of studies have been performed to assess the value of DCE-MRI 
in PCa. Hara et al.62 showed that DCE-MRI was able to detect clinically 
important PCa in 93% of the cases, with TRUS-guided biopsy as the gold 
standard. In patients with at least two negative TRUS-guided biopsy sessions 
and rising PSA level, MR imaging plays an important role63.
DCE-MRI is of importance in localization and staging of PCa (Fig. 2); several 
studies have found that DCE MRI is superior to T2-weighted MR imaging for 
PCa localization. The authors’ group showed in a recent study that the area 
under the ROC-curve (AUC) for localizing PCa increased significantly from 
0.68 with T2-weighted imaging to 0.91 when adding DCE-MRI26. DCE-MRI is 
less accurate in the localization of tumor within the TZ, whereas PZ 
localization is markedly improved. Although the literature is sparse on the 
Figure 2    68-year-old man with prostate cancer of the right peripheral 
zone
(A) Axial T2-weighted MR image shows a low signal intensity area in the right 
peripheral zone. Color parametric maps were calculated (B) and demonstrated 
increased washout in the right peripheral zone, (C and D) increased Ktrans and kep. (E) 
ADC map at the same level as in image A shows reduced ADC compared with the normal 
peripheral zone. (F) Histo- pathology confirmed these findings and showed a tumor 
with Gleason Score of 4+3=7 (red area).
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Introduction
Gleason grade of prostate cancer (PCa) is an important determinant of 
biologic activity and aggressiveness. A vast body of literature has established 
the Gleason grade as one of the paramount pathologic factors in the 
prediction of disease outcome in PCa. In fact, the grading scheme has now 
become so vital that it is often used as an integral piece of information for 
both disease management and treatment stratification in patients with 
prostate cancer before and after definitive therapy1-5. Pretreatment 
knowledge of the final Gleason grade would be an important advance; 
however, such information remains elusive. Biopsy determination of Gleason 
grade often does not provide an accurate reflection of final Gleason grade 
(ie, whole-organ pathologic characteristics)6-8. Partin tables and risk 
stratification schemes9,10 that incorporate information from biopsy-deter-
mined Gleason grades into decision making are therefore rendered less 
accurate and less reliable. There is a definite need for a noninvasive method 
with which to improve the accuracy in determining the true Gleason grade 
before treatment.
Diffusion-weighted MR imaging (DWI) is a functional imaging technique 
that quantifies random Brownian motion properties of water molecules 
(diffusion) in tissue. The degree of restriction to water diffusion in biologic 
tissue is inversely correlated to tissue cellularity and the integrity of cell 
membranes11. Diffusion of molecules also occurs across tissues, especially 
from areas of restricted diffusion to areas with free diffusion. The net 
displacement of molecules is called the apparent diffusion coefficient (ADC). 
With MR imaging, the ADC can be calculated by acquiring two or more images 
with a different magnetic field gradient duration and amplitude (b value). 
The contrast in the ADC map is dependent on the spatially distributed 
diffusion coefficient of the acquired tissues and does not contain T1 and T2* 
values12. The role of DWI in tumor localization within the prostate has been 
extensively reported13-16. However, its use in stratifying low- and high-grade 
PCa has not received much attention and is limited to biopsy-determined 
Gleason grades17,18.
The purpose of our study was to determine the relationship between ADCs 
obtained with 3-T DWI and Gleason grades for peripheral zone (PZ) PCa.
Abstract
Purpose  To retrospectively determine the relationship between apparent 
diffusion coefficients (ADC) obtained with 3-T diffusion-weighted MR 
imaging (DWI) and Gleason grades in peripheral zone (PZ) prostate cancer 
(PCa).
Materials and Methods The requirement to obtain institutional review board 
approval was waived. Fifty-one patients with prostate cancer underwent MR 
imaging before radical prostatectomy (RP), including DWI with b values 
of 0, 50, 500, and 800 sec/mm2. In RP specimens, separate slice-by-slice 
determinations of Gleason grade groups were performed according to 
primary, secondary, and tertiary Gleason grades. In addition, tumors were 
classified into qualitative grade groups (low-, intermediate-, or high-grade 
tumors). ADC maps were aligned to step-sections and regions of interest 
annotated for each tumor slice. The median ADC of tumors was related to 
qualitative grade groups with linear mixed-model regression analysis. The 
accuracy of the median ADC in the most aggressive tumor component in the 
differentiation of low- from combined intermediate- and high-grade tumors 
was summarized by using the area under the ROC curve (AUC).
Results In 51 RP specimens, 62 different tumors and 251 step-section tumor 
lesions were identified. The median ADC in the tumors showed a negative 
relationship with Gleason grade group, and differences among the three 
qualitative grade groups were statistically significant (p<.001). Overall, 
with an increase of one qualitative grade group, the median ADC (±standard 
deviation) decreased 0.18 × 10-3 mm2/s ± 0.02. Low-, intermediate-, and 
high-grade tumors had a median ADC of 1.30 × 10-3 mm2/s ± 0.30, 1.07 × 10-3 
mm2/s ± 0.30, and 0.94 × 10-3 mm2/s ± 0.30, respectively. ROC analysis showed 
a discriminatory performance of AUC=0.90 in discerning low-grade from 
combined intermediate- and high-grade lesions.
Conclusion ADCs at 3-T showed an inverse relationship to Gleason grades in PZ 
PCa. A high discriminatory performance was achieved in the differentiation of 
low-, intermediate-, and high-grade PCa.
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marked with ink by using three different colors, after which the entire 
prostate specimen was cut into serial transverse 4.0-mm-thick slices perpen- 
dicular to the dorsal-rectal surface. All slices were macroscopically 
photographed with a charge-coupled device camera. The apex and base were 
sliced sagittally to assess the caudal and cranial surgical margins. Seminal 
vesicles were amputated at their junction with the pros- tate, sliced parallel 
to their junction, and embedded in total. The remaining slices were 
subdivided into halves or quadrants to fit routine cassettes. After histologic 
staining, all specimens were evaluated by one expert urological pathologist 
(CHK), with 17 years of experience. Tumors were outlined on the microscopic 
slides and subsequently mapped on the macroscopic photographs to allow 
reconstruction of tumor extent and multifocality. Each individual tumor 
was graded according to the 2005 International Society of Urological 
Pathology Modified Gleason Grading System19. Tumors were staged according 
to the 2002 TNM classification, see appendix 3.
Annotations of MR Images
Retrospectively, after RP, annotations of MR images were performed in 
consensus by one radiologist (TH) and one urologist (DMS). To achieve good 
objective spatial coalignment accuracy, a number of strategies were applied. 
First, both ADC maps and RP step-sections were obtained perpendicular to 
the dorsal surface of the prostate. Second, the section and slice thicknesses 
used were similar. Third, objective mapping of MR sections to RP step-sections 
was performed by aligning the apex and base on MR images and step-sections 
in the cranial-caudal direction (Fig 1a). Starting from the apex, each 
consecutive ADC map was matched to the consecutive pathologic step- 
section. Finally, a per-slice subdivision was made. The PZ and transition 
zone (TZ) were identified on each slice and, with use of the urethra as 
reference, the PZ in both left and right halves was subdivided into the 
anterior horns, dorsolateral region, and dorsal segment (Fig 1b). The PZ, TZ, 
and urethra are well visible on ADC maps, allowing the schematic subdivision 
to be performed on ADC maps as well. The urethra again served to help 
identify the anterior horns, dorsolateral region, and dorsal segment. This 
schematic mapping allowed objective translation of tumor-containing 
regions from RP to ADC maps with a high degree of certainty.
A region of interest (ROI) was annotated and drawn to match the size and 
extent of the tumor determined from histologic examination as closely as 
Materials and Methods
Patients
Between August 2006 and January 2009, 70 consecutive patients with biopsy- 
proved prostate cancer, who were scheduled to undergo radical prostatectomy 
(RP), were referred from the departments of Urology at the Radboud University 
Nijmegen Medical Centre and the Canisius Wilhelmina Hospital in Nijmegen, 
The Netherlands, for clinically routine preoperative MRI of the prostate. The 
requirement to obtain institutional review board approval was waived.
MR Imaging Protocol
MRI was performed by using a 3-T MR system (Trio Tim; Siemens, Erlangen, 
Germany) and both an endorectal coil (Medrad, Pittsburgh, Pa) and a pelvic 
phased-array coil. The endorectal coil was filled with a 40-mL perfluorocar-
bon preparation (Fomblin; Solvay-Solexis, Milan, Italy). Peristalsis was 
suppressed with intramuscular administration of 20 mg of butylscopolamine 
bromide (Buscopan; Boehringer- Ingelheim, Ingelheim, Germany) and 1 mg 
of glucagon (Glucagen; Nordisk, Gentofte, Denmark).
After the correct endorectal coil position was confirmed with fast gradient- 
echo imaging, T2-weighted turbo spin- echo MRI was performed with the 
following parameters: in-plane resolution of 0.4×0.4 mm, repetition time of 
3250 msec and echo time of 116 msec (3250/116), 120° flip angle, 15–19 
sections, 3.0-mm-thick sections, echo train length of 15, 180×180-mm field 
of view, and 448×448 matrix; imaging was performed in transverse, coronal, 
and sagittal planes, covering the prostate and seminal vesicles. Then, 
single-shot echo-planar imaging was performed with diffusion-module and 
fat-suppression pulses. Water diffusion in three directions was measured by 
using b values of 0, 50, 500, and 800 s/mm2, 2500/81, a parallel imaging 
factor of three, 15–19 sections, 3-mm-thick sections, and an in-plane 
resolution of 1.5×1.5 mm. ADC maps were automatically calculated by the 
imager software with use of all four b values.
Reconstructed Whole-Mount Step-Section Preparation
After RP, prostate specimens were uniformly processed and entirely submitted 
for histologic investigation. Immediately after surgical resection, specimens 
were fixed in 10% neutral buffered formalin by using fine-needle formalin 
injections and stored overnight. Subsequently, the entire surface was 
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section if the corresponding pathologic step-section revealed a tumor 
smaller than 5 3 5 mm. This was due to the limit in spatial resolution of the 
DWI images. (b) Normal contralateral ROI of a particular section if the tumor 
extended beyond the midline (no mirror ROI possible) or if a second tumor 
was present in the mirror position of the first tumor.
possible (Fig 1). ROIs were also placed in the contralateral segment of the PZ 
in mirror position to the tumor and were similar in size to the tumor ROIs. 
Normal regions were annotated purely to provide a visual reference of 
heterogeneity within the PZ compared with tumor values. Each separate 
step-section–ADC section match was annotated as a different tumor ROI and 
normal ROI. Only tumors originating in the PZ were annotated. Annotation 
of the following was omitted if applicable: (a) tumor ROI for a particular 
Figure 1    (a) Images illustrate the systematic method used to obtain  
RP step-sections and corresponding ADC maps. The prostate  
was cut into step- sections perpendicular to the dorsal surface  
of the prostate (left), and the MR images were divided into the 
same number of sections (center). For each step-section, the 
corresponding ADC map was identified. Gl = Gleason grade,  
Mid = midline, T = tumor.
Figure 1    (b) Step-sections were subsequently schematically subdivided 
into  three different peripheral zone (PZ ) regions: anterior 
horns (AH), dorsolateral region (DL), and dorsal segment (D).  
The urethra (U) was identified. The PZ on the corresponding ADC 
maps were similarly divided. The relative position of the tumor 
(T) was therefore translatable and annotated on the ADC maps, 
matching the size and distribution of the tumor. ROI
Norm_Mirror 
= 
ROI of the contralateral segment of the PZ in mirror position, 
ROI
tumor
 = ROI of tumor, TZ = transition zone.
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when p<0.05. Statistical analyses were performed with software (SPSS, 
version 16.0.01; SPSS, Chicago, Ill.).
Results
Of the 70 consecutive patients, 56 had clinically significant PZ tumors (>0.5 mL). 
In the remaining 14 patients, 11 had TZ tumors only and three had PZ tumors 
that were less than 0.5cc in volume (with Gleason grade 2 and/or 3 
components only). In addition, five of the 56 patients were excluded owing to 
severe motion artifacts (n = 3), widespread intraprostatic hemorrhage (n = 1), or 
Assessment of histologic tumor grade
Following annotations of ROIs on ADC maps, one radiologist (TH), together 
with one genitourinary pathologist (CHK) re-evaluated all step-sections 
that contained tumor. For each tumor present in the PZ of the prostate, 
separate Gleason grades were identified and quantified in percentages of the 
tumor slice volume. For each step-section, the primary, secondary, and 
tertiary tumor grade components were noted; these are referred hereafter as 
the Gleason grade group. A qualitative grade per step-section was also made, 
as follows: (a) low-grade lesions consisting of grade 2 or 3 components only; 
(b) intermediate-grade lesions consisting of grade 4 secondary or tertiary 
components (without any grade 5 components); and (c) high-grade lesions 
consisting of grade 4 primary components and/or grade 5 primary, secondary, 
or tertiary components. Each tumor ROI on ADC maps was subsequently 
correlated to the matching Gleason grade group, and the qualitative grade 
was determined for each step-section slice. An MR analytical software 
workstation developed in- house was used to draw ROIs and summarize the 
median and standard deviations of ADCs (in ×10-3 mm2/s) calculated for each 
ROI.
Statistical Analysis
To determine the relationship between median tumor ADC and ordinal 
Gleason grade groups, a linear mixed-effect regression model with random 
tumor effect was used. This mixed-model regression analysis incorporates 
the dependency of repeated measurements within the same tumor. In an 
additional mixed-model analysis, the differences in median ADC between 
the three qualitative grade groups were estimated.
Apart from establishing a relationship between ADC and Gleason score, the 
diagnostic accuracy of using ADC to differentiate low-grade from combined 
intermediate- and high-grade tumors is of clinical importance. To this end, 
for every tumor, the histopathologic slice with the highest Gleason grade 
was matched to the corresponding ADC section, thereby identifying the 
median ADC that matched the most aggressive part of the tumor. If identical 
highest Gleason grade compositions were evident for different slices within 
the same tumor, the slice showing the lowest median ADC was used. The 
diagnostic accuracy of the median ADC in the differentiation of low-grade 
from combined intermediate- and high-grade groups was quantified with 
the area under the ROC curve (AUC). A significant difference was considered 
Table 1    Summary of clinical and pathological characteristics.
Parameter Value
No. of patients 51
Clinical characteristics*
Median PSA level (ng/ml) 6.8 (1.7-42)
Median age (y) 64 (49-69)
Pathological characteristics**
Stage T2a 5
Stage T2c 23
Stage T3a 18
Stage T3b 4
Stage T4 1
Gleason score ***
3+2 3
3+3 18
2+4 1
3+4 13
3+4(+5) 4
4+3 13
4+3(+5) 5
4+4 2
4+5 3
* PSA: prostate-specific antigen. Numbers in parentheses are ranges. **Data are given as 
numbers of specimens. *** Data are given as number of tumors. PSA: prostate-specific antigen
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The median tumor ADCs showed an association with the 14 Gleason grade 
groups (Fig 2). Results of the linear mixed-model analysis showed an inverse 
relationship (slope, -0.18×10-3 mm2/s; standard error, ±0.04; p<.001) between 
the median ADC and the three qualitative grade groups (Fig 3). Additional 
mixed-model analysis revealed that the difference (±standard deviation) 
between median ADCs of low- and intermediate grade tumors was 0.22×10-3 
mm2/s ±0.03 (p<.001). The difference between intermediate- and high-grade 
tumors was 0.14×10-3 mm2/ s ±0.03 (p<.001), and the difference between low- 
and high-grade tumors was 0.36×10-3 mm2/s ±0.04 (p<.001). Low-, 
intermediate-, and high-grade tumors had a median ADC of 1.30×10-3 mm2/s 
±0.30, 1.07×10-3 mm2/s ±0.30, and 0.94×10-3 mm2/s ±0.30, respectively. 
Overall, the median ADC for normal mirror ROIs in the peripheral zone was 
1.60×10-3 mm2/s ±0.25.
With use of ROC analysis of only the most aggressive part of the tumor, the 
median ADC enabled the differentiation of low-grade tumors from combined 
intermediate- and high-grade tumors with an AUC of 0.90 (95% confidence 
interval: 0.81-0.98) (Fig 4). Furthermore, it was noted that in 94% of tumors 
severe ghosting artifacts on the MR images (n = 1). In the 51 RP specimens 
from these 51 patients, histologic analysis revealed a total of 62 different PZ 
tumors and 251 tumor lesions on different step-sections of the specimens. In 
none of the patients were tumors identified with a volume of less than 0.5cc 
and containing a Gleason grade 4 and/or 5 component. In total, 14 different 
Gleason grade groups were identified according to the primary, secondary, 
and tertiary features present. The patient and tumor characteristics are 
summarized in Table 1, and the ADCs are summarized in Table 2.
Table 2    Summary of ADCs and pathological characteristics
Parameter No. of  
step-sections
Median ADC  
(×10-3 mm2/s)*
All peripheral zone lesions 251 1.02 ± 0.29
Gleason score
2+3 4 1.40 ± 0.18
3+2 11 1.16 ± 0.14
2+3(+4) 3 0.95 ± 0.04
3+2(+4) 3 1.20 ± 0.05
3+3 73 1.36 ± 0.26
3+3(+4) 3 1.29 ± 0.02
2+4 1 1.25 ± 0.0
3+4 46 0.97 ± 0.22
3+4(+5) 8 0.99 ± 0.11
4+3 54 0.92 ± 0.17
4+3(+5) 7 0.79 ± 0.15
4+4 17 0.68 ± 0.13
4+4(+5) 2 0.74 ± 0.02
4+5 19 0.79 ± 0.10
Qualitative grade
Low-grade tumor 94 1.30 ± 0.30
Intermediate grade tumor 50 1.07 ± 0.30
High-grade tumor 107 0.94 ± 0.30
Normal mirror ROI 186** 1.60 ± 0.25
* data are give as medians ± standard deviations. ** in 65 matches, the normal mirror ROI could 
not be annotated due to the presence of contralateral tumor or tumor extending beyond the 
midline. ADC: apparent diffusion coefficient, ROI: region of interest.
Figure 2    Graph shows the relationship between median tumor ADC and 
Gleason grade groups
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(58 of 62 tumors), the ADC section with the lowest median tumor ADC was in 
exact concordance with the pathologic slice with the most aggressive tumor 
composition. Figure 5 shows the visibility of different grade tumors on ADC 
maps.
Figure 3    Graph shows the relationship between median ADC, qualitative 
grade groups, and the normal mirror ROI in the peripheral zone 
(PZ) by using the tumor section with the lowest median ADC. 
Slope estimate with the linear mixed-effect regression model 
was -0.18×10-3 mm2/s
Figure 5    Histologic step-sections and corresponding ADC maps for three 
patients with tumors (T) of different aggressivity. 
Window levels were kept the same for all patients.  Gl. = Gleason grade, mADC = median 
ADC. (1) Images in a patient with a low-grade tumor (Gleason grade 3 + 3) and median 
tumor ADC of 1.24×10-3 mm2/s. (2) Images in a patient with an intermediate-grade 
tumor (Gleason grade 3 + 4) and a median tumor ADC of 0.99×10-3 mm2/s. (3) Images in 
a patient with a high-grade tumor (Gleason 4 + 5) and a median tumor ADC of 0.66×10-3 
mm2/s. Dashed lines on ADC maps indicate the tumor region.
Figure 4    ROC curve demonstrates the discriminating performance of 
median ADC in the differentiation between low-grade versus 
intermediate- and high-grade lesions. The tumor slice with the 
highest Gleason grade composition was used
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features of the epithelial, glandular, and extraductal components that exist 
in different grades of cancer23-25. With increasing Gleason grade, the change 
in tissue organization to a more solid and compact architecture (with higher 
cellular density) should be reflected in restrictions in the distances of free 
water motion within the tissue. Well-differentiated prostate carcinomas 
display tubular formation with a concomitant higher contribution of 
unrestricted water motion to ADCs. Lower grade tumors are also known to 
have a remarkable heterogeneity in glandular size and the ability to grow 
between pre-existing ducts. Conversely, poorly differentiated adenocarci-
nomas show more expansive masses of small, tightly packed cell groups with 
small-to-absent lumina. Gleason grade 2 tumors are defined histologically 
by tightly packed, well-differentiated glandular components, whereas grade 
3 tumors show wider-spaced tubuli with heterogeneity in ductal size and 
density, imposing fewer restrictions on extraglandular free water diffusivity 
motion. This basis also seems to be reflected in the finding that the ADCs for 
tumors with a grade 2 component were slightly lower than those in tumors 
with purely grade 3 components. Of the different Gleason grade groups, pure 
grade 3 (3 + 3) tumors showed the largest variation in median ADC, possibly 
reflecting the heterogeneity of lesions with sparse versus dense growth, 
akin to these. A large space for diffusion both between ducts and within 
ductal lumina in well-differentiated compared with poorly differentiated 
tumors is the most likely explanation for the observed differences in ADCs in 
low-grade compared with high-grade tumors.
Despite the fact that true Gleason score is not represented in transrectal 
ultrasound (TRUS)–guided biopsy cores in 30%–50% of patients, biopsy- 
determined Gleason score remains one of the most important factors in 
decision making. An accurate noninvasive method that improves the 
prediction of Gleason score may enable a substantial improvement in patient 
treatment by (a) enabling better treatment selection; (b) improving the 
targeting of lesions for biopsy, which would, therefore, provide a more 
representative Gleason score; (c) enabling better risk stratification and 
follow-up for patients who are being treated with active surveillance 
protocols; and (d) helping plan intensity-modulated radiation therapy for 
treatment of the dominant aggressive component.
For correlation analysis, each step-section that contained tumor was 
matched to an ADC map as a separate tumor lesion. The reasoning behind this 
Discussion
The results of this study showed that Gleason grade, and by inference 
aggressiveness, is related to the ADC determined at DWI. With use of a linear 
mixed-model approach, we determined that the median ADC significantly 
decreased an average of 0.18×10-3 mm2/ s per qualitative grade group 
interval. Further analysis showed that the difference between the median 
ADCs of low- and intermediate-grade tumors was larger than that between 
intermediate- and high- grade tumors. With use of the most aggressive 
component within the tumor as an end point, median ADC revealed an AUC of 
0.90 in the differentiation of low-grade tumors from combined intermediate- 
and high-grade tumors.
The Gleason grade subgrouping enables better comparison and assessment of 
the effect of microscopic glandular differentiation, growth features, and 
structure of different PCa subgrades on the free diffusivity of water. Correlation 
of ADC to qualitative grade groups potentially allows a more practical 
utilization of the information in routine clinical decision making, risk 
stratification, and patient-tailored treatment options. Furthermore, the 
subdivision into low-, intermediate-, and high-grade tumors can allow 
meaningful cutoff points to be defined and can be used to help differentiate 
patient groups with different prognoses and, therefore, different management 
needs.
DWI is increasingly being incorporated into oncologic imaging, and 
information obtained with this technique is appealing as an imaging 
biomarker20. Although the low ADCs found in most tumors have been attributed 
to increased cellular density, diffusion can also be influenced by fibrosis, 
glandular and stromal organization, and shape21. Within the prostate, the 
predominant contribution of DWI signal is from the extracellular component 
(from tubular structures and their fluid content), with a lesser contribution 
from the extracellular stromal space and the intracellular components 
(epithelial and stromal cells). Because of the abundant self-diffusion of water 
molecules within the predominant tubular components within the PZ, their 
contents provide a high signal on ADC maps22.
A rationale for the relationship between PCa aggressiveness and ADC can be 
suggested from the current understanding of the structural and organizational 
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dose, therefore improving outcome. With currently available prognostic 
factors such as preoperative prostate specific antigen (PSA) levels, tumor 
stage, and biopsy-determined Gleason grade, such a selection cannot be 
made with sufficient accuracy on an individual level30. Our findings suggest 
that DWI has the potential to play a role as a non-invasive adjuvant in the 
characterization of PCa. To which degree our findings will in practice affect 
individual patient treatment should be assessed with future prospective 
studies.
Although the role of multiparametric MRI (MP-MRI) in accurately staging 
and localizing prostate cancer has been firmly defined31–34, data regarding its 
value in improving the prediction of PCa aggressiveness are limited. A 
correlation between hydrogen 1 MR spectroscopy–determined choline + 
creatine/citrate ratios at 1.5-T and RP Gleason score has been reported35,36; 
however, the overlapping groups appear to be too large to determine 
meaningful cutoff points. Further observations have confirmed that 
T2-weighted signal intensity correlates to Gleason grade37, as poorly 
differentiated tumors are more readily detected on T2-weighted images than 
are well-differentiated ones38. A correlation between ADC and PCa cellularity, 
proliferation activity, and density of growth has recently been demonstrated 
in two studies39,40. In addition, a correlation between ADC and biopsy-deter-
mined Gleason grade has been reported by Tamada et al.41. These authors 
have shown a significant correlation (r = 0.497, p<.0001) between the biopsy 
Gleason grade and ADC. Furthermore, the same visual trend in the 
relationship between Gleason grade and ADC was also shown.
Our study had a number of limitations. We did not include TZ tumors in this 
study. TZ tumors are known to have different genetic mutations, biologic 
behavioral features, and prognoses42-44. In addition, ADCs for TZ tumors are 
known to differ from those for PZ tumors45. Therefore, the conclusions drawn 
from this study cannot be applied to TZ tumors. Another potential limitation 
is the reliability of the method we used to match transverse MR images to 
histologic step-sections31,36,46. We believe that using a number of strategies 
to improve the spatial mapping of MR images and step-sections allowed us 
to obtain good matching with a high degree of certainty. After section-by-
section matching of step-sections to ADC maps, we annotated ROIs on the 
basis of a schematic translation of the ground truth according to zonal 
subdivision and use of the urethra as a landmark.
approach was that tumors display remarkable intratumoral heterogeneity in 
their Gleason grade patterns and the ability to grow in between existing 
normal ducts and stromal tissue. This was evident, for example, in one tumor 
in which one slice revealed pure grade 4 components, one revealed mixed 
grade 4 and 3 components, and one revealed pure grade 3 components. 
Because the ADC maps and pathologic step-sections were matched to a high 
degree of certainty and an individual Gleason grade and ADC quantification 
provided for each match, a good impression on the assessment of the effect 
of Gleason grade on water diffusivity was obtained. At DWI, the section 
showing the tumor with the lowest median ADC will in clinical practice most 
often be used prospectively to predict aggressiveness, guide therapy, or 
direct targeted biopsies. Because this study was set up as a validation study, 
data selection for ROC analysis was done by choosing the tumor slice with the 
highest Gleason grade composition (ie, tumor slice with the highest 
proportion of Gleason grade 4 or 5 components). In 94% of tumors, this was 
the exact same slice that showed the lowest median ADC for the tumor, 
therefore indicating that, in a prospective setting, it may be useful to use 
the tumor section with the lowest median ADC as a starting point.
The clinical relevance of this imaging biomarker has noticeable potential. 
On a solitary basis, median ADC may contribute to patient risk stratification. 
With a good discriminatory performance between low-, intermediate-, and 
high- grade tumors, incorporating this information into decision-making 
will depend on the clinical question and of course the particular sensitivity 
and specificity desired. Differentiating men who can be treated expectantly 
(active surveillance) from those requiring active treatment is therefore a 
potential application of DWI26. Patients with high-grade cancer (including 
those with Gleason grade 4 as a primary pattern or Gleason grade 5 as a 
primary, secondary, or tertiary pattern) represent a group with a particularly 
detrimental prognosis27-29. The noninvasive identification of these patients 
before surgery could be of importance to avoid unnecessary surgery, consider 
early adjuvant therapy, or order additional diagnostic tests for the 
assessment of metastasis. A prospective advantage of identifying the most 
abnormal part of the tumor on the basis of the median ADC is that this can 
facilitate targeted biopsies to obtain cores from the regions with the worst 
Gleason scores, providing a better basis for further patient treatment. 
Furthermore, when focal therapy (ie, intensity-modulated radiation 
therapy) is used, the most aggressive component could receive the highest 
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We have demonstrated the relationship between ADC and tumor aggressiveness; 
in the future, prospective multireader studies should be performed to 
validate the ability of DWI to improve risk stratification on an individual 
patient basis, in addition to clinical parameters. The effect of such 
stratification on patient treatment should also be evaluated. Evaluation of 
the reproducibility of absolute ADCs between vendors and field strengths as 
well as correlation of ADCs with TZ cancers should also be priorities for future 
studies.
In conclusion, quantitative DWI may be a noninvasive biomarker that is well 
suited for determining PCa aggressiveness. Median tumor ADCs inversely 
relate to Gleason grade groups and qualitative grade groups. A high 
discriminatory accuracy of AUC=0.90 suggests that ADC will prove to be a 
useful biomarker that can help improve the identification of patients with a 
particular tumor aggressiveness risk.
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Introduction
Prostate specific antigen (PSA) testing for prostate carcinoma (PCa) has led 
to earlier detection of PCa, with a tendency to downstaging for the entire 
population1,2.
 
Recent publications from the European Randomized Study of 
Screening for Prostate Cancer (ERSPC) trial showed a significant prostate 
cancer mortality reduction from PSA screening, however at the cost of 1410 
men screened and, more importantly, 48 additional cases of PCa treated to 
prevent one PCa death3.
The dilemma of the clinical insignificant tumor has been addressed with 
increasing frequency and would even become more important with the 
implementation of PSA screening4,5.
 
In a recent European Association of 
Urology (EAU) position statement on PSA screening for PCa, the authors 
underline the paramount importance of the development of reliable monitoring 
and prognostic markers and/or imaging modalities to prevent overtreatment 
before widespread implementation of population-based PSA screening6.
 
Clinical staging and accurate grade assessment of PCa has become of utmost 
importance in decision making regarding the need for active treatment at any 
time point following the diagnosis of PCa in individual cases.
Accurate identification of insignificant and/or low-risk PCa remains the 
cornerstone of selection of patients for active surveillance (AS), but is 
currently severely hampered by absence of reliable pre-treatment 
predictors7,8.
 
PSA levels in patients with histological proven PCa do grossly 
correlate with the risk of extraprostatic extension (EPE), seminal vesicle 
invasion (SVI) and positive surgical margins (PSM), but correlate poorly with 
differentiation9. Other PCa markers, such as PCA3 or hK2, have not been able 
to identify low-risk PCa with sufficient accuracy for clinical decision 
making10,11.
 
In current practice, transrectal ultrasound (TRUS)-guided 
schematic prostate biopsies are the predominant method to obtain a 
histological diagnosis of PCa and to determine pathological characteristics 
of the tumor. Subsequently, biopsy-determined combined Gleason score 
remains a cornerstone of pre-treatment risk stratification for localized PCa. 
However, when correlated with radical prostatectomy (RP) specimens, 
Gleason grading obtained by TRUS-guided biopsy has been shown to 
underestimate tumor Gleason score in up to 40% of cases12,13,
 
a phenomenon 
further referred to as Gleason undergrading in this paper.
Abstract
Introduction Diffusion-weighted MR Imaging (DWI) might be able to fulfill 
the need to accurately identify high-grade prostate carcinoma, in patients 
initially selected for active surveillance in the PSA screening era based upon 
transrectal ultrasound (TRUS)-guided biopsy Gleason score. We aimed to 
determine whether DWI is able to correctly identify those patients with a 
biopsy Gleason score of ≤3+3=6, but harboring Gleason 4 and/or 5 components 
in their radical prostatectomy (RP) specimen.
Materials and methods Whole-mount RP specimens were used to identify 
regions of interest (ROI) corresponding with tumor on the DWI-derived 
Apparent Diffusion Coefficient (ADC) maps in 23 patients with a Gleason 
≤3+3=6 upon biopsy. ADC values were correlated with RP Gleason grades. 
Statistical analysis was performed by calculating area under the ROC-curve 
(AUC) for identification of prostate cancer with Gleason 4 and/or 5 
components using DWI, and Mann-Whitney U-testing was performed to 
detect differences in median ADC values for tumors with presence of Gleason 
grade 4 and/or 5 versus a highest Gleason grade of ≤3 upon RP. 
Results A diagnostic accuracy of median ADC values for identifying patients 
subject to TRUS-guided biopsy undergrading with an AUC of 0.88 was 
established using RP Gleason score as a reference. In patients harboring a 
Gleason 4 and/or 5 component the median ADC was 0.86×10-3 mm2/s 
(SD±0.21), whereas patients harboring no Gleason 4 and/or 5 component 
displayed a median ADC of 1.16×10-3 mm2/s (SD±0.19) for the single tumor 
slice with the lowest median ADC (p<0.002).
Conclusions DWI is able to predict the presence of high-grade tumor in 
patients with a Gleason ≤3+3=6 upon biopsy, providing important 
information for treatment decisions.
136 137
Ch
ap
te
r 
 4
G
ra
d
in
g 
of
 p
ro
st
at
e 
ca
n
ce
r 
u
si
ng
 D
if
fu
si
on
-W
ei
gh
te
d 
M
R
 I
m
ag
in
g 
(D
W
I)
Imaging parameters
MP-MRI of the prostate was performed using a 3-T MR scanner (Siemens Trio 
Tim, Erlangen, Germany) combined with an ERC (Medrad, Pittsburgh, USA) 
in combination with a pelvic phased array coil. The routine MR imaging 
protocol consisted of anatomical T2-weighted turbo spin echo sequences in 
the axial, sagittal and coronal direction, covering the prostate and seminal 
vesicles. Axial images were obtained perpendicular to the dorsal surface of 
the prostate to facilitate comparison with whole-mount sectioned RP 
specimens. DWI was performed using a fat-saturated single-shot-echo-pla-
nar imaging sequence with 3-scan trace imaging with b-values of 0, 50, 500, 
and 800 s/mm2. The scanner software automatically calculated ADC maps 
using all b-values. Further imaging parameters are shown in appendix 2.
Specimen handling
Following RP, prostate specimens were fixed overnight in 10% neutral 
buffered formaldehyde and routinely processed according to protocol24. In 
brief, after inking of the surface, the prostate specimen was cut into serial 
transverse 3-4 mm thick slices, perpendicular to the dorsal-rectal surface 
and all slices were macroscopically photographed. The apex and base were 
sagittally sectioned to assess the caudal and cranial surgical margins. 
Seminal vesicles were amputated at their junction with the prostate and 
sectioned parallel to their junction and embedded in total. The remaining 
slices were subdivided into halves or quadrants to fit routine cassettes. After 
histological staining all specimens were evaluated by one expert urological 
pathologist (CHK). Tumors were outlined on the microscopic slides and 
subsequently mapped on the macroscopic photographs to allow reconstruction 
of tumor extent and multifocality. For every RP specimen and each separate 
tumor in case of multifocality the presence of primary, secondary and 
tertiary Gleason grade pattern as well as a combined Gleason score was 
recorded. For every tumor slice a separate Gleason grade assessment was 
made. The presence of EPE was reported for all cases.
Data retrieval
Retrospectively, after RP, annotations of MR images were performed in 
consensus by one urologist (DMS) and one radiologist (TH). To achieve good 
objective spatial co-alignment accuracy, a number of strategies were applied. 
First, both ADC maps and RP step-sections were obtained perpendicular to 
the dorsal surface of the prostate. Secondly, a similar slice thickness was 
RP series including patients considered eligible for AS according to 
contemporary inclusion criteria showed that up to 27% of patients had a 
Gleason score of at least 7 upon RP14,15.   An AS series by Duffield et al. outlined 
that most patients progressing on such a protocol did so 1 to 2 years after 
diagnosis, suggesting significant undergrading upon initial TRUS-guided 
biopsy16. Only 52% of patients consequently undergoing RP had a combined 
Gleason score of ≤3+3=6. These series clearly underline the need for more 
accurate grading and staging of PCa precluding inclusion in AS protocols.
Diffusion-weighted MR Imaging (DWI) is a functional MR technique that 
quantifies the freedom of movement of hydrogen protons, predominantly a 
part of water molecules, in tissue. In PCa the diffusion of water will be limited 
due to increased cellular density of tumor compared with normal glandular 
prostate tissue, leading to lower apparent diffusion coefficient (ADC) levels in 
PCa when compared with benign prostate tissue17. Previous reports on the 
value of DWI in the detection and localization of PCa have been published18-20. 
Furthermore the correlation of ADC to tumor Gleason score and tumor volume 
has recently been shown21-23. Therefore, another merit of DWI might be in 
correctly identifying those patients that would have been selected for AS 
protocols based on their TRUS- guided biopsy Gleason score of ≤3+3=6, but do 
harbor Gleason 4 and/or 5 components not sampled by random biopsies. In this 
series we aimed to establish the potential value of DWI to identify patients 
subject to pre-operative Gleason undergrading by TRUS-guided biopsy, using 
RP Gleason score as a gold standard, thus enabling more accurate pre-treatment 
risk stratification and treatment  decision-making.
Materials and Methods
Study population
Inclusion criteria were histologically proven PCa with a Gleason score of 
≤3+3=6 upon TRUS-guided biopsy in patients consequently scheduled for RP. 
Patients were referred for multiparametric MRI (MP-MRI) from two hospitals, 
following the histological diagnosis of PCa by 8-10 core schematic TRUS- 
guided biopsies. In these patients endorectal coil (ERC) MP-MRI at 3 
Tesla (3-T) preceding RP was performed. Patients in whom the diagnosis of 
PCa was established using MR-guided biopsy (MRGB) were excluded. Patient 
characteristics for the complete cohort were registered.
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predicting correct Gleason grading versus Gleason undergrading was 
calculated. Furthermore, the Mann-Whitney U-test was performed to 
determine whether there was a difference in mean PSA, mean ADC (of the 
single slice with the lowest median tumor ADC) and mean index tumor 
volume for these groups. Level of significance was set at P<0.05. Statistical 
analysis was performed using SPSS software (SPSS, version 16.0.01, Chicago, 
Illinois, USA.).
Results
Twenty-three patients were identified with a Gleason score ≤3+3=6 upon 
TRUS-guided biopsy that underwent 3-T MP-MRI before RP. The mean age 
was 61 years (range 42-69) with a mean PSA of 8.0 ng/ml (range 1.7-37.5). In 
23 prostatectomies, 56 different tumors were found. The prevalence of PZ 
tumors was 68% (38/56) and for TZ tumors this was 32% (18/56). In all 
patients one index prostate cancer exceeding a volume of 0.2cc in the RP 
specimen was identified. The median index tumor volume was 4.09cc (range 
chosen. Thirdly, objective mapping of MR slices to RP step-sections, was 
performed by aligning the apex and base on MR and step-sections in the 
cranial-caudal direction. Starting from the apex, each consecutive ADC map 
was matched to the consecutive pathology step-section. Finally, a per-slice 
subdivision was made. On each slice, the peripheral zone (PZ) and transition 
zone (TZ) were identified and using the urethra as reference, the tumor maps 
were translated to a schematic subdivision of the PZ (figure 1) including 
anterior horns, dorsolateral region and dorsal segment in both left and right 
halves. The PZ, TZ and urethra are well visible on ADC maps, thus allowing 
the schematic subdivision applicable to ADC maps as well. This schematic 
mapping allowed objective translation of tumor containing regions from RP 
to ADC maps with a high degree of certainty. A region of interest (ROI) was 
annotated and drawn to match the size and extent of the tumor determined 
from histology, as closely as possible. Separate ROI’s were placed on every 
ADC slice containing tumor. Therefore, for each tumor, multiple ROI’s were 
determined, depending on the tumor extent on different step-sections. 
Tumor foci with an inplane area less than 5×5mm were excluded from analysis 
due to the limit in spatial resolution obtained with DWI (inplane voxel sizes 
1.5×1.5mm). From each of the designated ROI’s median ADC values were 
calculated on a per-slice basis for statistical analysis. Following median ADC 
estimation, for the purpose of this study, the index tumor was identified as 
the tumor within the whole RP specimen revealing the highest combined 
Gleason score and having a volume of ≥ 0.2cc. If multiple tumors revealed the 
same Gleason score, the tumor with the largest volume was subsequently 
identified as the index tumor. For this tumor the slice with the lowest median 
ADC was used for further analysis.
Statistical analysis
Patients with a Gleason score of ≤3+3=6 upon TRUS-guided biopsy were 
stratified according to their final RP Gleason score for the presence or 
absence of a Gleason 4 and/or 5 component. This resulted in two groups. The 
first, where the TRUS-guided biopsy Gleason score ≤3+3=6 had an exact 
concordance with RP Gleason score and the second, where TRUS-guided 
biopsy resulted in Gleason undergrading (combined Gleason score ≥7 in RP). 
The median ADC for the tumor slice with lowest ADC values was identified 
and matched to these two groups. Area under the ROC curves (AUC) were 
determined for the median ADC’s for predicting correct Gleason grading 
versus Gleason undergrading. In addition, the AUC for median PSA values 
Figure 1    Schematic translation of tumor regions from macroscopic 
step-section histopathology maps to ADC maps. 
Left image shows prostatectomy step-section with tumor in the left-peripheral zone. 
The middle image shows the subdivision of the prostate in the peripheral zone (PZ - 
red dashed lines) and transition zone (TZ - blue dashed line). The urethra (U) is 
identified in the centre. The peripheral zone is furthermore subdivided using the 
urethra as reference landmark into left and right anterior horns (AH), dorsolateral 
regions (DL) and dorsal (D) region. The schematic subdivision is anatomically 
translated to the corresponding ADC maps (image on right) with tumor translated 
and annotated in yellow dashed lines. For each tumor slice, the pathologist 
documented the presence and volume percentages of the primary (prim.), secondary 
(second.) and tertiary (tert.) Gleason grade components.
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Eleven of the 23 (48%) included patients had a primary or secondary Gleason 
4 and/or 5 component in their final RP specimen, leaving 12 cases that were 
correctly identified as low-grade prostate cancer by pre-operative TRUS- 
guided biopsy. Patients subject to Gleason undergrading had a median PSA 
of 6.10 (range 1.7 - 37.5), while patients with a Gleason score of ≤3+3=6 upon 
RP had a median PSA of 6.08 (range 2.2-9.8; p=0.11). Furthermore, the 
median index tumor volume in patients with Gleason undergrading was 
6.62cc (range 0.31-28 cc) compared to patients with a final Gleason score of 
≤3+3=6 where this was 2.59cc (range 0.36-10.01; p=0.006). None of the 
patients correctly identified by TRUS-guided biopsy as Gleason ≤3+3=6 PCa 
had EPE. In contrast, 82% (9/11) of patients that had been undergraded by 
TRUS-guided biopsy displayed EPE upon RP.
A diagnostic accuracy of median ADC for discriminating patients subject to 
pre-operative Gleason undergrading by TRUS-guided biopsy with an AUC of 
0.88 (95% CI: 0.64-1.00) was established (figure 2). In patients harboring a 
primary or secondary Gleason 4 and/or 5 component the median ADC was 
0.86×10-3 mm2/s (SD±0.21), whereas patients harboring no significant 
0.31 – 28cc). Almost all index tumors were located in the PZ (96%; 22/23). In 
one patient tumor substantially involved both the PZ and TZ, therefore 
primary zone of origin was not determinable. A summary of the patient and 
pathology characteristics is provided in table 1.
Table 1    Patient, pathology and ADC characteristics
No Undergrading Undergrading p-values
Number 12 11 N/A
Median PSA value ng/ml  
(range)
6.08 (2.2 - 9.8) 6.10 (1.7 - 37.5) 0.11
Median Index Tumor Volume cc  
(range)
2.59 (0.36 – 10.01) 6.62 (0.31 – 28) 0.006 *
Extraprostatic Extension  
(EPE)
0% (0/12) 82% (9/11) N/A
Median ADC values x10-3  
mm2/s (±SD)
1.16 (±0.19) 0.86 (±0.21) 0.002 *
Figure 2    ROC curve for differentiation of low-grade (no Gleason 4 and/or 5 
component) and high-grade prostate carcinoma upon RP using 
median ADC in a TRUS-guided biopsy Gleason ≤3+3=6 population 
(AUC 0.88)
Figure 3    Box-plot of median ADC of low-grade (no primary or secondary 
Gleason 4 and/or 5 component) and high-grade prostate 
carcinoma upon RP in a TRUS-guided biopsy Gleason ≤3+3=6 
population (p<0.002)
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The diagnostic accuracy of mean PSA values in discriminating patients into 
these two groups revealed an AUC of 0.58 (95% CI: 0.32-0.83).
Discussion
In this study we have primarily shown that median quantitative ADC values 
obtained from 3-T DWI are able to accurately separate patients where a 
histological diagnosis of Gleason ≤3+3=6 PCa upon TRUS- guided biopsy 
represents undergrading of true Gleason score from those subjects where it is 
a correct assessment of true Gleason score at RP. Because it is known that 
biopsy Gleason score is a poor predictor of true Gleason score identified in RP, 
a definite need exists to improve identification of undergraded patients as 
this has important implications in treatment selection and prognostication. 
From our results, it seems that DWI has a strong potential to fill this current 
gap in pretreatment aggressiveness determination for PCa.
DWI has been established to reliably localize areas of PCa within a 3-T 
MP-MRI approach. Reported ADC values for PCa (1.13-1.38×10-3 mm2/s) and 
normal prostate tissue (1.58-1.96×10-3 mm2/s) differ widely17,10,25,26, which to 
some degree can be explained by different sequences using varied b-values, 
and thus obtaining different levels of diffusion-weighting. Also, popula-
tion-based differences in Gleason score prevalences can also account for 
differences in ADC values for PCa in different series.
Reliable pre-treatment grading of PCa remains a major issue, especially with 
the emergence of AS programs for low-risk prostate cancer and the growing 
interest for focal ablative therapies. A RP correlated series by Haider et al. 
showed a very promising role of DWI in combination with T2-weighted 
imaging in the detection of significant prostate cancer, defined by a Gleason 
score ≥ 6 and tumor diameter >4mm. They reported a sensitivity of 81% and 
a specificity of 84% for T2-weighted MRI and DWI combined18. Low-grade 
tumors reveal low tumor cellularity, intermixed with various amounts of 
normal prostatic stroma and glands as well as showing larger extracellular 
and glandular luminal spaces compared with higher-grade tumors. The latter 
are characterized by higher cellularity density and loss of glandular duct 
formation27,28.
 
As a consequence, the space for free water movement both 
intraluminally and extracellularly, reduces as the Gleason grade of the tumor 
increases. Based on the results from Wang et al.29 it is evident that the ADC of 
Gleason 4 and/or 5 component displayed a significantly higher median ADC 
of 1.16×10-3 mm2/s (SD±0.19; p<0.002) for the single slice with the lowest ADC 
(figure 3). The slice with the lowest median ADC in all patients corresponded 
with the part of the tumor with the highest combined Gleason score upon RP. 
Figure 4    Patient with TRUS-guided biopsy Gleason score of 3+3=6 and a 
PSA of 5.2 ng/ml 
Histopathological step sections 1a - 3a reveal the extent of prostate carcinoma in the 
peripheral zone (light-blue area). For every separate slice, a Gleason grade 
composition expressed in grade and volume percentage of tumor region is given. 
Every histopathology slice is matched to the corresponding ADC map (1b - 3b) and the 
tumor-containing region translated for placement of a ROI placed over the tumor. For 
each ADC slice, a median ADC (mADC) value was calculated. The mADC values are 
expressed in x10-3 mm2/s. The region of tumor with the largest proportion of higher 
Gleason grades (3a) corresponds also to the slice with the lowest  mADC tumor values 
(3b). The window level for ADC maps are defined to range from 0.5-1.5x10-3 mm2/s. A 
small additional insignificant transition zone tumor (green region) is also shown in 
1a. The red line indicates the area of extraprostatic extension. The final diagnosis on 
RP was Gleason 3+4=7 PCa, stage pT3a.
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more extensive TRUS-guided biopsy schemes have been shown to improve 
detection rates and decrease the rate of Gleason undergrading, this issue 
still remains substantial36. We therefore are of the opinion that the effect of 
more TRUS-guided biopsies taken might not have altered the outcome of our 
series significantly; further investigation in a series with extended biopsy 
schemes is however warranted. A further limitation is the fact that we only 
included patients with a Gleason score ≤3+3=6 upon TRUS-guided biopsy for 
our analysis. However, as the clinical approach is based upon a biopsy 
Gleason score ≤3+3=6 upon TRUS-guided biopsy as representative of the true 
tumor features, we opted to only include these patients for this series. This 
however resulted in a fairly low number of patients in each subgroup. A 
further drawback is that, although TZ tumors represented 32% of all tumors 
found in our patients, the index tumor in 96% of patients was a PZ tumor. 
Because the normal TZ and PZ are known to have different ADC values, our 
results may therefore be biased towards revealing the discriminatory 
performance of ADC exclusively for PZ tumor undergrading. A larger cohort 
with more patients harboring TZ index tumors is needed to establish the 
value of ADC in a larger perspective.
DWI has been established as a diagnostic modality in oncology now for over 
a decade. Its main merits lie in the detection of solid tumor within 
surrounding normal tissue and more recently research has focused upon the 
ability of DWI to characterize the aggressiveness of tumors. We confirmed 
this potential of DWI to characterize prostate cancer aggressiveness. DWI 
should be an integral part of any MP-MRI approach to PCa, whether localizing 
or characterizing the tumor is the aim. Its main contribution to the 
diagnostic arena for PCa might lie in its ability to identify high-grade 
components in PCa precluding adequate pre-treatment risk stratification 
and aiding in therapeutic decision-making. Prospective research will need 
to focus upon the performance of DWI in candidates for AS to predict and 
evaluate progression to curative therapy.
PCa decreases with an increase in tumor cellularity and proliferation rate. 
This association has also been shown by Zelhof et al30. Apart from inherent 
tumor cellularity, the degree of tumor intermixing with normal prostatic 
tissue, also infers variation in ADC values between tumors. Langer et al.31 
identified sparse vs. dense growing prostate tumors and determined a 
correlation with ADC. They identified that all sparse growing tumors (with 
normal tissue intermixing) had a combined Gleason score ≤6. Therefore, it 
appears that inherent tumor cellularity (which is directly related to the 
Gleason grade) as well as intermixing pattern, are important factors that 
influence the diffusion characteristics of PCa on ADC.
The ability of ADC to predict biopsy Gleason score has been established in 
several series32-34, but this approach is methodologically hampered by the 
well-known phenomenon of Gleason undergrading of true combined Gleason 
score by pre-operative biopsies. Two earlier reports on the correlation of ADC 
and RP Gleason score have recently been published showing a high diagnostic 
accuracy of ADC in predicting high-grade PCa22,23.
 
To our knowledge we are 
the first to report on the use of DWI in identifying patients subject to Gleason 
undergrading upon TRUS-guided biopsy.
For selection of patients for AS protocols or focal therapy a reliable technique 
with a high sensitivity for any Gleason 4 and/or 5 component could be a 
parameter of paramount importance to increase reliability and safety of 
such protocols. It is known that higher PSA values are associated with 
increased odds of undergrading by TRUS-guided biopsies. Isariyawongse et 
al.35 have shown that patients with PSA values between 10-20 ng/ml had 
odds ratios of 2.11 compared to patients with PSA < 10 ng/ml for harbouring 
undergrading of true Gleason score upon RP. Despite this, PSA values alone 
are insufficient for accurate stratification in this regard. This was reaffirmed 
in our series by the relative poor AUC of 0.58 achieved using PSA values as 
classifier. In this retrospective series we were able to identify cases subject 
to pre-operative biopsy Gleason undergrading with good accuracy using 
median ADC of the most aggressive part of the tumor. Notably, none of the 
patients in this series that were correctly graded as ≤3+3=6 PCa by TRUS- 
guided biopsy displayed EPE in their final RP pathology.
A major limitation of our series might be the establishment of pre-operative 
Gleason score based upon 8-10 core TRUS-guided biopsies. However, while 
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Introduction
With the increasing incidence of low-risk prostate cancer (PCa) due to 
prostate specific antigen (PSA) testing1, active surveillance (AS) for PCa has 
become an appealing strategy in an increasing number of patients2. Although 
there is an ongoing debate on the use and implications of PSA screening on a 
population-based scale, AS as a strategy for low-risk PCa may turn out to be 
an important measure to prevent overtreatment of patients with PSA- 
detected low-risk PCa. Because more experience is accumulating with AS, a 
consistent intervention rate of 14% to 37% has been reported within the first 
years after diagnosis following unfavorable PSA kinetics and/or Gleason 
score/cancer volume progression at repeated transrectal ultrasound 
(TRUS)-guided biopsy3-7, even when the wide diversity in inclusion criteria 
and definition of progression renders comparison between series difficult. 
This substantial intervention rate could be explained by true PCa progression 
or incorrect risk stratification at the time of initiation of AS. At this moment, 
the initiation of AS has been based predominantly upon PSA and TRUS- 
guided biopsy histopathological characteristics. Our hypothesis is that multi-
parametric MR imaging (MP-MRI) and MR-guided biopsy (MRGB) at the 
initiation of AS might provide better risk stratification of PCa resulting in 
lower intervention rates during follow-up. Limited reports on the use of 
 diffusion-weighted MR imaging (DWI) as a monitoring tool within AS 
protocols for PCa have been published, showing that the DWI-derived 
apparent diffusion coefficient (ADC) is a highly significant predictor of 
adverse random repeat biopsy findings in an AS cohort8. We describe a series 
of AS participants in which DWI/ADC was performed at inclusion with 
immediate histopathological verification by targeted biopsies by MRGB of 
the abnormal regions suspicious for PCa. To the best of our knowledge, this is 
the first report on the use of DWI at inclusion in an AS protocol, with histo-
pathological verification obtained by targeted biopsies of cancer-suspicious 
regions (CSR).
Materials and Methods
We prospectively identified patients eligible for AS according to the PSA and 
biopsy criteria as used within the Prostate Cancer Research International 
Active Surveillance (PRIAS) study (Dutch Trial Register NTR1718): 
asymptomatic cT1c/cT2 PCa, PSA level of 10.0 ng/mL or lesser, PSA density of 
Abstract
Purpose We aimed to determine whether diffusion-weighted MR imaging 
(DWI), by means of the apparent diffusion coefficient (ADC), is able to guide 
MR-guided biopsy (MRGB) in patients fit for active surveillance (AS) and 
identify patients harboring high-grade Gleason components not suitable for 
AS.
Materials and Methods Our study was approved by the institutional review 
board of all participating hospitals, and all patients signed informed consent 
at inclusion. Fifty-four consecutive patients with low-risk prostate cancer 
(PCa) underwent multiparametric MRI (MP-MRI) at inclusion for AS. Cancer 
suspicious regions (CSRs) upon 3-T MP-MRI were identified in all patients, 
and MRGB was per- formed in all CSRs to obtain histopathological verification. 
For all CSRs, a median ADC (mADC) was calculated. Wilcoxon signed ranks 
and Mann-Whitney tests were performed to detect differences between the 
groups. We used the area under the ROC curve (AUC) to evaluate the accuracy 
of mADC to predict the presence of PCa in a CSR. Level of statistical 
significance was set at P<0.05. 
Results Mean mADC in the CSRs with PCa was 1.04 ×10-3 mm2/s (SD: 0.29), 
whereas the CSRs with no PCa displayed a mean mADC of 1.26 ×10-3 mm2/s 
(SD: 0.25; p<0.001). CSRs with a high-grade Gleason component displayed a 
mean mADC of 0.84 ×10-3 mm2/s (SD: 0.35) vs. a mean mADC for the low-grade 
CSRs of 1.09 ×10-3 mm2/s (SD: 0.25; p<0.05). A diagnostic accuracy of mADC 
for predicting the presence of PCa in a CSR with an AUC of 0.73 was established 
(95% confidence interval: 0.61-0.84).
Conclusions Median ADC is able to predict the presence and grade of PCa in 
CSRs identified by MP-MRI.
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Determination of ADC Characteristics
In a consensus reading by 2 observers (DMS, CMH) who were blinded to 
patient and biopsy characteristics, regions of interest (ROI), measuring 
5×5×1 mm, were annotated on the MRGB procedure ADC maps according to 
needle position (Fig. 1). In case of multiple MRGB cores of a single CSR, the 1 
biopsy with the presence of PCa and/or the highest combined Gleason score 
upon histologic examination was used for the ROI analysis. In case of a can-
cer-negative MRGB, the 1 biopsy with the most adequate position in the CSR 
was used for further ROI analysis. A contralateral normal ROI was also 
annotated when appropriate; in case of a bilateral CSR, no contralateral 
normal ROI was annotated. For every ROI, the median ADC (mADC) was 
calculated and used for further analysis.
Pathology Review
All TRUS-guided biopsy results were centrally reviewed by a single pathologist 
with 18 years of experience in uropathology (CAH) using the International 
Society of Urological Pathology- modified Gleason score classification11. 
Identically, all biopsy cores obtained by MRGB were evaluated by the same 
pathologist in a separate session.
Statistics
Mann-Whitney U testing was performed to detect differences in PSA, 
PSA-density (PSA-D), or number of positive TRUS-guided biopsy cores for 
patients with Gleason upgrading vs those without Gleason upgrading upon 
MRGB. The acquired ADC characteristics were used for analysis of all ROIs. 
For detecting the differences between CSRs and contralateral normal ROIs, 
the Wilcoxon signed ranks test was used. For detecting the differences 
between CSRs harboring low- grade PCa vs. those harboring high-grade 
(Gleason 4 and/or 5 component) PCa, Mann-Whitney testing was performed. 
ROC analysis was used for determination of the area under the ROC curve for 
differentiation between CSRs containing PCa upon MRGB vs. those failing to 
histologically diagnose PCa. Statistical analysis was performed using SPSS 
version 19.0 (Statistical Package for Social Sciences, Chicago, IL). Level of 
significance was set at P<0.05.
less than 0.2 ng/mL/mL, TRUS-guided biopsy Gleason score of 3 + 3 = 6 or 
less, and 2 positive TRUS-guided biopsy cores or less. Initial TRUS-guided 
biopsies were obtained according to local protocols with 9 to 13 cores taken. 
All consecutive patients included in PRIAS in 4 participating referral centers 
without contraindications for MRI were asked to sign informed consent for 
inclusion in a separate arm of PRIAS incorporating MP-MRI and MRGB (MR- 
PRIAS, Dutch Trial Register NTR2006), which was approved by the local 
institutional review board.
Multiparametric MRI and MRGB
All patients underwent MP-MRI including anatomical T2- weighted and DWI 
sequences within 12 weeks from the inclusion in our protocol. Two 
radiologists (JJF, JOB), with 9 and 18 years of experience in prostate MRI, 
evaluated the MP-MRI studies while being informed on the clinical data of 
the patients during the reading. MP-MRI was obtained on a 3-T MR system 
(Trio Tim; Siemens, Erlangen, Germany) using a pelvic phased-array coil and 
an endorectal coil (ERC) (Medrad, Pittsburgh, PA) filled with 40 mL of 
 perfluorocarbon. Dynamic contrast-enhanced MR imaging (DCE-MRI) was 
performed using fast intravenous injection (2.5 mL/s) of 0.1 mmol of 
gadopentetate dimeglumine per kilogram of body weight. The used MP-MRI 
parameters are shown in appendix 2. Every CSR was defined on anatomical 
T2-weighted MRI using DWI and DCE-MRI as described earlier9. In short, all 
obtained MP-MRI imaging modalities were separately analyzed for CSRs 
according to the established criteria10, and in case of an equivocal suspicion 
of PCa on any of the imaging modalities, the region was defined as a CSR 
delivering a high sensitivity reading. Importantly, DWI-derived b800 images 
(s/mm2) were used to delineate CSRs. A lesion was defined as a CSR on DWI in 
case of focal restriction on the conventional ADC map in combination with 
an iso-intense to hyperintense signal intensity on the b800 image. From 
every CSR, at least 1 real-time MRGB was obtained on a 3-T scanner 
(MAGNETOM Skyra; Siemens, Erlangen, Germany) in a separate session by a 
single radiologist (CMH) with 3 years of experience in prostate MRGB 
according to local protocol; MP-MRI data obtained at the MRGB procedure 
was not used for determination of additional CSRs. All patients received 
antibiotic prophylaxis with ciprofloxacin (500 mg) twice a day for 3 days, 
which started on the day before the biopsy. Two radiologists (CMH, TH), with 
3 and 6 years of experience in MRGB, determined CSR sampling accuracy in a 
blinded consensus reading of MRGB confirmation scans.
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Multiparametric MRI, including T2-weighted (A), dynamic contrast-enhanced (B), 
and diffusion-weighted (C) MR images of the presented patient showing a discrete 
hypointense lesion in the left peripheral zone upon T2-weighted corresponding to an 
area of hyperperfusion on dynamic contrast-enhanced and hypointensity on the ADC 
map, defined as CSR. Conventional ADC map at MRGB (D) showing a hypointense 
lesion in the left peripheral zone corresponding to CSR on the pre-MRGB multipara-
metric MRI (blue dotted outline). MRGB of CSR as identified on multiparametric MRI 
(E). Apparent diffusion coefficient calculation of this specific CSR (red) established a 
median ADC of 0.88×10-3 mm2/s, with a mADC of 1.70×10-3 mm2/s for the contralateral 
normal ROI (green). Pathological examination of the obtained MRGB cores confirmed 
a Gleason 3+3=6 PCa.
Figure 1    Case presentation: a 62-year-old patient with an initial PSA of 
7.2 ng/ml and a PSA-D of 0.11 ng/ml/cc. Digital rectal 
examination revealed no abnormalities (cT1c), with a Gleason 3 
+ 3 = 6 PCa in 2 of 9 random TRUS-guided biopsies. MP-MRI 
revealed a single CSR of which MRGB was performed confirming  
a Gleason 3 + 3 = 6 PCa at histopathology.
A D
B
C
E
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Results
We included 54 consecutive patients from November 2009 to September 2011 
according to the criteria for AS as stated in the Methods section. Median age 
in our cohort was 65.0 (interquartile range: 62.0-69.0), with a mean PSA of 
6.2 ng/mL (SD: 1.85) and a mean PSA-D of 0.13 ng/mL/mL (SD: 0.05). The 
number of positive TRUS-guided biopsy cores was 1 in 35 participants, 
whereas 19 participants showed PCa in 2 cores. We were able to identify at 
least 1 CSR in 53 participants, with a median of 2 CSRs (range: 0-4) per 
patient, accounting for a total of 111 CSRs eligible for analysis. Of these, 7 
CSRs were consequently excluded from the analysis because they were 
subject to inadequate tissue sampling by MRGB, as verified by the absence of 
prostate tissue on the final histopathologic examination or severe motion 
artifact rendering the obtained imaging not useful for analysis. From the 
remaining 104 CSRs, at least 1 MRGB was performed, with a median number 
of 2 cores taken from every CSR (range: 1-4) and a median number of 4 cores 
taken per patient (range: 0-6). In 5 CSRs, we were not able to identify a 
contralateral normal ROI. MRGB confirmed PCa in 29 of the 53 patients 
(54.7%) and 32 of 104 CSRs (30.8%), thus leaving 24 of the 53 patients (45.3%) 
with no histological evidence of disease upon MRGB after MP-MRI despite a 
histological diagnosis of PCa upon random TRUS-guided biopsies. Six 
patients had 1 CSR with a high-grade Gleason component (Gleason grade 4 
and/or 5) upon MRGB, of which 5 were upgraded to a Gleason 3 + 4 = 7 PCa and 
1 had a Gleason 3 + 5 = 8 PCa. No statistically significant differences in PSA, 
PSA-D, or number of positive TRUS-guided biopsy cores were recorded for the 
patients with Gleason upgrading vs those without Gleason upgrading upon 
MRGB (see table 1). The mean mADC for all CSRs was 1.19×10-3 mm2/s (SD: 
0.28) compared with a mean mADC of 1.43×10-3 mm2/s (SD: 0.29; p<0.001) for 
the contralateral normal ROIs. The mean mADC in a CSR positively sampled 
for PCa by MRGB was 1.04×10-3 mm2/s (SD: 0.29), whereas the CSRs with no 
PCa upon MRGB displayed a mean mADC of 1.26×10-3 mm2/s (SD: 0.25; 
p<0.001). A diagnostic accuracy of mADC for predicting the presence of PCa 
in a CSR sampled by MRGB with an area under the ROC curve (AUC) of 0.73 was 
established (95% confidence interval: 0.61-0.84) (Fig. 2). Cancer-suspicious 
regions with a high-grade Gleason component upon MRGB displayed a mean 
mADC of 0.84×10-3 mm2/s (SD: 0.35) vs a mean mADC for the low-grade CSRs of 
1.09×10-3 mm2/s (SD: 0.25; p<0.05; Fig. 3).
Table 1    Patient characteristics
All subjects  
(n=54)
MRGB Gleason  
≤3+3=6 or no PCa  
(n=48)
MRGB Gleason  
>3+3=6  
(n=6)
Mean PSA (range) 6.2 (1.2-10.1) 6.3 (1.2-10.1) 6.2 (4.9-7.3)
Mean PSA-density (range) 0.13 (0.02-0.28) 0.13 (0.02-0.28) 0.16 (0.09-0.19)
Mean number of positive 
TRUS-guided biopsy cores 
(range)
1.4 (1-2) 1.3 (1-2) 1.5 (1-2)
Mean number of CSRs 
identified at MP-MRI 
(range)
2.1 (0-4) 2.1 (0-4) 1.7 (1-2)
Mean number of MRGB 
cores taken (range)
3.9 (0-6) 3.8 (0-6) 4.0 (3-5)
Mean number of positive 
CSRs on MRGB (range)
0.6 (0-2) 0.5 (0-1) 1.2 (1-2)
MRGB: MR-guided biopsy; TRUS: transrectal ultrasound; CSR: cancer-suspicious region; MP-MRI: 
multiparametric MR imaging.
Figure 2    ROC curve of mADC for discrimination between CSRs harboring 
no PCa vs any PCa upon MRGB (AUC: 0.73)
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established at 1 year of follow-up and this might comprise a mix of true grade 
and/or volume progression as well as initial undergrading and/or under -
staging, whereas we performed restaging at inclusion, leaving true progression 
unlikely to occur in the presented cohort.
Stringent inclusion for AS will lead to low secondary intervention rates, 
however, at the cost of greatly limiting the number of candidates for such 
protocols. On the other hand, liberal inclusion criteria for AS will reduce the 
number of patients considered not eligible for AS while harboring true 
low-risk PCa but consequently lead to substantial higher intervention rates 
during follow-up. In our opinion, the delicacy of this balance is largely 
determined by inadequate staging and grading tools used to identify 
candidates for AS. Therefore, controversy persists on adequate inclusion 
criteria used for such protocols6,12. The use of Gleason grade as an inclusion 
parameter for AS is definitely hampered by the well-known phenomenon of 
Gleason undergrading by TRUS-guided biopsies13,14. This potentially leads to 
high ‘‘progression’’ rates during AS representing initial undergrading and/
or understaging of PCa by TRUS-guided biopsies, which has been shown in up 
to 27.8% of candidates for AS undergoing radical prostatectomy15-17. An 
interesting approach by Eggener et al.18 incorporated an immediate restaging 
biopsy round before inclusion in an AS protocol, showing a consequently low 
intervention rate of 9% at 2 years of follow-up in their cohort. Unfortunately, 
they did not report separately on the results of this immediate restaging 
biopsy and it remains unknown how many patients were not included based 
upon upstaging at this second biopsy round. The importance of this issue is 
also underlined by 2 recent series showing a 16% to 18% rate of Gleason 
upgrading after immediate repeat biopsy in an AS population19,20.
Approaching the problem of Gleason undergrading by another set of 
TRUS-guided biopsies before inclusion in an AS protocol obviously has 
limitations of its own. MP-MRI of the prostate in combination with MRGB 
might be very well able to fill in this lacuna. T2-weighted MRI as a single 
entity has not been able to differentiate reliably between the low- grade and 
high-grade PCa21, whereas T2-weighted MRI combined with DWI in a radical 
prostatectomy (RP) correlated series has been shown to have good sensitivity 
and specificity for detecting clinical significant PCa, defined as a Gleason 
score of 6 or greater and a tumor diameter greater than 4 mm22. The 
discriminatory value of ADC for the low-risk group vs the intermediate-risk/
Discussion
In our presented series, we found mADC, as acquired from DWI, to significantly 
predict the presence of PCa when sampled by targeted MRGB in the lesions 
qualified as CSR upon MP-MRI. We therefore think that obtaining DWI within 
an MP-MRI setting might be able to efficiently guide targeted biopsies in 
participants who are supposed to be fit for AS. In our cohort, MRGB was able 
to establish high-grade (Gleason 4 and/or 5 component) PCa not sampled by 
TRUS-guided biopsy in 6 of the 54 patients (11.1%), with CSRs harboring 
high-grade PCa displaying a significantly lower mADC compared with the 
low-grade CSRs. Because the progression rate in AS is likely to be dependent 
on the inclusion criteria used, we can only refer to the published short-term 
results of the PRIAS project, with 22% Gleason and/or volume upgrade at 
repeat biopsy.5 Inter- estingly, 10% of the patients in this series were subject 
to Gleason upgrade, which is more or less comparable with the 11.1% percent- 
age we found in our current series. However, direct comparison be- tween 
the 2 series is difficult because the progression rates within PRIAS are 
Figure 3    Box plots of mADC for CSRs harboring no, low-grade or 
high-grade PCa
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strict inclusion criteria, possibly leaving the added value of ADC less 
impressive while evaluating a more true low-risk population upfront. We 
aimed to correlate the DWI features of the AS participants with histopathology 
obtained at inclusion. MRGB has been established to more accurately sample 
prostate cancer Gleason grade compared to TRUS-guided biopsies32 and 
therefore seems to be a more appropriate method to determine histopatho-
logical Gleason grade in AS candidates who are not undergoing RP. For this 
reason, we chose to obtain histopathological verification of our CSRs by 
MRGB in every participant. In the present series, we showed that ADC is able 
to differentiate tumor-bearing CSRs from noncancerous CSRs with reasonable 
accuracy and should thus be considered in any MRI protocol used for 
identification of CSRs and targeting of biopsies in AS candidates.
The main limitation of our series is the lack of follow-up, leaving unrevealed 
how patients who are confirmed to harbor low-risk PCa by MP-MRI and MRGB 
do fare. It is, at this point, impossible to determine whether these patients 
are at a lower risk for progression during follow-up. However, a substantial 
proportion of the participants were identified as participants who have 
incorrectly stratified low-risk prostate carcinoma and were referred for 
definitive curative treatment after the MP-MRI, including DWI, and MRGB. 
Another methodological limitation of our series might be that the ROIs 
defined as contralateral normal were not sampled histologically by MRGB to 
confirm their benign character and might thus be harboring foci of 
low-volume/low-grade cancer in some cases. However, mADC was found to 
be a significant predictor of high-grade PCa upon MRGB in all participants. 
The use of DWI as a single measure to identify and grade PCa is limited by the 
wide variability of ADC values between and within patients, making the 
identification of a threshold for (high-grade) PCa impossible. For this reason, 
DWI should always be part of a MP-MRI setting in which histopathological 
verification of the identified CSRs should be obtained. Within such a 
framework, DWI is a very valuable tool to guide targeted biopsies.
We conclude that DWI is a promising tool for risk stratification in patients 
eligible for AS upon clinical and TRUS-guided biopsy criteria and may aid in 
identification and targeting biopsy of PCa to determine true Gleason grade 
and identify patients subject to Gleason undergrading. Further prospective 
evaluation of our MR- PRIAS cohort will be needed to establish whether 
incorporation of MP-MRI and MRGB at inclusion does lower the risk for 
high-risk groups based upon PSA and TRUS-guided biopsy histopathology 
has been described23. ADC-values have been established to correlate well 
with Gleason score in TRUS-guided biopsies24,25 and, more importantly, RP 
specimens26-28. In addition, ADC has been shown to be able to predict Gleason 
score undergrading in patients with a Gleason grade 3+3=6 or less upon 
TRUS-guided biopsy29 and did outperform TRUS-guided biopsy Gleason 
grade as a predictor of low-risk Gleason grade vs intermediate/high-risk 
Gleason grade upon RP30, suggesting that DWI might be able to identify 
patients who are not correctly graded by TRUS-guided biopsy.
In an AS cohort, the proportion of very low-volume/low-grade PCa is likely to 
be high, which might lead to a high false-negative ratio of MP-MRI for 
predicting the presence of PCa upon MRGB. This was confirmed by the 
inability of MP-MRI and MRGB to detect PCa in 45.3% of patients in our 
series, thus failing to diagnose PCa in a substantial number of AS patients. 
Potentially, TRUS-biopsy artifacts upon MP-MRI might have been 
contributing to the high rate of false-positive CSRs; however, in our 
experience, an interval of more than 4 weeks from TRUS-guided biopsies 
does not hamper PCa detection and should be able to limit biopsy artifacts. 
So far, the lack of follow-up in our described cohort does not elucidate 
whether the patients in whom the presence of PCa was not histologically 
confirmed after MP-MRI and MRGB do harbor truly low-risk disease. If this 
holds true after a prolonged follow-up, in our opinion, MP-MRI with MRGB 
remains the test of choice to confirm the low-risk character of PCa in 
participants eligible for AS and might even be used as a technique to identify 
patients who need to be subjected to further histological diagnosis in case of 
an elevated PSA.
Published data on the performance of DWI in AS use progression at repeat 
biopsy and risk of definitive treatment during follow-up as outcome 
parameters and do not elaborate on the issue of incorrect risk stratification 
at inclusion in AS protocols. Using these outcomes within an AS cohort with 
a PSA less than 15 and a Gleason score of 7 or less, 1 group found ADC to be a 
significant predictor of both adverse repeat biopsy findings and progression 
to definitive curative treatment8,31. However, the criteria used for AS in 
these series make inclusion of a larger proportion of high-grade PCa in 
comparison to our series likely, reflected by a high rate of adverse repeat 
biopsy findings of 40% at 1 year. Most contemporary AS protocols use more 
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for low-risk PCa through a more adequate prediction of biopathological 
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Introduction
Surgical margin status is an important prognostic factor for biochemical 
recurrence following radical prostatectomy (RP) and the only factor to be 
influenced by surgical method and nerve-sparing strategies. Knowledge of 
the presence and localization of extraprostatic extension (EPE) is likely to 
reduce the number of positive surgical margins (PSM) since it enables the 
surgeon to select patients eligible for nerve-sparing procedures1-3. Prediction 
of pT3 prostate cancer by digital rectal examination (DRE)4-6 and transrectal 
ultrasound (TRUS)6,7 is known to have low accuracy. The staging performance 
of MRI for prostate cancer (PCa) has been extensively reported upon with 
sensitivity and specificity rates of 40-77.8% and 76.5-98%, respectively8-14. 
Traditionally, radiologists have been providing high-specificity readings to 
prevent unnecessary abolition of curative surgery while favouring external 
beam radiotherapy over RP in case of suspected pT3 PCa15. While achieving 
good results with RP in patients with possible pT3 PCa16, the focus of 
radiologist might have to shift to high-sensitivity readings aimed at 
reducing PSM rates. Clinicians are mainly concerned with the predictive 
values of the test, rather than its sensitivity or specificity. Using the same 
test in a population with higher prevalence automatically increases positive 
predictive value (PPV). Conversely, increased prevalence results in decreased 
NPV for the same test17. Risk-stratified subgroup analyses for the staging 
performance of multiparametric MRI (MP-MRI) are scarce, while this could 
be an important factor influencing the predictive values for EPE at RP. In 
general, in low- and intermediate risk patients the urologist would be most 
helped by a high NPV to select candidates for active surveillance or 
nerve-sparing RP. In high-risk patients a high PPV is of utmost importance 
as knowledge of the site of EPE might help in reducing the substantial risk of 
a PSM. We evaluated the staging performance of endorectal coil (ERC) 
MP-MRI at 3-Tesla (3-T), including T2-weighted, diffusion-weighted (DWI) 
and dynamic contrast-enhanced (DCE) sequences. Sensitivity, specificity, 
PPV and NPV of MP-MRI for EPE were recorded for different d’Amico risk 
groups (low-, intermediate and high-risk groups). Furthermore we evaluated 
the predictive value of MP-MRI for EPE in a multivariable analysis 
incorporating other well-established predictors of EPE at RP.
Abstract
Purpose We aimed to determine the positive and negative predictive values 
of multiparametric MRI (MP-MRI) for extraprostatic extension (EPE) at 
radical prostatectomy (RP) for different prostate cancer (PCa) risk groups. 
Materials and Methods We evaluated a cohort of 183 patients that underwent 
3 Tesla (3-T) MP-MRI, including T2-weighted, diffusion-weighted MR Imaging 
(DWI) and dynamic contrast-enhanced MRI (DCE-MRI) sequences, with an 
endorectal coil before RP, pathological stage at RP was used as standard 
reference for EPE. The cohort was classified into low-, intermediate and high- 
risk groups according to the d’Amico criteria. We recorded prevalence of EPE 
at RP and determined sensitivity, specificity, positive predictive value (PPV) and 
negative predictive value (NPV) of MP-MRI for EPE in each group. Uni- and 
multivariable analyses were performed to identify predictors of EPE at RP.
Results Overall prevalence of EPE at RP was 49.7% ranging from 24.7-77.1% 
between low- and high-risk categories. Overall staging accuracy of MP-MRI 
for EPE was 73.8%, with sensitivity, specificity, PPV and NPV of 58.2%, 89.1%, 
84.1% and 68.3%, respectively. PPV of MP-MRI for EPE was best in the 
high-risk cohort with 88.8%. NPV was highest in the low-risk cohort with 
87.7%. With an odds ratio (OR) of 10.3 MP-MRI is by far the best pre-operative 
predictor of EPE at RP.
Conclusions For adequate patient counselling, knowledge of predictive 
values of MP-MRI for EPE is of utmost importance. High NPV, important for 
decisions on nerve-sparing strategies at RP, is only reached in low-risk 
subjects.
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gadopentetate dimeglumine (Dotarem, Guerbet, Paris, France). We refer to 
appendix 2 for the specific MP-MRI characteristics. 
All MP-MRI imaging was prospectively evaluated for the presence of EPE by one 
of two experienced radiologists (JJF, JOB) with 8 and 18 years of experience in 
prostate MRI. Following PCa localization using all MP-MRI sequences, presence 
of EPE upon MP-MRI was scored on T2-weighted imaging, according to 
established criteria for EPE and based on personal training and knowledge19. 
Both readers were not blinded to the clinical characteristics of individual 
cases. The MP-MRI reports were categorised by two observers (DMS, EHH) 
using a dichotomous scale for suspicion of EPE at MP-MRI to be used for further 
analysis. Explicit statements about presence or absence of EPE at MP-MRI were 
Material and methods
Subjects
Between January 2007 and December 2010, 183 consecutive patients 
prospectively scheduled for RP underwent MP-MRI at 3-T with an endorectal 
coil, including T2-weighted, DWI and DCE sequences in two referral centres. 
Our institutional review board waived the need for an informed consent. 
Patients with extensive cT3 disease were not considered candidates for RP and 
are therefor not included in this series. MP-MRI staging results were not used 
to exclude patients for RP, as there is no current evidence to what extent a 
suspicion of EPE on MP-MRI would translate into a poor prognostic factor 
before RP. Only evidence of nodal metastasis upon MP-MRI would lead to 
exclusion for RP. For all patients age, prostate specific antigen (PSA) level, 
clinical stage as determined by DRE, and TRUS-biopsy combined Gleason score 
were documented. The majority of patients underwent an 8-12 core 
TRUS-guided biopsy procedure in their referring hospital. Patients were 
stratified according to the d’Amico risk groups as follows; low-risk: PSA less 
than or equal to 10, combined Gleason score less than or equal to 6, and clinical 
stage T1-2a;  intermediate risk: PSA between 10 and 20 and/or Gleason score 7 
and/or clinical stage T2b; high-risk: PSA more than 20 and/or combined 
Gleason score equal or larger than 8 and/or clinical stage T2c-3a18. Within the 
low-risk cohort we classified a subset of patients as low-volume, low-risk PCa 
using a PSA less than or equal to 10, combined Gleason score less than or equal 
to 6, a clinical stage T1 and less than 3 positive biopsies. 
MP-MRI imaging and interpretation
MP-MRI with an ERC was performed using a 3-T MR scanner (Siemens Trio 
Tim, Erlangen, Germany). Patients were examined in the supine position 
using a pelvic phased-array coil in combination with an inflatable ERC 
(Medrad, Pittsburgh, PA, USA). The MP-MRI protocol was consistent over 
time and incorporated anatomical T2-weighted imaging in the axial, sagittal 
and coronal plane, covering the prostate and seminal vesicles. Axial images 
were obtained perpendicular to the ventral surface of the rectal wall to 
facilitate comparison with whole-mount sectioned RP specimens. DWI was 
performed with b-values of 0, 50, 500, and 800 s/mm2. The scanner software 
performed an automated calculation of ADC maps using all acquired b-values. 
DCE was acquired in the transversal plane (time resolution 3.5s, 45 repetitions) 
using intravenous injection (0.1 mmol per kilogram of bodyweight) of 
Figure 1    Case example of true-positive EPE at MP-MRI with correlation of 
RP specimen in a high-risk patient. Patient aged 63 years, 
pre-operative PSA 16 ng/ml, DRE: clinical right-sided T3. 
TRUS-guided biopsy: bilateral Gleason 4+3=7 prostate cancer.
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scored accordingly. In less explicit cases a strong suspicion of EPE was 
classified as positive, whereas cases for whom EPE could not be ruled out were 
classified as negative. For case examples, see figures 1 and 2.
Pathology processing
Following RP, prostate specimens were fixed overnight in 10% neutral 
buffered formaldehyde and routinely processed according to local procedure, 
which is similar for both pathology departments involved. In brief, after 
inking of the surface, the prostate specimen was cut into serial transverse 
 MP-MRI imaging, showing hypo-intensity of the right peripheral zone with ipsilateral 
involvement of the neurovascular bundle on T2-weighted MR imaging (A), confirmed 
by an area of hyperperfusion on dynamic contrast-enhanced MR imaging (B) and 
restriction of diffusion on diffusion-weighted (C) MR imaging, see white arrow.  
RP specimen showing pT3b Gleason 4+5=9 prostate cancer with extensive 
right-sided EPE (D)
Figure 2    Case example of false-negative MP-MRI for EPE with correlation 
of RP specimen. Patient aged 61 years, pre-operative PSA 24, 
DRE: clinical left-sided T2. TRUS-guided biopsy: Gleason 3+4=7 
prostate cancer.
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was used, incorporating all significant predictors of EPE at RP on univariable 
analysis, to identify independent predictors of EPE at RP. The SPSS software 
package version 19.0 (Statistical Package for Social Sciences™, Chicago, IL, 
USA) was used for statistical analysis, with the 2-tailed level of significance 
set at p<0.05.
Results
Patient characteristics are shown in table 2. Overall, 91 patients had EPE in 
their RP specimen, accounting for an overall prevalence of EPE of 49.7%. SVI 
was reported in 21 patients accounting for an overall 11.5% prevalence of 
SVI. Overall accuracy, sensitivity, specificity, PPV and NPV of MP-MRI for EPE 
were 73.8%, 58.2%, 89.1%, 84.1% and 68.3%, respectively. 
Univariable analysis identified PSA, DRE, biopsy Gleason score, d’Amico risk 
group and stage at MP-MRI as significant predictors of EPE at RP, and these 
variables were consequently included in multivariable analysis. Logistic 
regression analysis identified PSA level and MP-MRI stage as significant 
independent predictors of EPE at RP (p<0.05), with stage at MP-MRI being 
the strongest predictor of EPE at RP with an odds ratio (OR) of 10.3 (see table 1).
D’Amico risk groups (see table 2)
Low-risk cohort
According to the d’Amico risk classification 73 patients were stratified as 
low-risk, of which 18 patients had EPE upon RP, thus accounting for a 
prevalence of EPE of 24.7%. SVI was present at RP in one case (1.4%) of the 
low-risk cohort. In this cohort sensitivity, specificity, PPV and NPV of 
MP-MRI for EPE were 61.1%, 90.9%, 68.8% and 87.7%, respectively. 
Low-volume, low-risk PCa was established in 18 patients, with 3 patients 
having EPE upon RP, accounting for a prevalence of EPE of 16.7% in this 
subset. In this subset sensitivity, specificity, PPV and NPV were 33.3%, 
86.7%, 33.3% and 86.7%, respectively.
Intermediate risk cohort
Sixty-two patients had intermediate risk disease according to the d’Amico 
risk classification, with 36 patients diagnosed with EPE upon RP, a 58.1% 
prevalence of EPE. Five patients (8.1%) had SVI in this cohort. Sensitivity, 
3-4 mm thick slices, perpendicular to the dorsal-rectal surface. The apex and 
base were sagittally sectioned to assess the caudal and cranial surgical 
margins. Seminal vesicles were amputated at their junction with the prostate 
and sectioned parallel to their junction and embedded in total. After 
histological staining all tumors were outlined on the microscopic slides and 
subsequently mapped on the macroscopic photographs to allow reconstruction 
of tumor extent and multifocality. For every RP specimen the presence of 
primary and secondary Gleason grade pattern as well as the combined 
Gleason score was recorded. The presence of EPE was reported for all cases, 
including localization and extent. Also the presence of seminal vesicle 
invasion (SVI) was documented in all cases, defining a subset of the EPE 
cohort.
Statistical analysis
Descriptive statistics for all described risk groups were performed to 
calculate accuracy, sensitivity, specificity, PPV and NPV of MP-MRI for EPE at 
RP (see appendix 4). Univariable analysis for age, PSA, DRE, biopsy Gleason 
score, d’Amico risk group and MP-MRI stage was performed using the 
Mann-Whitney U test for continuous variables and the chi-square test for 
categorical variables. For multivariable analysis logistic regression analysis 
MP-MRI imaging, showing hypo-intensity of the left peripheral zone with an intact 
prostatic capsule with some irregularity on T2-weighted MR imaging (A), confirmed by 
an area of hyperperfusion on dynamic contrast-enhanced MR imaging (B) and 
restriction of diffusion on diffusion-weighted (C) MR imaging, see white arrow. RP 
specimen showing pT3a Gleason 4+3=7 prostate cancer with multifocal microscopic 
left-sided EPE (D)
D
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Table 1    Patient characteristics including uni- and multivariate analysis 
of pre-operative predictors of EPE at RP
Variable Overall Low-risk Intermediate 
risk 
High-risk Univariate 
analysis
Multivariate 
analysis
Number/statistics 183 73 62 48 P-value OR (95% CI) P-value
Age (continuous) mean±SD 62.4±4.9 61.1±6.2 63.4±5.2 63.3±6.0 0.158 N/A N/A
Clinical stage cT1 95 (51.9%) 45 (61.6%) 40 (64.5%) 10 (20.8%) <0.001* 1.8 (0.9-3.4) 0.091
cT2 67 (36.6%) 28 (38.4%) 22 (35.5%) 17 (35.4%)
cT3 21 (11.5%) 0 (0%) 0 (0%) 21 (43.8%)
PSA (continuous) mean±SD 10.0±8.4 6.2±2.4 9.4±4.6 16.6±13.1 <0.001* 1.1 (1.0-1.2) 0.029*
Biopsy combined Gleason ≤3+3=6 102 (55.7%) 73 (100%) 17 (27.4%) 12 (25.0%) <0.001* 1.5 (0.8-2.8) 0.269
3+4/4+3=7 58 (31.7%) 0 (0%) 45 (72.6%) 13 (27.1%)
≥4+4=8 23 (12.6%) 0 (0%) 0 (0%) 23 (47.9%)
D’Amico risk classification N/A N/A N/A N/A <0.001* 1.4 (0.6-3.1) 0.458
EPE at MP-MRI T2 120 (65.6%) 57 (78.1%) 42 (67.8%) 21 (43.8%) <0.001* 10.3 (4.4-24.2) <0.001*
T3 63 (34.4%) 16 (21.9%) 20 (32.3%) 27 (56.3%)
EPE at RP pT2 92 (50.3%) 55 (75.3%) 26 (41.9%) 11 (22.9%) N/A N/A N/A
pT3 91 (49.7%) 18 (24.7%) 36 (58.1%) 37 (77.1%)
EPE: extraprostatic extension, RP: radical prostatectomy, OR: odds ratio, CI: confidence interval, 
PSA: prostate-specific antigen, MP-MRI: multiparametric MRI, N/A: not applicable, *significant 
at p<0.05
Table 2    Performance of MP-MRI for predicting EPE upon RP according to 
d’Amico risk groups
D’Amico risk group N EPE prevalence Sensitivity Specificity PPV NPV
All risk groups 183 49.7% 58.2% 89.1% 84.1% 68.3%
Low-risk 73 24.7% 61.1% 90.9% 68.8% 87.7%
Intermediate risk 62 58.1% 50.0% 92.3% 90.0% 57.1%
High-risk 48 77.1% 64.9% 72.7% 88.9% 38.1%
MP-MRI: multiparametric MRI, EPE: extraprostatic extension, RP: radical prostatectomy, N: 
number of cases, PPV: positive predictive value, NPV: negative predictive value.
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EPE in clinically organ-confined disease (<cT3)30. The prevalence of ≥pT3 
disease in their series was 27% and they found an area-under-the-ROC-curve 
(AUC) of 0.80 for the Partin nomograms alone and an AUC of 0.88 when 
augmented with the MR findings. Using the ROC-curve, they concluded that 
the highest incremental value was present in intermediate and high-risk 
groups. However, the ROC-curve does not incorporate predictive values and 
therefore is not likely to be influenced greatly by population prevalence of 
EPE. Cornud et al. found no difference between low- versus intermediate/
high-risk groups9. Only 10% of their patients were categorized as high-risk 
(PSA>20 and Gleason>7) and cT3 disease was excluded from their analysis. 
They reported a sensitivity of 55% and a specificity of 96% for EPE, as well as 
excellent PPV (81%) and NPV (89%) in their series with an EPE prevalence of 
21% for the whole patient group, which is more comparable to our low risk 
cohort with a prevalence of EPE of 24.7%. Possibly their superior NPV is 
explained by their evaluation of a population at a lower risk for EPE compared 
to ours, which underlines our conclusion that the NPV of MP-MRI for EPE is 
best in a low-risk population. 
When MP-MRI is used to select patients eligible for active surveillance a high 
NPV for EPE is of paramount importance and this series shows a very good 
NPV in the low-volume, low-risk subset. An acceptable NPV for ruling out EPE 
using pre-operative imaging should be able to strike the right balance 
between unneeded resection of the neurovascular bundle and the risk of 
PSM and is only reached in the low-risk cohort in our series. The relative high 
proportion of false negative MP-MRI results in intermediate risk subjects 
should place the emphasis on the risk of PSM while discussing the option of 
a nerve-sparing RP in these cases. The NPV of 57.7% for EPE in this cohort is 
hardly sufficient and could benefit most from an adapted high-sensitivity 
reading. When MP-MRI is used to exclude patients with evident EPE from 
curative surgery, high-specificity readings should be performed, leading to 
a high PPV of 88.9% in high-risk subjects. In high-risk cases the high PPV of 
MP-MRI for EPE might aid the urologist in decreasing the risk of PSM even 
when performing a non-nerve-sparing RP.
The first and foremost limitation of our series is the performance of a 
traditional high-specificity reading in all cases as discussed earlier. One 
might argue that if a tailored reading according to risk category, as promoted in 
our conclusion, had been performed, the overall performance of MP-MRI would 
specificity, PPV and NPV of MP-MRI for EPE were 50.0%, 92.3%, 90.0% and 
57.1%, respectively.
High-risk cohort
High-risk disease was established in 48 patients, with EPE present upon RP 
in 37 patients, accounting for an EPE prevalence of 77.1%. In the high-risk 
cohort 15 patients (31.3%) had SVI upon RP. Sensitivity, specificity, PPV and 
NPV of MP-MRI for EPE in this cohort were 64.9%, 72.7%, 88.9% and 38.1%, 
respectively.
Discussion
It has been well established that prevalence of EPE in RP specimens differs 
greatly among risk groups for prostate cancer with a prevalence ranging from 
9.4-16.5% for low-risk subjects20,21 to 44.7-53% for high-risk subjects22,23. The 
prevalence of EPE is also influenced by several established parameters such 
as PSA, clinical stage and biopsy Gleason score5,23-28. We found the overall 
prevalence of EPE in our series to be higher for all risk-groups compared to 
the literature. A contributing factor to our high rates of EPE over all risk 
categories might be the fact that PSA-screening was not very widespread in 
our country in the evaluated period, possibly leading to inclusion of an 
overall higher stage PCa population. 
Sensitivity and specificity of multimodality MRI for detecting EPE differ 
among published series29 and are influenced by magnetic field strength, use 
of an ERC and MRI parameters used. Also, these are influenced by the way the 
radiologist is performing the interpretation, especially in equivocal or 
difficult cases. At present, radiologists have been focusing on high-specific-
ity readings in order to prevent incorrectly ruling out a patient for curative 
surgery while having the lowest false-positive ratio for EPE possible. 
However, one might argue that in current clinical practice high-sensitivity 
readings should be the standard as patients with a suspicion of EPE on 
MP-MRI are not definitely ruled out for curative surgery. 
To our knowledge, only two earlier series evaluated the staging performance 
of MP-MRI in a risk-stratified population. Wang et al. looked at the 
incremental value of MR staging to the Partin nomogram for prediction of 
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increase, especially in the intermediate risk group. Also, the radiologist was not 
blinded to the patient characteristics and an interpretation bias cannot be 
excluded. Lastly, all MP-MRI studies and reports were from one of two very 
experienced readers and it remains unknown whether the presented results 
are reproducible in a centre with a different experience level.
Conclusions
Compared with other pre-operative parameters MP-MRI is the best predictor 
of EPE at RP. With the presence of EPE in one out of four patients in the 
low-risk cohort it is justifiable to evaluate every subject pre-operatively with 
MP-MRI before deciding upon nerve-sparing approaches with a NPV of 87.7% 
for EPE. In intermediate risk subjects the reassurance by MP-MRI for 
performing a nerve-sparing approach in selected cases implies a risk of PSM 
due to the high proportion of false-negative MP-MRI. The radiologist can 
deliberately influence the sensitivity and specificity of a reader-dependent 
test such as MP-MRI and should therefor be aware of the different clinical 
issues posed according to risk categories. Considering this, the radiologist 
will be able to provide a tailored estimation of EPE according to these 
implications, which warrants a high-sensitivity MP-MRI reading in low- and 
intermediate risk subjects, and a high-specificity MP-MRI reading in 
high-risk patients. 
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Prognostic relevance  
of number and bilaterality of 
positive surgical margins after 
radical prostatectomy
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Introduction
The 5- and 10-year overall survival rates of radical prostatectomy (RP) are 
excellent1, leading to significant survival benefit compared to watchful 
waiting2. In the absence of extraprostatic extension (EPE) and positive 
surgical margins (PSM), the rates of biochemical recurrence (BCR) are low3. 
This does not stand true for patients with a PSM, a common pathological 
feature following RP, with a prevalence varying between 5 and 43% in 
different series4,5. Several studies have shown PSM to be one of the most 
important prognostic factors for BCR following RP4-13.
The EORTC 22911 trial14 established that adjuvant external irradiation after 
RP improves biochemical recurrence (BCR)-free survival in patients with a 
PSM or pathological T3 stage. Whether this translates into an overall survival 
benefit could not be detected due to a relative short follow-up. In this trial, 
43.7% of the patients in the wait-and-see arm experienced biochemical or 
clinical progression or death. This percentage was reduced to 26.1% in the 
irradiation arm. However, if all patients in this series would have received 
immediate radiotherapy, over fifty percent would have received intervention 
without ever progressing to BCR at the cost of radiotherapeutic toxicity. 
Therefore, characterization of patients at high risk of BCR after RP would be 
of great help to identify those patients benefitting most of immediate 
postoperative radiotherapy. Reevaluation of the EORTC 22911 data by van 
der Kwast et al.15 stressed that among patients with adverse pathological 
features on RP, those with PSM benefit most from immediate radiotherapy, 
preventing 291 BCR events for every 1,000 treated. We hypothesized that the 
number of PSMs or bilaterality of PSMs is an additional risk factor of BCR in 
patients with a PSM and may indicate who will be ideal candidates for 
adjuvant postoperative radiotherapy.
Patients and methods
Study population and data retrieval
The pathology reports of 1,395 open retropubic RP procedures performed at 
the Department of Urology, Université Catholique de Louvain, Brussels, 
between 1980 and 2006 by two surgeons were retrospectively evaluated for 
PSM status. Since 1999, intra-operative frozen sections were used to avoid 
Abstract
Purpose Positive surgical margin (PSM) status following radical prostatectomy 
(RP) is a well-established prognostic factor. The aim of the present study is 
to evaluate whether number of PSMs or bilaterality of PSMs might have 
prognostic significance for biochemical recurrence (BCR) in the population 
with a PSM status following RP.
Methods We evaluated 1,395 RP pathology reports from the Université 
Catholique de Louvain, Brussels, Belgium between 1980 and 2006. All 
patients who underwent (neo)-adjuvant therapy were excluded, leaving a 
cohort of 1,009 patients, with 249 (24.7%) subjects having a PSM at RP of 
whom 29.4% had multiple PSMs (≥2 sites), while 13.6% had bilateral PSMs. 
Median follow-up was 40 months (range 0–258 months). We used BCR-free 
survival as the primary study outcome. BCR was defined as any rise in PSA 
above or equal to 0.2 ng/ml.
Results Of patients with a PSM status, 41% (95% CI: 33– 49%) developed BCR 
within 5 years, compared to 12% (95% CI: 9–15%) in the population without 
a PSM. Multivariable analysis identified PSA at diagnosis and RP Gleason 
score as independent predictive factors for BCR. Increasing number and/or 
bilaterality of PSM did not lead to significant higher rates of BCR.
Conclusion In patients with a PSM, the number of positive sites or bilaterality 
of PSM status does not add prognostic information for risk of BCR. Survival 
curve slopes were different for patients with bilateral PSM, showing a 
significant tendency to progress to BCR earlier during follow-up than 
patients with unilateral PSM.
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With the numbers of single and multiple PSM cases in our series, and an 
assumed 40% 5-year risk of BCR, we had an 80% power to detect a hazard 
ratio (HR) of 1.5. Likewise, we had a power of 80% of detecting a HR of 1.7 for 
the comparison between unilateral and bilateral PSM.
Results
We found sufficient data on surgical margin status for 1,314 patients to 
include them in our study. Of these, 378 (27.1%) had one or more PSMs. Those 
who received immediate postoperative radiotherapy (n = 181), neo-adjuvant 
(n=171), or adjuvant hormonal therapy (n=18) were excluded, leaving a 
cohort of 1,009 patients, with 249 (24.7%) subjects having one or more PSMs. 
Of 723 patients with a pT2 status, 122 (16.9%) had a PSM, compared to 123 of 
266 (46.2%) patients with a pT3 status, 8 patients had pT4 tumor, of which 4 
had PSM (50.0%). Seven patients had pT0 status upon RP, and in 5 patients, 
the pathological stage could not be established. The median follow-up was 
40 months (range 0-258 months). We found sufficient data on number of 
PSMs in 218/249 pathology reports; of these, 70.6% had a single PSM, while 
the remaining 29.4% had two or more PSMs. In 191/249 subjects, sufficient 
data were reported to determine PSM bilaterality; of these, 86.4% of the PSMs 
were unilateral and the remaining 13.6% bilateral. Pathological stage 
differed significantly between single and multiple PSM status (P = 0.04) and 
unilateral versus bilateral PSM status (P = 0.03), with patients with multiple 
or bilateral PSMs having higher pathological stages. Age, PSA at diagnosis, 
and RP Gleason score did not differ significantly among groups. Table 1 
summarizes all relevant patient characteristics as identified in our series.
Overall, 41% (95% CI: 33–49%) of subjects with a PSM developed a BCR within 
5 years, compared to 12% (95% CI: 9–15%) in the population without a PSM. 
When subdivided into single and multiple PSMs, these percentages were 43% 
(95% CI: 32–54%) versus 46% (95% CI: 31– 61%), respectively. Unilateral 
versus bilateral PSM subjects had 5-year BCR rates of 45% (95% CI: 35–55%) 
versus 46% (95% CI: 24–68%), respectively. Patients with data missing on 
number of PSMs had a 5-year BCR rate of 24% (95% CI: 6–42%), while those 
with missing data on bilaterality had a 5-year BCR rate of 30% (95% CI: 16– 
44%). When we used the Wilcoxon test to detect differences in the slope of 
the survival curves, we found that survival curve slopes for unilateral versus 
PSMs. Patient and tumor characteristics were retrospectively reviewed for 
all subjects with a PSM. All subjects who were treated with neo-adjuvant 
and/or adjuvant hormonal therapy or immediate postoperative radiotherapy 
were excluded. Data on number and bilaterality of PSM, as well as pathological 
stage, RP Gleason score and the presence of perineural invasion (PNI) were 
obtained from the original pathology reports. Charts were retrospectively 
reviewed for PSA at diagnosis and follow-up data. BCR was defined as any 
rise in PSA (ng/ml) above or equal to 0.2 ng/ml.
Pathology processing
The left and right sides of the prostate gland were identified by a longitudinal 
incision into the right anterior half. Following fixation in buffered 10% 
formaldehyde, the 5-mm thick proximal and distal transections of the 
prostate were serially sectioned at 2-mm intervals parallel to the urethra. 
The tips of the vasa deferentia were transected, and the seminal vesicles 
were longitudinally sectioned up to their junction with the prostate. The 
remaining prostate gland was then serially sectioned perpendicularly to the 
apical-basal axis at 5-mm intervals to perform whole mount sections. The 
external surface of surgical radical prostatectomy specimens was covered 
with ink since 1990. Surgical margins were considered as positive or negative 
when the malignant cells were separated without or with any amount of 
benign tissue from the inked edge of the surgical resection of the gland, 
respectively. The paraffin-embedded tissues were recut if necessary until 
visualization of the inked margin. When the margins had not been inked, 
the paraffin blocks were recut until the whole circumference of the tissue 
sample was mounted on the slide. The edges of the artifactual disruptions of 
prostatic or extraprostatic tissue were not considered as surgical margins.
Statistical analysis
For statistical analysis, we used SPSS software (SPSS, version 16.0.01, 
Chicago, Illinois, USA). Kaplan–Meier survival analysis was performed with 
BCR-free survival as outcome for both single versus multiple PSM and 
unilateral versus bilateral PSM. The Wilcoxon test was used to detect 
significant differences in BCR-free survival rates between groups. 
Multivariable Cox proportional hazards regression models were composed to 
determine prognostic factors for BCR. As multiple PSMs will represent a large 
subgroup of bilateral PSMs, we performed multivariable analysis for both 
factors separately. Statistical significance in our study was set at P < 0.05. 
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bilateral PSM did differ significantly (P = 0.029), as the bilateral PSM cohort 
did progress to BCR earlier during follow-up, with the curves closing in later 
on (see figure 1).
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Figure 1    Kaplan Meier BCR free survival curves for unilateral and  
bilateral PSM
Month 0 12 24 36 48 60
Unilateral PSM cumulative number of events 0 16 31 42 47 51
remaining number at risk 165 134 92 65 45 28
Bilateral PSM cumulative number of events 0 9 10 10 10 10
remaining number at risk 26 12 10 9 9 7
BCR: biochemical recurrence, PSM: positive surgical margin, F/U: follow-up.
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Univariable analysis identified PSA at diagnosis, pathological stage, RP 
Gleason score, and perineural invasion (PNI) as possible predictors of BCR 
after RP in this PSM series, and these factors were consequently included in 
the multivariable analysis. Bilateral PSM status and multiple PSM status had 
no prognostic value for BCR on univariable analysis. Multivariable analysis 
identified PSA at diagnosis and RP Gleason score as independent prognostic 
factors for BCR. Bilateral PSM status and number of PSMs did not add 
prognostic information (see Table 2).
Discussion
Data on 5-year risk of BCR for PSM patients following RP are reported between 
25 and 47%5,10–12. No effect on prostate cancer-specific survival or overall 
survival has been determined for PSM status, probably because the available 
follow-up does not suffice to detect these differences if present. Preoperative 
PSA, RP Gleason score, and pathological stage are well-established predictors 
of BCR following RP3,16–19. In correspondence with other series, we identified 
RP Gleason score as a prognostic factor for BCR among patients with a 
PSM5,7,9,11. All these earlier reports identified pathological stage as a 
prognostic factor for BCR as well, which we could only confirm in univariable 
analysis. This might be contributed to the 370 patients that were excluded 
from our analysis because of (neo)-adjuvant therapy leading to a dispropor-
tional exclusion of poor-risk subjects with higher pT-stages. Furthermore, 
pT3 subjects were more likely to have PSM, which was included in 
multivariable analysis, and might, due to its profound effect on BCR rates, 
diminish the effect of pT3 stage on BCR rates. Much debate remains over the 
prognostic value of PNI in RP specimens20, 21. In our subset of patients with 
PSMs, we could not identify PNI as an independent prognostic factor for BCR 
on multivariable analysis.
Five studies address the number of PSMs in detail in populations that did not 
receive immediate postoperative therapy and yielded contradictory results. 
In a subset of 80 PSM patients analyzed by Lowe and Lieberman, a significant 
increase in BCR for patients with multiple PSMs compared with single PSM 
was found22, a finding confirmed in another series by Sofer et al. with 210 
patients with PSM23. Both series did not include pathological stage in their 
multivariable analyses, which may have led to biased results as one might Ta
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To our knowledge, no study on bilaterality of PSM status has been published 
before. Nevertheless, one might hypothesize that bilateral PSM status might 
influence BCR- free survival, as it might express more extensive tumor 
involvement of the prostate bed after RP. Nevertheless, we could not identify 
an independent prognostic value of bilateral PSM status on multivariable 
analysis in our series. We found patients with bilateral PSM to progress to 
BCR earlier during follow-up, with survival curves closing in at about 5-years 
of follow-up.
The main limitation of our series is the retrospective data collection, which 
led to a substantial number of missing data in which we could not establish 
the details of PSM status on number and bilaterality. Interestingly, patients 
with missing data did better as far as BCR rates are concerned, which might 
be attributed to less detailed pathological reporting on number and 
bilaterality of PSM in case of a single or limited multiple PSM status. Another 
concern is the relatively low power of our series to detect differences between 
groups; this is mainly an issue in the comparison of unilateral versus bilateral 
PSM, as only 26 subjects were documented to have bilateral PSM. Furthermore, 
the median follow-up of approximately 40 months could be insufficient to 
detect differences in long-term BCR in our series.
Conclusions
We conclude that number or bilaterality of PSM are not independent 
predictors of BCR, although patients with bilateral PSMs did show a 
significant tendency to progress to BCR earlier during follow-up compared to 
patients with unilateral PSMs. For conclusive evidence, future prospective 
series with longer median follow-up addressing this issue are needed. The 
search for more valid prognostic markers for disease recurrence following RP 
continues for better risk stratification and decision making regarding 
timing of adjuvant radiotherapy in post-RP subjects.
hypothesize that extraprostatic extension (pT3) is far more common in the 
subgroup with multiple PSM status. In our series, we could confirm that 
pathological T3 stage was significantly more common in the multiple and 
bilateral PSM cohorts compared with the single PSM cohort. This hypothesis 
is supported by a larger series by Blute et al. of 697 pT2 patients with a PSM in 
which only a slightly higher rate of BCR was found for patients with multiple 
PSM when compared with those with a single PSM24. Also, a more recent 
report on PSM status in 354 patients with extraprostatic carcinoma (pT3a/b) 
on RP could also not detect a significant difference in BCR between patients 
with single and multiple PSMs11. Therefore, we think that any report on PSM 
status should include pathological stage in the multivariable analysis in 
order to be able to assess the independent prognostic value of PSM status 
properly. Furthermore, as patients with multiple or bilateral PSMs tend to 
experience BCR earlier during follow-up with Kaplan-Meier curves closing in 
later on, the relative short follow-up of 22 months by Sofer et al.23 could have 
led to a false impression of increased BCR for multiple PSMs when processing 
Kaplan-Meier curves on these data. This is supported by the difference in 
calculated 5-year BCR rates for multiple PSMs between ours and their series, 
41% versus approximately 60% (read from the Kaplan–Meier curve), 
respectively. A series by Jayachandran et al. reporting on 902 patients with 
PSM and/or pT3 disease could not identify pathological stage as an 
independent predictor of BCR on univariable analysis, and thus, did not 
incorporate this factor in their multivariable analysis25. Consequently, they 
found number of PSM to be significantly associated with BCR on univariable 
and multivariable analysis, a finding we could not confirm. In their series, 
they did however exclude a substantial number of patients (n = 205) with 
seminal vesicle invasion, which could account for a large number of BCR 
subjects in our series as these are relative poor-risk subjects within the pT3 
subgroup.
We did not take the extent or length and site of PSM into account, and 
contradictory reports have been published on this issue. Some finding 
length of PSM as a prognostic marker for BCR26, whereas others could not 
identify extent of PSM as a prognostic marker8,27. Most series did not find site 
of PSM to be predictive of BCR23,27, while Blute et al.24 identified the prostate 
base as the only anatomic site of PSM predictive for recurrence at that specific 
anatomic site with a significant effect on 5-year risk of BCR, which increased 
from 15 to 44% in case of a PSM at the prostate base.
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Chapter 6
SUMMARY OF THESIS 
NEDERLANDSE SAMENVATTING
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6. Summary of thesis 
Chapter 3 elaborates on current biopsy strategies and confirms the 
reluctance with TZB for baseline TRUS-guided biopsies as currently 
advocated in most (inter)national guidelines. It describes the efficacy of 
MRGB following repeated negative TRUS-guided biopsies. Chapter 3 also 
gives information on the role of MP-MRI and consequent MRGB in an AS 
protocol (MR-PRIAS) excluding a substantial number of undergraded and/or 
understaged patients from AS.
In chapter 3.1 we present a series on the added value of TZB in a baseline 
TRUS-guided biopsy setting. We found TZB to have little incremental value 
over sextant PZ biopsies with regard to the diagnosis of PCa, increasing the 
diagnostic yield from 40.5% to 42.2% for PCa detection. Furthermore, TZB 
did not increase the grading performance of PZB importantly as only 2.4% of 
patients had Gleason 4 and/or 5 components in their TZB cores not present in 
the sextant PZB cores. Interestingly, there is a persistent need for repeat 
biopsy procedures as 8.1% of patients not diagnosed with PCa upon baseline 
TRUS-guided biopsy were diagnosed with PCa during follow-up. Overall, 
26.8% of consequent biopsy procedures, including repeated TRUS-guided 
biopsy and MRGB, were positive for PCa.
Chapter 3.2 shows that MRGB is able to detect PCa in a majority of cases 
suspected to have PCa following 2 or more negative TRUS-guided biopsy 
sessions. Overall, 59% (40/68) of MRGB procedures in this series led to a 
diagnosis of PCa, of which the majority were deemed clinically significant 
based upon PSA-characteristics, biopsy Gleason score and/or RP specimen. 
Within this highly selected population referred for MRGB, 57% of PCa 
locations were found anteriorly, an area not sampled easily by TRUS-guided 
biopsies. This underlines the need for focusing repeated (TRUS-guided) 
biopsy procedures at the anterior aspects of the prostate. The high diagnostic 
yield of MRGB for patients following negative TRUS-guided biopsies has now 
been reproduced by several larger series from different centers.
Chapter 3.3 illustrates the potential role of MP-MRI and consequent MRGB at 
inclusion in an AS protocol. MRGB of CSRs identified upon MP-MRI detected 
a Gleason 4 and/or 5 component not detected by TRUS-guided biopsies in 
10.9% (7/64) of cases. Four out of 64 patients (6.3%) had a suspicion of EPE at 
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Gleason undergrading when evaluating their RP specimen. The slice with the 
lowest ADC-value, representing the most aggressive part of the tumour, was 
used for evaluation. DWI was able to identify those patients subject to 
Gleason undergrading with high accuracy with an area under the ROC-curve 
of 0.88. 
In chapter 4.4 ADC characteristics of subjects considered eligible for AS 
according to PRIAS-criteria are discussed. We found patients harbouring no 
PCa, low-grade PCa (no Gleason 4 and/or 5 component) or high-grade PCa 
(any Gleason 4 and/or 5 component) upon MRGB of CSRs defined upon 
MP-MRI evaluation to display significantly different ADC-values of 1.26 x 
10-3 mm2/s, 1.09 x 10-3 mm2/s and 0.84 x 10-3 mm2/s, respectively. With an AUC 
of 0.73 for prediction of PCa in a CSR the reliability of DWI to accurately rule 
out PCa is in our opinion too low to abolish targeted biopsies of CSRs at this 
point. However, DWI seems able to guide the targeted biopsies to the most 
aggressive part of the tumour with fair accuracy. The implications of a 
false-negative MP-MRI evaluation in an AS population with an earlier 
histological diagnosis of PCa, leading to negative MRGB in 45.3% of cases in 
this series, remain to be determined with prolonged follow-up.
Chapter 5 defines the possibilities of personalized decision-making based 
upon staging MP-MRI results and the finding of PSM status following RP. 
Knowledge of the predictive values of MP-MRI for EPE stratified for different 
PCa risk categories facilitates patient counselling on treatment options. 
Similarly, the appraisal of PSM status and possible subsets at high-risk of 
BCR provides the urologist with tools to discuss the need for immediate 
adjuvant radiotherapy following RP.
Chapter 5.1 confirms the ability of MP-MRI to stage PCa reliably, 
outperforming all the other pre-operative characteristics currently available 
with an odds-ratio (OR) of 10.3 upon multivariate analysis. We established 
an overall sensitivity, specificity, positive predictive value (PPV) and 
negative predictive value (NPV) of 58.2%, 89.1%, 84.1% and 68.3%, 
respectively, of MP-MRI for EPE at RP. More specifically this series introduces 
the varying performance of staging MP-MRI in different risk-stratified PCa 
subsets. It identifies superior NPV in low-risk patients, suggesting that the 
finding of no suspicion of EPE on MP-MRI confirms the possibility of AS or a 
nerve-sparing RP to the urologist. On the other hand the PPV in this same 
a MRGB-positive CSR and were consequently excluded from AS. Six patients 
were excluded from the protocol at the referring physicians discretion while 
harbouring multifocal PCa. In total, 23.4% of patients were excluded from AS 
based upon MP-MRI/MRGB findings. As far as re-evaluation at 1 year is 
concerned, only 3/30 (10.0%) patients were excluded based upon MP-MRI/
MRGB findings alone, suggesting little added value during follow-up 
compared to standard evaluation with repeated TRUS-guided biopsies. 
However, the very limited number of patients reaching the 1-year follow-up 
landmark in this series makes it hard to draw any meaningful conclusions so 
far and follow-up will continue.
In chapter 4, we explore the benefits of DWI and DWI-derived ADC values in 
optimizing pre-treatment grading of PCa and identifying patients at risk for 
Gleason undergrading by TRUS-guided biopsies. This specific quality of DWI 
finds its main merits in selection of patients eligible for AS and pre-treatment 
risk stratification.
Chapter 4.1 presents and overview of state-of-the-art MP-MRI imaging and 
a review of literature providing a framework for the series presented in the 
consequent subchapters. This review identifies MP-MRI, combining 
T2-weighted MR imaging, DWI and DCE-MRI, as a reliable localization and 
staging tool for PCa and outlines the promises that MP-MRI, and more 
specifically DWI, behold for adequate grading of PCa.
Chapter 4.2 outlines the correlation between ADC and final RP Gleason score 
for PZ PCa, establishing an area under the ROC-curve (AUC) of 0.90 for dif-
ferentiation between low-grade (Gleason ≤3+3=6) and intermediate and 
high-grade PCa. ADC-values differed significantly (p<0.001) for low-, 
intermediate and high-grade PCa, with 1.30 x 10-3 mm2/s, 1.07 x 10-3 mm2/s 
and 0.94 x 10-3 mm2/s, respectively . ADC-values thus enable correct 
pre-treatment grading of PCa and DWI might be able to overcome the 
limitations of current grading of PCa by TRUS-guided biopsies. This series 
identifies DWI as an important adjunct for clinical decision-making.
Chapter 4.3 addresses the clinically important issue of Gleason undergrading 
by TRUS-guided biopsies and explores ADC as a possible tool to identify 
patients subject to Gleason undergrading prior to RP. In a set of patients with 
a TRUS-guided biopsy Gleason score ≤3+3=6, 48% of patients were subject to 
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6. Nederlandse Samenvatting
Dit proefschrift omhelst de uitdagingen in de diagnostiek en gradering/
stadiëring van het gelokaliseerd prostaatcarcinoom (PCa). De nadruk ligt 
allereerst op het optimaliseren van biopsiestrategieën om op een zo min 
mogelijk belastende wijze tot een adequate diagnose te komen. Verder wordt 
uitgebreid ingegaan op de rol van gevanceerde multiparametrische MRI- 
technieken om de diagnostiek rondom het PCa te verbeteren en op die wijze 
tot optimale therapiekeuzes te komen voor de individuele patient.
Hoofdstuk 3 gaat in op de huidige biopsiestrategieën voor PCa en bevestigt 
de terughoudendheid met transitiezone biopten (TZB) voor een eerste sessie 
TRUS-geleide biopsieën zoals momenteel bepleit in de meeste (inter)
nationale richtlijnen. Het beschrijft de effectiviteit van MR-geleide biopten 
(MRGB) na herhaalde negatieve TRUS-geleide biopsieën. Hoofdstuk 3 geeft 
ook informatie over de rol van de multiparametrische MRI (MP-MRI) en 
daaruit voortvloeiende MRGB in een active surveillance (AS) protocol (MR- 
PRIAS) met als gevolg exclusie van een aanzienlijk aantal patiënten als 
gevolg van ondergradering en onderstadiëring bij TRUS-geleide biopsieën. 
In hoofdstuk 3.1 presenteren we een serie over de toegevoegde waarde van 
TZB in de context van eerste TRUS-geleide biopsieën. We stelden vast dat TZB 
weinig toegevoegde waarde hadden ten opzichte van sextantbiopten van de 
perifere zone (PZ) met betrekking tot de diagnose van prostaatcarcinoom 
(PCa), met een toename van PCa detectie van 40,5% tot 42,2%. Bovendien 
bleken TZB niet veel bij te dragen in de gradering van PCa, aangezien slechts 
2,4% van de patiënten een Gleason 4 en/of 5 component in hun TZB had die 
niet in de sextant perifere zone biopten (PZB) gevonden werd. Er is er een 
duidelijke indicatie voor herhaalde biopsieën aangezien 8,1% van de 
patiënten die niet werd gediagnosticeerd met een PCa bij eerste TRUS-geleide 
biopsie, alsnog werd gediagnosticeerd met PCa tijdens de follow-up. Hierbij 
waren 26,8% van de biopsieprocedures gedurende follow-up, waaronder 
herhaalde TRUS-geleide biopsieën en MRGB, positief voor PCa.
Hoofdstuk 3.2 laat zien dat MRGB in staat is om PCa op te sporen in een 
meerderheid van de gevallen met een persisterende verdenking op PCa na 2 
of meer negatieve TRUS-geleide biopsiesessies. In het algemeen leidde 59% 
(40/68) van MRGB procedures in deze serie tot een diagnose van PCa, 
category is low, possibly leading to some unneeded non-nerve-sparing 
procedures or incorrect exclusion from AS protocols, when using MP-MRI for 
these decisions. On the other end of the risk spectrum, PPV for EPE is 
specifically high in high-risk patients, establishing MP-MRI as a meaningful 
study to have good knowledge of the site of EPE during RP, or explore other 
treatment options such as external beam radiotherapy in case of extensive 
EPE not likely to be cured by RP. 
Chapter 5.2 aims to identify a subset of patients with PSM following RP at 
high risk for BCR. The expansion of the set of known risk factors for BCR 
following a PSM status, such as length of PSM and localization at the base of 
the prostate, might improve the identification of patients likely to benefit 
from immediate adjuvant radiotherapy following RP. We present a negative 
study not able to identify multiple and/or bilateral PSM as a predictor of BCR, 
while adequately powered to do so. We did, however, find a significant 
tendency of patients with bilateral PSM status to progress to BCR earlier 
during follow-up.
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gecreëerd voor de daarna volgende series in dit hoofdstuk. Dit review 
identificeert MP-MRI, bestaande uit een combinatie van T2-gewogen MRI, 
DWI en dynamic contrast-enhanced (DCE) MRI, als een betrouwbare 
lokalisatie- en stadieringstool voor PCa en schetst de mogelijkheden die 
MP-MRI, en meer specifiek DWI, hebben voor een adequate gradering van 
PCa.
Hoofdstuk 4.2 beschrijft de correlatie tussen ADC en radicale prostatectomie 
(RP) Gleason score voor PCa in de PZ, met een area-under-the-ROC-curve 
(AUC) van 0,90 voor differentiatie tussen laaggradig (Gleason ≤ 3 +3 = 6) en 
intermediair en hooggradig PCa. ADC-waarden verschilden significant (p 
<0,001) voor laag-, intermediair en hooggradig PCa, met 1,30x10-3 mm2/s, 
1,07x10-3 mm2/s en 0,94x10-3 mm2/s, respectievelijk. Juiste gradering van 
PCa middels DWI/ADC voorafgaand aan behandeling overwint dus mogelijk 
de huidige beperkingen voor de classificatie van PCa middels TRUS-geleide 
biopsieën. Als zodanig identificeert deze serie DWI als een belangrijk 
hulpmiddel voor klinische besluitvorming.
Hoofdstuk 4.3 behandelt de klinisch belangrijke kwestie van Gleason 
ondergradering middels TRUS-geleide biopsieën en verkent ADC als een 
mogelijk instrument om patiënten met Gleason ondergradering voorafgaand 
aan RP te identificeren. In een reeks van patiënten met een TRUS-geleide 
biopsie Gleason score ≤3+3=6, had 48% van de patiënten Gleason onder- 
gradering bij de beoordeling van hun uiteindelijke RP specimen. Het 
segment met de laagste ADC-waarde, hetgeen het meest agressieve deel van 
de tumor identificeert, werd gebruikt voor evaluatie. DWI kon patiënten met 
Gleason ondergradering met hoge nauwkeurigheid identificeren met een 
area-under-the-ROC-curve van 0,88.
In hoofdstuk 4.4 worden de ADC kenmerken van patiënten die in aanmerking 
komen voor AS volgens de PRIAS-criteria besproken. We stelden vast dat 
patiënten die geen, laaggradig (geen Gleason 4 en/of 5 component) of 
hooggradig PCa (Gleason 4 en/of 5 component) hadden bij MRGB van de 
 geïdentificeerde CSR’s significant verschillend ADC-waarden hadden van 
1,26x10-3mm2/s, 1,09x10-3 mm2/s en 0,84x10-3 mm2/s, respectievelijk. Met 
een AUC van 0,73 voor het voorspellen van de aanwezigheid van PCa in een 
CSR is de betrouwbaarheid van DWI om PCa nauwkeurig uit te sluiten naar 
onze mening te laag om af te zien van gerichte biopten van de betreffende 
waarvan de meeste klinisch significant werden geacht op basis van PSA- 
karakteristieken, biopsie Gleason score en/of het uiteindelijke RP specimen. 
Binnen deze sterk geselecteerde populatie verwezen voor MRGB, werden 57% 
van de aangetoonde PCa locaties aan de ventrale zijde van de prostaat 
gevonden, een gebied dat niet gemakkelijk bereikt wordt door TRUS-geleide 
biopsieën. Dit onderstreept de noodzaak voor het richten van herhaalde 
(TRUS-geleide) biopsieën op de ventrale zijde van de prostaat. De hoge 
diagnostische opbrengst van MRGB voor patiënten na eerdere negatieve 
TRUS-geleide biopsieën is inmiddels bevestigd door een aantal grotere series 
uit verschillende centra.
Hoofdstuk 3.3 illustreert de mogelijke rol van MP-MRI en daaruit voort-
vloeiende MRGB bij inclusie in een AS protocol. MRGB van cancer-suspicious 
regions (CSR) zoals geïdentificeerd op MP-MRI toonde een Gleason 4 en/of 
5-component aan die niet was gevonden met TRUS- geleide biopsieën in 
10,9% (7/64) van de gevallen. Vier van de 64 patiënten (6,3%) had een 
vermoeden van extraprostatische extensie (EPE) bij een MRGB-positieve 
CSR en werden daardoor uitgesloten van AS. Binnen dit protocol werden zes 
patiënten uitgesloten van AS door de verwijzend uroloog in verband met 
multifocaal PCa. In totaal werden 23,4% van de patiënten van AS uitgesloten 
op basis van de MP-MRI/MRGB bevindingen. Wat betreft de herbeoordeling 
na 1 jaar, werden slechts 3/30 (10,0%) patiënten uitgesloten op basis van enkel 
de MP-MRI/MRGB bevindingen, hetgeen weinig toegevoegde waarde tijdens 
de follow-up suggereert in vergelijking met de standaard evaluatie met 
herhaalde TRUS-geleide biopsieën. Het zeer beperkte aantal patiënten dat 
tot dusver de 1-jaar follow-up bereikte in deze serie maakt het echter 
moeilijk om zinvolle conclusies te trekken.
In hoofdstuk 4 exploreren we de mogelijkheden van diffusie-gewogen MRI 
(DWI) en de DWI-afgeleide apparent diffusion coefficient (ADC) waarden in 
het optimaliseren van de gradering en behandeling van PCa en het 
identificeren van patiënten met een risico op Gleason ondergradering door 
TRUS-geleide biopsieën. Deze specifieke kwaliteit van DWI heeft zijn 
belangrijkste verdienste in de selectie van de patiënten die in aanmerking 
komen voor AS en voor risicostratificatie voorafgaand aan behandeling.
Hoofdstuk 4.1 presenteert een overzicht van state-of-the-art MP-MRI 
beeldvorming en een review van de literatuur. Hiermee wordt een kader 
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Hoofdstuk 5.2 richt zich op het identificeren van patiënten met een hoog 
risico op BCR in geval van een PSM bij RP. De uitbreiding van het aantal 
bekende risicofactoren voor BCR na een PSM, zoals lengte van PSM en 
lokalisatie ter hoogte van de basis van de prostaat, kan de identificatie van 
patiënten die baat hebben bij onmiddellijke radiotherapie na RP verbeteren. 
Het betreft hier een negatieve studie, waarbij we multifocale of bilaterale 
PSM-status niet hebben kunnen identificeren als een voorspeller van BCR. Er 
is wel sprake van een significante tendens tot een eerder BCR in geval van 
een bilaterale PSM-status. 
CSRs. Daarentegen lijkt DWI in staat om deze gerichte biopten met grote 
nauwkeurigheid naar het meest agressieve deel van de tumor te leiden. De 
implicaties van een vals-negatieve MP-MRI evaluatie in een AS populatie 
met een eerdere histologische diagnose van prostaatkanker op basis 
van TRUS-geleide biopsieen, hetgeen in deze serie leidt tot een negatief 
MRGB in 45,3% van de gevallen, zal nog moeten worden vastgesteld middels 
langduriger follow-up.
Hoofdstuk 5 definieert de mogelijkheden van geïndividualiseerde 
besluitvorming op basis van stadiërings MP-MRI resultaten en in geval van 
een positief snijvlak (PSM) na RP. Kennis van de verschillende voorspellende 
waarden van MP-MRI voor EPE binnen de uiteenlopende risicogroepen 
faciliteert het correct voorlichten van de patiënt over de mogelijke 
behandelingen. Ook de constatering van een PSM en identificatie van 
patiënten met een hoog risico op biochemisch recidief (BCR) biedt de uroloog 
handvatten om de noodzaak van onmiddellijke adjuvante radiotherapie na 
RP te bespreken.
Hoofdstuk 5.1 bevestigt het vermogen van MP-MRI om betrouwbaar het 
pT-stadium van PCa vast te stellen (zie appendix 3), en presteert beter dan 
alle andere pre-operatieve kenmerken met een odds-ratio (OR) van 10,3 bij 
multivariate analyse. Wij stelden een sensitiviteit, specificiteit, positief 
voorspellende waarde (PPV) en negatief voorspellende waarde (NPV) van 
58.2%, 89.1%, 84.1% en 68.3%, respectievelijk, vast van MP-MRI voor EPE bij 
RP. Meer specifiek verduidelijkt deze serie de wisselende voorspellende 
waarden van stadiërings MP-MRI in de verschillende risicogroepen. In geval 
van laag-risico patienten is we sprake van een hoge NPV, hetgeen de 
mogelijkheid van een zenuwsparende RP in geval van het ontbreken van een 
verdenking op EPE bij MP-MRI in deze populatie onderschrijft. Daarentegen 
kan de lage PPV in deze populatie leiden tot een aantal onnodige niet-ze-
nuwsparende procedures of onjuiste uitsluiting van AS protocollen bij 
gebruik van MP-MRI voor deze beslissingen. Aan de andere kant van het ri-
sico-spectrum, is de PPV voor EPE zeer hoog in hoog-risico patiënten, 
hetgeen het nut van MP-MRI voor het verkrijgen  van kennis over de exacte 
lokalisatie van EPE in geval van RP onderschrijft. Tevens onderstreept deze 
hoge PPV de mogelijkheid om andere therapiemodaliteiten, zoals externe 
radiotherapie, te exploreren in geval van zeer uitgebreide EPE, waarbij de 
kans op curatie middels RP beperkt wordt geacht. 
Chapter 7
GENERAL DISCUSSION
AND CLINICAL IMPLICATIONS
214 215
Ch
ap
te
r 
 7
G
en
er
al
 d
is
cu
ss
io
n 
an
d 
cl
in
ic
al
 i
m
pl
ic
at
io
n
s
7. General discussion and clinical implications
7.1 Diagnostic strategies for prostate cancer
Over recent decades the number of recommended biopsy cores for the 
diagnosis of PCa has increased from classical sextant biopsy to the more 
extended TRUS-guided biopsy protocols we use today. Current guidelines 
recommend extended (10-12 core) PZ sampling of the prostate in case of a 
suspicion for PCa due to an elevated PSA and/or an abnormal DRE1. TZB is not 
recommended for baseline TRUS-guided biopsies, based upon several reports 
showing little incremental value2.
Chapter 3.1 of this thesis also shows little incremental diagnostic value over 
of TZB over sextant PZ biopsy, thus confirming the exclusion of TZ biopsies 
for baseline TRUS-guided biopsies. Still, TRUS-guided biopsies have a 
significant false-negative rate and therefor the need for repeated 
TRUS-guided biopsies in case of a persistent suspicion of PCa has not been 
eliminated. The ideal scheme and approach for repeat TRUS-guided biopsies 
has not been established yet and the concept of repeating a procedure with a 
substantial false-negative rate obviously has limitations of its one. Different 
alternatives have been advocated including saturation biopsies, 
transperineal biopsies and targeted prostate biopsies, such as MRGB. It is 
clear that repeat biopsy sessions in any form induce a significant procedure 
burden to the patient accompanied by the prolonged insecurity whether or 
not harbouring PCa. Furthermore, every biopsy session, especially in case of 
transrectal procedures, incorporates a new risk of infectious adverse events, 
which seem to be increasing over recent years mainly due to antibiotic 
resistance of micro-organisms3. 
MRGB has been shown to have a high diagnostic yield in a population 
following 2 or more negative TRUS-guided biopsies in chapter 3.2, 
establishing a PCa diagnosis in 40/68 (59%) of patients of which the majority 
were deemed clinically significant. In the past years these results have been 
reproduced in larger series and a recent review of literature by Moore et al. 
outlined MRI in combination with targeted biopsies of CSRs to be an effective 
method to diagnose clinically significant PCa4. Our main challenge as 
clinicians should be to minimise the false-negative rate of any diagnostic 
algorithm for PCa, obtained at the minimum number of biopsy cores needed. 
A recent series by Komai et al. has shown that MP-MRI misses about 14% of 
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7.2   Role of MP-MRI in active surveillance for low-risk 
prostate cancer
With regard to improving inclusion in AS protocols, MP-MRI is the most 
promising tool currently available. We need to elucidate whether MP-MRI is 
able to reliably and reproducibly identify patients subject to Gleason 
undergrading and/or understaging at TRUS-guided biopsy. 
DWI-derived ADC-values correlate well with RP Gleason score and DWI is the 
most appropriate tool to estimate the true Gleason score following a diagnosis 
of low-volume, low-risk PCa. In chapter 4.2 a series on the correlation of ADC 
and RP Gleason score is presented, showing good accuracy, which has been 
confirmed by other series8-10. Prediction of the true Gleason grade can be of 
great importance as decisions on treatment options are at least partially 
based on the biopsy-acquired combined Gleason score. By means of the ADC, 
DWI is able to identify patients subject to Gleason undergrading following a 
diagnosis of Gleason ≤3+3=6 PCa upon TRUS-guided biopsies, as outlined in 
chapter 4.3, and could be an important tool in AS inclusion. However, with 
an AUC of 0.73 for prediction of PCa in a CSR as presented in chapter 4.4 of 
this thesis, MP-MRI is not yet able to predict the presence of PCa with 
sufficient accuracy to abolish histological verification of CSR’s in an AS 
population. 
The substantial rate of Gleason undergrading using TRUS-guided biopsies 
has been shown to be virtually a non-issue in case of MRGB11. In case of 
candidates for AS chapter 3.3 and chapter 4.4 of this thesis have shown that 
MRGB is able to identify a substantial number of cases subject to Gleason 
undergrading, who are therefore not considered eligible for AS. Interestingly, 
in a substantial number of cases MP-MRI/MRGB evaluation was not able to 
confirm a diagnosis of PCa in these patients who had histologically proven 
PCa upon their TRUS-guided biopsies. Vargas et al. showed that a negative 
MRI study had a high NPV and high specificity for upgrading upon immediate 
confirmatory biopsy in low-risk PCa patients, whereas a positive MRI study 
had a very high sensitivity for upgrading7. Prolonged follow-up of patients 
with a negative MP-MRI within AS protocols, such as MR-PRIAS, will show 
whether a negative MP-MRI evaluation does truly represent clinically 
insignificant disease, which in turn might have important implications for 
diagnostic strategies for PCa.
significant cancers diagnosed by an extensive biopsy protocol combining 
12-core transrectal PZ biopsies with 14-core sampling of the anterior aspect 
of the prostate using a transperineal approach5. Therefore, it does not seem 
possible to refrain from schematic biopsies of the prostate to exclude 
significant PCa at this moment. In our opinion the ideal scenario might be a 
pre-biopsy MP-MRI to determine the need for anterior sampling and/or 
targeted biopsies in combination with a 10-12 core biopsy scheme sampling 
the PZ, as recommended by the current guidelines. 
Significant PCa seems to be very unlikely in case of negative TRUS-guided 
biopsies sampling the PZ combined with a negative MP-MRI examination. In 
case of a CSR upon MP-MRI it is imminent that targeted biopsies should be 
performed, the role of schematic anterior prostate sampling in this context 
however remains to be established. This strategy is likely to reduce the rate 
of incidental PCa during follow-up and a series by Hoeks et al has shown that 
only 2.7% (9/330) of patients with a negative MP-MRI/MRGB evaluation 
following negative TRUS-guided biopsies were diagnosed with PCa during 
follow-up6. On the other hand we know from AS series, like the one presented 
in chapter 4.4 of this thesis, that MP-MRI fails to diagnose approximately 
half of low-grade, low-volume cancers. As long as we are not confident that 
those cancers missed by MP-MRI will remain indolent over an extended 
period of time, MP-MRI is not ready to serve as a stand-alone PCa test. While 
MP-MRI does not detect a substantial number of low-risk PCa diagnosed by 
schematic TRUS-guided biopsy7, prolonged follow-up in our AS cohort will 
elucidate how patients with no CSR upon MP-MRI or no PCa upon concomitant 
MRGB of CSRs will fare. If a negative MP-MRI evaluation will turn out to be a 
good predictor of true clinically insignificant disease, this could have 
important repercussions for diagnostic strategies for PCa in a PSA-screened 
population. Eventually, MP-MRI might evolve to an up-front pre-biopsy test 
in patients with an elevated PSA to preclude the need for TRUS-guided and/
or targeted prostate biopsies. As urologists we have to identify our strength, 
which beholds the diagnosis of PZ PCa using TRUS-guided biopsies; however, 
the radiologist will probably lead in detecting and targeting anterior PCa 
using MP-MRI. 
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clinician to discuss unneeded neurovascular bundle resection in cases with 
a suspicion of EPE upon MP-MRI. As far as the intermediate risk group is 
concerned the relative high proportion of false negative MP-MRI results 
should place the emphasis on the risk of positive margins while counselling 
the patient on the options for nerve-sparing RP. On the contrary, when 
MP-MRI is used to exclude patients with evident EPE from curative surgery, 
high-specificity readings should be performed, leading to a high PPV in 
high-risk subjects. Even when performing a non-nerve sparing RP in these 
cases, staging MP-MRI might aid the urologist in decreasing the risk of PSMs. 
Clinical stage T3 PCa, as established by DRE, represents locally advanced 
disease and is a poor prognostic factor before RP20-22. The role of RP in this 
subset of PCa patients is under debate and many urologists favour external 
beam radiotherapy over RP in this specific patient group. In this context, 
radiologists have been performing high-specificity readings of staging 
MP-MRI studies to avoid exclusion of potentially curative RP based upon a 
false-positive EPE call by the reporting radiologist23. However, the true 
meaning of an MRI-established suspicion of EPE compared with the classical 
cT3 as determined by DRE remains unclear. It is likely that an imaging-based 
cT3 has a better prognosis as MP-MRI will pick up less extensive EPE than 
DRE, but how this should translate to clinical practice remains unclear. On 
the other hand, it is known that any EPE induces a significantly greater risk 
of BCR following RP22, which is even aggravated in case of a PSM24. 
As outlined in chapter 5.2 surgical margin status remains an important 
independent predictor of BCR following RP. In fact, it is probably the most 
relevant pathological predictor of BCR as it is the only factor that to a certain 
extent can be influenced by the operating urologist. Therefore any measure 
that enables us to reduce the risk of a PSM, especially in case of suspected 
EPE, should be considered relevant in clinical practice. Several predictors of 
BCR within a PSM population have been identified, such as localization at 
the prostate base22,25 and the length of PSM26,27. It is evident that while 
performing RP in patients with suspected EPE our main focus should be on 
limiting the number and extent of PSM’s. Staging MP-MRI outperforms any 
other pre-operative characteristic for prediction of EPE, including clinical 
stage, as shown in chapter 5.1 and delivers information on the presence, site 
and extent of EPE to the urologist performing a RP. MP-MRI thus enables us 
to select candidates for nerve-sparing procedures more adequately28,29, 
potentially reducing the number and extent of PSM’s. 
Even in a population considered eligible for AS, EPE is a rather common 
feature at RP12,13. When staging MP-MRI is used to identify patients eligible 
for AS a high NPV for EPE is of paramount importance. Translating the staging 
performance of MP-MRI as outlined in Chapter 5.1 to AS protocols we found 
MP-MRI to have a high NPV of 86.7% for EPE in low-volume, low-risk PCa 
subjects, and therefore a MP-MRI study with no evidence of EPE in candidates 
for AS is very likely to rule out any significant EPE, which is considered a 
contra-indication for AS. In the results of MP-MRI at inclusion in MR-PRIAS, 
as presented in chapter 3.3, 6.3% of patients considered eligible for AS had a 
suspicion of EPE, which corresponds with the reported 5-8% incidence of EPE 
in AS candidates undergoing RP12,13.  
Whereas evidence for the merits of MP-MRI at inclusion in AS is 
accumulating7,14,15, the role of MP-MRI in follow-up during AS is unclear. At this 
point only limited reports on the use of MP-MRI for detection of progression 
under AS have been published indicating that there might be a role for MP-MRI 
during AS follow-up16,17. Our preliminary results for the 1-year follow-up point in 
MR-PRIAS, as described in chapter 3.3, suggest only limited value for MP-MRI/
MRGB when compared to conventional repeated TRUS-guided biopsies but 
numbers are too small to draw significant conclusion. The potential benefits of 
DWI in this context have been published by Van As et al. establishing the 
potential of ADC as a marker for progression under AS18.
7.3  Pre-treatment staging MP-MRI for prostate cancer
MP-MRI has evolved to a widely available modality to establish PCa stage 
before RP. Fair sensitivity and good specificity of MP-MRI for EPE at RP have 
been reported consistently19 and staging MP-MRI must now be considered a 
reproducible test. Interestingly, as outlined in chapter 5.1 predictive values 
of MP-MRI for EPE are very wide apart in the different d’Amico risk groups, 
indicating the need for the radiologist and urologist alike to be aware of 
these differences for adequate interpretation of MP-MRI examinations and 
the resulting MP-MRI reports. 
An acceptable NPV for ruling out EPE should be able to strike the right 
balance between unneeded resection of the neurovascular bundle and the 
risk of a PSM and is only reached in low-risk patients. In this subgroup 
absence of EPE upon MP-MRI reassures the surgeon to pursue a nerve-sparing 
approach, however, the possibility of false positive results would urge the 
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8. Future perspectives
8.1  Diagnostic strategies for prostate cancer
There is a definite need to evolve our diagnostic strategies for PCa in such a 
manner that we can dispose of frequent serial PSA measurements and the 
substantial level of uncertainty on the presence of significant PCa that are 
now common following negative TRUS-guided biopsy schemes. The need for 
our cautious approach to subjects with a negative baseline series of 
TRUS-guided biopsies originates in the well-documented substantial 
false-negative rate for significant PCa of this test. This in turn leads to high 
rates of repeated biopsy procedures in case of a persistent suspicion of PCa. If 
we could reduce the false-negative rate of our diagnostic algorithm to a 
minimum, we would be able to ensure that the chances of bearing significant 
PCa are small. This would most likely lead to a reduction of patients’ anxiety 
while being subjected to serial PSA-measurements and repeat biopsy 
procedures, while on the other hand limiting the burden of frequent 
outpatient consultations and repeat biopsy procedures on our health care 
system.
Evaluation of pre-biopsy MP-MRI
Recently several series have reported upon the performance of pre-biopsy 
MP-MRI in the evaluation of subjects with an elevated PSA, showing a fair to 
good NPV of MP-MRI for presence of clinically significant PCa. However, a 
substantial number of significant PCa are still missed by pre-biopsy MP-MRI. 
Major limitations of these series at this point are the absence of follow-up 
and the different criteria used for significant PCa. Furthermore, varying 
techniques were used as a reference diagnostic tool, including transperineal 
template biopsies, combined transperineal and transrectal biopsies, and 
MP-MRI targeted biopsies only. In any case it is far too early to consider 
MP-MRI as a stand-alone diagnostic tool for PCa, as validation in larger 
series with prolonged follow-up to determine the incidence of PCa following 
such an approach are absent. We think that future research on pre-biopsy 
MP-MRI should incorporate the current standard of 10-12 cores of TRUS- 
guided biopsies, enhanced with some form of anterior prostate sampling ánd 
targeted biopsy of CSRs as identified on MP-MRI for histopathological 
evaluation. 
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Impact of negative MP-MRI evaluation of patients with (a suspicion of) 
low-risk PCa
Recently some series have been published that identify a negative MP-MRI 
evaluation indeed as an important predictor of insignificant PCa. Most series 
used a biopsy-based definition of insignificant PCa for this and are therefore 
limited by the well-known phenomenon of undergrading of PCa by 
TRUS-guided biopsies. At this point RP correlated studies remain scarce 
while being most suitable to evaluate the true rate of clinically insignificant 
PCa in a population with a negative MP-MRI. However this approach is also 
likely to introduce a bias as the decision to pursue a RP is also initiated by 
the diagnosis and characteristics of PCa by TRUS-guided biopsies in most 
cases. Ideally, we would follow-up on patients with a negative MP-MRI 
evaluation, for example in AS protocols, to establish the number of patients 
that would progress to more aggressive disease after all and would be in need 
of radical treatment. This approach would elucidate how patients with a 
negative MP-MRI evaluation would fare and could ultimately have important 
repercussions for diagnostic strategies for PCa. For example, if a negative 
MP-MRI evaluation with TRUS-guided biopsies showing no or low-grade PCa 
would be a reliable predictor of insignificant disease, MP-MRI could evolve to 
be an important adjunct tool for identifying patients not likely to display 
progressive PCa during follow-up, who would be ideal candidates for AS.
MP-MRI as a follow-up tool in active surveillance
While MP-MRI has been shown to be a very promising tool at inclusion in AS 
protocols, its role in follow-up of those patients remains unclear. Our 
preliminary results shows only limited added value of MP-MRI/MRGB 
evaluation at 1-year of follow-up in an AS protocol, however numbers are far 
too low to draw significant conclusions and many more subjects have to 
reach the 1-year follow-up timepoint to be able to evaluate the real (in)
significance of MP-MRI at this point. There is a burning need for more series 
using MP-MRI as a follow-up tool within AS and we think that any new 
research endeavour in AS should at least consider including MP-MRI as a tool 
at inclusion and during follow-up. Future validation of MP-MRI in AS 
protocols is of great importance and its reproducibility outside centres of 
excellence remains to be determined. 
Future of targeted prostate biopsies
As discussed in this thesis MP-MRI is a very promising tool to detect PCa in a 
population with a persistent suspicion of PCa following negative TRUS-guided 
biopsies. In this context MRGB has been the modality of choice to sample 
CSRs as identified at MP-MRI and obtain a histological diagnosis of PCa. 
However, due to its costly and time-consuming nature the use of MRGB in 
clinical practice has remained limited to centres of excellence. While MRGB 
will remain too technically challenging to be available for every patient in 
every location in the short-term we have to look at alternatives integrating 
MP-MRI results into clinical practice. A relatively easy approach could be the 
implementation of fusion of MP-MRI images with real-time TRUS (MR-TRUS 
fusion), integrating targeted biopsies into baseline and/or repeat biopsy 
procedures. MR-TRUS fusion might be the perfect hybrid approach blending 
MP-MRI acquired CSR data within a schematic biopsy approach of the 
prostate delivering the best of both worlds to the urologist’s office. Future 
research in this field will therefore need to focus upon optimization of 
MR-TRUS fusion techniques and validation of these techniques in clinical 
practice, aiming to prove its superiority to schematic repeat TRUS-guided 
biopsy protocols ánd equivalence to MRGB. 
8.2   The role of MP-MRI in risk-stratification of PCa and 
identifying candidates for active surveillance
It has now been established that DWI-derived ADC-values correlate well with 
PCa Gleason score, and this makes it an extremely useful tool in the 
evaluation of patients considered candidates for AS, while harbouring 
low-grade, low-volume PCa based upon DRE, PSA and TRUS-guided biopsies. 
Several series on the impact of MP-MRI, and in this context especially DWI, 
have now been published and without exception have shown ADC-values to 
be of great help in detecting patients subject to Gleason undergrading 
following TRUS-guided biopsies in AS candidates. In the future it might not 
be necessary to obtain histopathological sampling of every CSR in AS 
candidates, limiting the need for immediate repeat (targeted) biopsies to 
those subjects revealing an ADC-value suspicious for a high-grade Gleason 
component. Prolonged follow-up in our MR-PRIAS cohort will show whether 
a negative MP-MRI evaluation following a diagnosis of low-risk PCa correlates 
with true clinically insignificant disease and prolonged high progression-
free rates in AS protocols.
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Reduction of PSM rates using MP-MRI
While evidence for the performance of MP-MRI as a staging tool for localized 
PCa is accumulating, its role in reducing the number of PSM remains unclear. 
The knowledge of presence and localization of EPE is likely to reduce the 
number of PSM at RP, but its ability to do exact so has not been studied 
thoroughly. Comparing pre-operative planning with or without staging 
MP-MRI results is a challenge and randomizing patients to staging MP-MRI 
before RP seems unethical now. Ideally, a decision-aid using MP-MRI results 
in deciding upon nerve-sparing techniques should be validated in a clinical 
setting. 
8.3   The individualization of staging MP-MRI and its impact 
on surgical margin status
Currently, in everyday clinical practice staging MP-MRI is evaluated in a 
standardized manner, regardless of risk of EPE of the individual patient. This 
simply means that the available criteria for EPE are used to provide the 
urologist with staging results obtained from MP-MRI, whereas the 
information could be more valuable should it be interpreted in its correct 
context. For example, when nerve-sparing strategies are considered, the 
urologist and patient would benefit most from a high NPV to minimize the 
risk of PSM at RP, resulting from a high-sensitivity reading. On the other 
hand, when patients with extensive EPE are to be excluded from RP and 
referred for external beam radiotherapy, a high PPV is warranted to exclude 
incorrect exclusion of potentially curative RP. A high PPV is obtained by 
high-specificity readings of staging MP-MRI, the type of reading most 
radiologists are performing at this point. While staging MP-MRI does not 
represent a ‘black-or-white’ test, the interpreting radiologist should be 
aware of the clinical consequences of his call. Therefore, communication 
between the disciplines, ideally in a consensus meeting, might be the crux 
for correct individualized interpretation of a staging MP-MRI.  
Individualized staging MP-MRI reports
From a clinical point of view it is very important to discuss the influence of 
MP-MRI reports on impending treatment with the radiologist, who is then 
able to provide the urologist with a tailored high-sensitivity or high-speci-
ficity reading. All currently published series on staging performance MP-MRI 
have shown fair to good sensitivity for EPE, while at the same time 
establishing superior specificity. This is in concordance with our earlier 
statement that high-specificity readings are now the standard. However, 
with the increase of patients diagnosed with low-risk PCa, the emphasis for 
this specific population might have to shift to high-sensitivity readings. One 
could postulate that incorrect exclusion from AS or an unneeded excision of 
the neurovascular bundle in an individual case is to be preferred above an 
inclusion in AS of a patient with EPE or a PSM following RP. We suggest 
therefore that future series on staging MP-MRI will report upon the different 
risk subsets categorically to be better able to determine its value for an 
individual PCa case.
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9. Conclusions
	 	PCa diagnosis, treatment and follow-up remain the urologist’s domain, 
who needs to call in the radiologist’s help in time to provide him with 
the relevant data from MP-MRI evaluation to be used in the process. 
	 	Grading of PCa is evolving from a biopsy-based feature to a MR 
imaging-based prospect, greatly facilitated by advanced MP-MRI 
techniques such as DWI.
	 	PCa staging is teamwork, including the urologist, radiologist and 
radiation oncologist, who in consensus are able to determine the most 
adequate management options for an individual patient.
	 	Ultimately, a well-informed patient, facilitated by his urologist who is 
able to discuss and explicate the biopsy and MP-MRI results, should take 
his personal management decisions when confronted with localized 
PCa.
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Matthijs en Joost, broertjes, onze vriendschap is vanzelfsprekend en ik ben 
blij met de vele familiemomenten die wij delen. We wonen ver uit elkaar, 
maar toch voelt dat niet zo. We grijpen gelukkig elke gelegenheid aan om iets 
te vieren of elkaar weer te spreken of te zien. Ik waardeer het zeer dat jullie 
dit project met toenemende belangstelling hebben gevolgd.
Lieve Maxime en Loek, hoewel jullie te klein zijn om te beseffen waarom papa 
altijd moest schrijven, laat staan te weten wat een prostaat is, zijn jullie voor 
mij steeds een bron van vreugde en motivatie geweest. Jullie geven mij 
steeds weer de energie die ik nodig heb en jullie kinderwijsheden zijn 
onmisbaar. Ik geniet elke dag van jullie bestaan! 
Willemijn, tsja, dit valt eigenlijk niet in woorden uit te drukken. Ik ben me 
bewust van de druk die dit proefschrift op ons heeft gelegd. Onze momenten 
samen zijn goud waard, hoewel ze te vaak moesten sneuvelen voor de 
wetenschap. Toch heb je me altijd gesteund en ben je mijn geweten én beste 
raadgever. Je attendeert mij op zaken die ik zelf nog niet eens gesignaleerd 
heb en bent mijn steun en toeverlaat. Zonder jou had ik dit nooit kunnen 
volbrengen en daarvoor ben ik je eeuwig dankbaar. Ik houdt zielsveel van je 
en hoewel je er misschien niet aan zult willen is dit ook jouw feestje.
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Appendix 1
Inclusion and exclusion criteria used in the 
PRIAS/MR-PRIAS study
Inclusion criteria
	 Histopathologically proven adenocarcinoma of the prostate
	 Men should be fit for curative treatment
	 PSA level at diagnosis ≤10.0 ng/mL
	 PSA density <0.2 ng/mL/mL
	 Clinical stage T1c or T2
	 Gleason score ≤3+3=6
	 ≤2 biopsy cores invaded with prostate cancer
	 Participants must be willing to attend the follow-up visits
Exclusion criteria
	 Men who cannot or do not want to be operated or irradiated
	 A former therapy for prostate cancer
	 	Contra-indications to MRI or gadolinium based contrast agents 
(MR-PRIAS only)
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Appendix 3
2002 TNM Classification for Prostate Cancer
Stage Substage Definition
T1 T1a Incidental histological finding; ≤5% of tissue resected during TUR-P
T1b Incidental histological finding; >5% of tissue resected during TUR-P
T1c Tumor identified by needle biopsy
T2 T2a Tumor involves half of the lobe or less
T2b Tumor involves more than one half of one lobe bur not both lobes
T2c Tumor involves both lobes
T3 T3a Extraprostatic extension (unilateral or bilateral)
T3b Tumor invades seminal vesicle(s)
T4 T4a Tumor invades bladder neck and/or external sphincter and/or rectum
T4b Tumor invades levator muscles and/or is fixed to pelvic wall
N Nx Regional lymph nodes can not be assessed
N0 No regional lymph node metastasis
N1 Regional lymph node metastasis
M Mx Distant metastasis can not be assessed
M0 No distant metastasis
M1a Non-regional lymph node(s)
M1b Bone(s)
M1c Metastasis at other site(s)
TUR-P: transurethral resection of the prostate.
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Appendix 4
Crosstabs used for establishing prevalence, accuracy, 
sensitivity, specificity, PPV and NPV of MP-MRI for EPE at RP
No EPE at RP EPE at RP
MP-MRI positive for EPE a b
MP-MRI negative for EPE c d
Prevalence = (b+d)/(a+b+c+d)
Accuracy = (b+c)/(a+b+c+d)
Sensitivity = b/(b+d)
Specificity = c/(a+c)
PPV = b/(a+b)
NPV = c/(c+d)
PPV: positive predictive value, NPV: negative predictive value, MP-MRI: multiparametric MR 
imaging, EPE: extraprostatic extension, RP: radical prostatectomy.

